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Human platelet responsiveness can be modulated (stimulated 
or inhibited) by a variety of stimuli, many of which act at 
specific receptors on the external surface of the plasma membrane 
The mechanisms by which this external stimulus is transferred 
to the final cellular response are termed generically "stimulus 
response coupling" and invariably involve the production of 
second messenger molecules which govern the final cellular 
response. In platelets, and some other cells, stimulation is 
believed to be associated with, and mediated by, the production 
of two second messengers, 1,2 diacylglycerol (DAG) and inositol
1,4,3 trisphosphate (lns(l,4,3)P^)• Agonist receptor interaction 
results in the phospholipase C catalysed hydrolysis of phos- 
phatidylinositol 4,3 bisphosphate (PIP^) to yield DAG and 
Ins(l,4,3)P^ directly. Ins(l,4,3)P^ mobilises calcium from an 
intracellular store, and this elevated cytosolic calcium level 
activates a Ca—calmodulin dependent protein kinase which, in 
turn, catalyses the phosphorylation of a protein of M^ = 20,000 
which plays an integral role in the stimulation of platelets.
At resting calcium levels, DAG translocates a soluble cytosolic 
enzyme, protein kinase C, to the membrane and subsequently 
activates it. Protein kinase C in turn phosphorylates a protein 
with a M^ of 40,000, which also has been implicated in platelet 
function and which may act independently of, or synergistically 
with, the calcium mediated activation. In contrast, platelets 
are maintained in a quiescent state by agents which cause an 
elevation in the intracellular concentration of either cAMP
- Xll -
or cGMP. These two inhibitory platelet mediators presumably 
activate specific kinases which phosphory1ate proteins which 
function to maintain the quiescent state.
Cellular reactivity is the subject of control by a number 
of factors, apparently dependent upon extracellular conditions. 
For example numerous exogenous agonists promote platelet 
activation whereas endogenous compounds such as PGl^ and PGD^ 
inhibit platelet reactivity. Platelets elicit the phenomenon 
of desensitisation whereby the addition of an agonist renders 
them less responsive to agonists which act on the same receptor 
(homologous desensitisation) or to agonists that act upon 
distinct receptors (heterologous desensitisation). In contrast 
under some conditions, combinations of agonists can produce 
a response which is larger than that evoked by either agonist 
alone (potentiation).
I attempted to clarify the role of receptor stimulated 
phosphoinositide hydrolysis in mediating the activity of a 
number of agonists whose putative mechanism of action was 
unknown or controversial. Phosphoinositide hydrolysis was 
routinely monitored by measuring the formation of [^^p] 
phosphatidic acid (Ptd OH) in platelets prelabelled with ^^^pj 
orthophosphate. Ptd OH is the phosphorylated product of DAG, 
and the experimental conditions adopted allowed j^^^P j Ptd OH 
to obtain isotopic equilibrium with gamma- [ ^^p] ATP such that 
changes in label reflect changes in Ptd OH content. In addition 
in some studies depletion of PIP2 monitored.
- Xlll -
Cytosolic free calcium concentration was measured by Quin 2.
In addition, I evaluated the role of various putative endogenous 
mediators of desensitisation on the stimulatory transduction 
process(es) and addressed the possible mechanism(s) whereby 
agonist—induced platelet reactivity could be potentiated.
The major findings are outlined below:—
1) ADP failed either to elicit the formation of [^^P]
Ptd OH or to cause the degradation of [^^P ] PIP^»
2) The stable thromboxane A^ analogue, EPI7I, elicits a 
concentration dependent secretion of ATP, formation of [^^pj 
Ptd OH and also depletion of PIP^* The effects of EPI7I 
on ATP secretion and [^^p] Ptd OH formation are attenuated
by u 44069 and Et PGH^.
3 ) Thrombin stimulated both [^^p] Ptd OH formation and 
|^32p j PIP^ hydrolysis. In both respects thrombin is the most 
efficacious of all agonists of potential patho-physiological 
importance (PAF, 3HT, TxA^ (ergo EPI7I or U44o69), vasopressin).
4) Trypsin stimulates elevated levels of [^^p] Ptd OH.
3 ) EPI7I iu combination with ADP, 3HT and PAF did not
synergise in the formation of ^^P j Ptd OH, whereas the 
combination of EPI7I and trypsin did produce additive effects.
6) PGD^, sodium nitroprusside and phorbol ester activators 
of protein kinase C all inhibit and reverse an agonist induced 
elevation in |ca^^j and [ ^ ^p] Ptd OH formation but do not 
affect the resting levels of either.
7 ) Adrenaline and ADP, neither of which stimulate the 
Ptd OH, both potentiate agonist-induced
Ptd OH. This effect is opposed by agents
which stimulate adenylate cyclase.
formation of  ^^ ^P 
formation of  ^^ ^P
- XIV -
These results indicate that thrombin and TxA^ (ergo EPI71) 
but not ADP induced stimulation of platelets is mediated by 
phospholipase C activation. Thrombin is the most efficacious 
platelet agonist and this may reflect stimulation via both a 
receptor-mediated and proteolytic manner. U44o69, like Et 
PGH^, is a partial agonist at the platelet Tx receptor.
Adenylate cyclase, guanylate cyclase and protein kinase C 
stimulants all inhibit receptor mediated production of stimulator] 
second messengers. Therefore cAMP, cGMP and/or DAG may act as 
endogenous mediators of desensitisation. Adrenaline and ADP 
induced potentiation of platelet reactivity may be due to an 




CHAPTER I; THE PLATELET
1. General
The observations of Bizzozero and of Hayem, both in 1882, 
demonstrated the presence of small elements in circulating 
blood which adhered initially to damaged vascular walls and 
subsequently to each other to form haemostatic plugs. Prior 
to these initial reports of the existence of platelets, their 
presence had been neglected by microscopists due to the small 
size of the cell in comparison to the larger red and white 
cells. The proposal that platelets were artifacts of inadequate 
blood preparation (Buckmaster, I906) was quickly dispelled by 
much work carried out in the early 20th century. Although 
the majority of these early studies were concerned with the 
role of the platelet in coagulation, it soon became evident 
that platelets had a wide range of physiological and pathological 
functions. In addition platelets are widely used as a model 
system for studying other processes due, at least in part, 
to their ease of availability at little cost, the facility 
with which a homogenous population of cells can be obtained 
and the multiplicity of receptors which they possess.
2. Formation of platelets
The origin of the platelet was identified by Wright in 
1906 as being the megakaryocyte. It is believed that the 
megakaryocyte shares a common precursor,,or pluripotential 
stem cell, with myeloid and erythroid cells (Becker al. ,
1963)* Once these cells become committed to the production 
of megakaryocytes, they undergo three stages of maturation
- 3 -
during each of which there is continual cell growth (Levin 
et al., 1981).
Firstly, the megakaryoblast stage, during which the cell 
initially can be identified under a light microscope (Paulus, 
1970). There is intense protein synthesis at least part of 
which can be accounted for by the formation of specific membranes 
These membranes become internalised and this, when combined 
with the endomitosis that occurs, may represent a specialised 
form of the intracellular development of daughter cells 
(Pennington, I98I).
Secondly, the basophil megakaryocyte phase, where the 
RNA synthesis becomes more marked. It is also clear from 
electron microscopic studies, that specific organelles are 
present in greater quantity and much more diffused throughout 
the cell than in the megakaryoblast phase (Pennington, I98I).
By the end of this stage, endomitosis has ceased (Ebbe &
Stohlman, I965) and the mitochondria are of comparable size 
to those in platelets (Pennington & Streatfield, 1975)»
Thirdly, the granular megakaryocyte phase in which the 
membrane system becomes open and communicates with the external 
environment (Behnke, I968) and microtubule rich pseudopodia 
appear and penetrate the wall of the marrow sinusoid (Becker 
& de Biuyn, 1976; Lichtman ejfc ad., 1978).
The release of platelets from megakaryocytes into 
circulating blood may occur by either, or both, of two mechanisms 
The pseudopodia protruding through the sinusoidal wall may be 
removed by the circulating blood (Tavassoli, 1979)» or 
alternatively, between 20^ and 30?^ of the whole mature
-  4 -
megakaryocytes pass into the circulation (Kaufman e_fc al., I963). 
The site of transformation from megakaiyocyte fraction to 
platelet is unknown, although it is believed that large 
megakaryocyte fragments trapped in small pulmonary vessels would 
be further fragmented releasing smaller fractions. These 
fractions are then classified as platelets when there is a 
regular arrangement of both microtubules and the dense tubular 
system, which corresponds to the characteristic discoid form 
of the platelet. This regular arrangement of intracellular 
organelles is absent from megakaryocyte fractions (Pennington 
et al., 1976). It has been estimated that about 3000 platelets 
are released from a single megakaryocyte.
Several radio—chemicals have been employed in vitro to
51assess the life-span of normal platelets. Studies using Cr, 
believed to be the most reliable method, estimates an 8 to 11 
day life time for the platelet (Marker & Slichter, 1972). The
g
normal human blood platelet count is about 2.3x10 cells per 
ml of whole blood and the turnover rate is estimated to be 
around 3*3x10^ cells/ml/day (Marker & Finch, I969). Platelets 
are removed from circulating blood either by their incorporation 
into haemostatic plugs or by being engulfed by the liver or 
the reticulo-endothelial system in the spleen (Gordon, I98I).
3* Platelet morphology
The advent of electron microscopic techniques have allowed 
an insight into the complex nature of the intracellular 
environment of the platelet and have permitted the investigation 
of the relationship between the intracellular constituents and 
the physiological functions of the cell.
- 5 -
In their quiescent state the platelet exists in circulating 
blood as a biconvex disc with an equatorial diameter of 2-3 
microns and a thickness of about 1 micron. The mammalian 
platelet has no nucleus and so differs from the analogous cell, 
the thrombocyte, in lower animals such as birds and reptiles.
The main features of the human platelet are diagramatically 
represented in Figure 1. The external surface of the plasma 
membrane (PM) is associated with the platelet surface coat 
or "glycocalyx" (GC) (Jamieson & Smith, 1976). This is a 
covering, 20-50 nm thick, rich in glycoproteins which appears 
fuzzy on electron micrographs when stained with lanthanum.
The plasma membrane itself is a lipid structure of 7-10 nm 
thickness.
The external surface area of the platelet is markedly 
increased by the presence of the open canalicular system (OCS). 
These extensive and deeply penetrating invaginations give 
the platelet a "sponge-like" appearance and allow additional 
area for the actions of chemical and particulate stimuli 
(Gordon, I98I).
The major and most discernable of the cyto-skeletal proteins 
is the microtubular system (MT) which lies immediately beneath 
the plasma membrane in the equatorial plane. They appear to be 
polymeric assemblies of sub unit proteins of which the major 
one is tubulin (Crawford, 1985)* The primary role of the 
microtubules seems to be to help maintain the discoid shape of 
the platelet. The contractile protein complex, thrombosthenin, 
isolated from platelets (Bettex-Galland & Luscher, 1959) was 
found to closely resemble the actomyosin of smooth muscle.
The fibrillar forms of actin, or microfilaments (m f ), are 
seen both free in the cytoplasm and as a network of filaments 
attached to the inner plasma membrane. Myosin filaments, 
although present in the cytoplasm, are rarely observed (Crawford, 
1985).
The dense tubular system (DTS) is situated distal to the 
marginal microtubular bundle. It is a system of membranes 
unconnected to the external milieu and probably analogous to 
the endoplasmic reticulum in other secretory, mammalian cells 
(Cerrard et al., I98I). The dense tubular system, like the 
endoplasmic reticulum, is possibly a Ca^^ sequestration organelle 
which serves as a source of intracellular Ca^ "*” which may be of 
importance in stimulus response coupling with particular 
importance in actomyosin contraction.
The platelet also contains multiple types of storage 
granules. Of these the three most distinct are the dense 
granules (DG), or dense bodies, the alpha granules (AG) and 
lysosomes (LYS). The term dense granule was coined due to 
their opaque appearance when viewed with an electron microscope 
(Tranzer e_t aT. , I966). This is because these organelles are 
relatively Ca^* rich, indeed it has been proposed that up to 
60^ of the cellular Ca^* is associated with the dense granules 
(Skaer, 1975) although this may be a liberal estimation 
(Gerrard et al., I98I). This Ca^* may be complexed in some 
way with the ADP which is present within the granule (Lages 
et al., 1975)" The dense granule is also the storage site 
for 5HT within the cell. The platelet is a major source of 
5HT within the body as it removes the amine from the circulation 
by an avid and specific active uptake process. In addition to
GC
l y s
Figure 1. Diaqramatic representation of the structure of the human platelet.
PM - Plasma membrane; GC - Glycocalyx; OCS - Open canalicular system;
MT - Microtubules; MF - Microfilaments; DTS - Dense tubular system;
DG - Danse granules; AG - Alpha granules; LYS - Lysosomes; MC - Mitochondria; 
GLC - Glycogen granules. (After Crawford, 1985).
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Ca^^f 3HT and ADP the dense granules also contain ATP, 
pyrophosphate» phospholipid and antiplasmin. Due to its 
smallness relative to alpha granules and lysosomes, it is 
possible to quantify the dense granules within the platelet, 
a property relatively unique to its cell type. It has been 
estimated that there are 6-10 dense granules per platelet 
each with a diameter of around 198 nm (Costa ejfc ad., 1977)*
The alpha granule appears to be the site where a variety 
of functionally significant proteins are localised. Included 
among these proteins are fibrinogen, fibronectin, thrombospondin 
(TSP), von Willebrand Factor, Platelet Factor 4, low affinity 
Platelet Factor 4, Factors V and Va, Factor VIII-related 
antigen, beta thromboglobulin, albumin, Platelet Derived Growth 
Factor (PDGF) and beta Transforming Growth Factor (BTGF)
(Kaplan, 1981). Lysosomes contain a number of enzymes such 
as beta N-acetylglucosaminidase, beta galactosidase, beta 
glucuronidase and beta glycerophosphatase (Skaer, I98I ).
The energy necessary for cellular reactivity derives from 
two major sources;-
a) Oxidative phosphorylation occurs in the mitochondria 
(m g ) and this represents the major organelle for the maintenance 
of cellular ATP levels.
b) Glycolysis, which occurs in the cytosol, utilises 
glycogen, which is stored in granular form (g LC), as substrate.
4. Platelet reactivity
Damage to blood vessel walls with the resultant removal 
of, at least part of, the endothelial lining induces two processes
- 8 -
designed to terminate the loss of blood.
Firstly when platelets come into contact with the exposed 
collagen of the damaged vascular wall a number of phenomena 
occur which collectively constitute the platelet response and 
results in the formation of a primary haemostatic plug (Gordon, 
1981). The platelet response can be divided into a number of 
separate but related processes: - i ) shape change; ii) adhesion; 
iii) aggregation; iv) secretion. In addition to sub endothelial 
collagen, a number of soluble compounds and particulate fractions 
can, to varying degrees, stimulate the platelet either in vivo 
or in vitro.
The second procoagulant process is the release of tissue 
thromboplastin by the damaged vessel wall which initiates the 
activation of the coagulation cascade, leading to the formation 
of thrombin and the deposition of an insoluble fibrin network 
(Bevers ejfc al., 1983)» This thrombin further activates platelets 
and the fibrin network enmeshes the platelet aggregate and 
converts the primary haemostatic plug into a stable thrombus.
4.1 Shape change
When platelets are challenged with agonists such as ADP, 
thrombin, 3HT or the calcium ionophore A23I87, the initial 
response is a marked change from the distinct, quiescent 
discoid shape (Gordon & Milner, 1977)» This rapidly occurring 
event involves the cell becoming orbicular with the formation 
of pseudopodia which emanate from the cell body. These 
pseudopodia may extend up to 10 microns from the cell and are
- 9 -
therefore larger than the platelet itself (Harris, I98I).
As a consequence of this change there is a dramatic increase 
in the surface area of the platelet, although the cellular 
volume remains unaltered. This increase in surface area 
most probably results in a decrease in net charge density 
which presumably facilitates platelet to platelet interaction.
These extracellular events are accompanied by the re­
organisation of the cytoskeletal elements within the cell.
Each pseudopod contains a bundle of parallel microfilaments 
and also, occasionally, microtubules. In addition there is a 
contraction of the marginal microtubules resulting in the 
centralisation of the intracellular organelles, although they 
are still surrounded by a band of microtubules (Harris, I98I). 
Although these effects of the contractile proteins are believed 
to be Ca^* dependent, the platelets do not require the presence 
of Ca^* in the bathing medium to sustain shape change. This
suggests that the Ca^* requirement is fulfilled by the mobilis- 
2 +ation of Ca from intracellular storage granules, probably 
the dense tubular system.
4.2 Adhesion
The circulating platelet is indifferent to the intact 
vascular walls and to other blood constituents, such as 
erythrocytes and leucocytes. In contrast, exposure of sub- 
endothelial fibrillar collagen initiates activation of the 
platelet, which adheres avidly to the connective tissue (Gordon, 
1981). This adhesion is a complex process which evidently 
depends upon the presence of the plasma protein von ¥illebrands
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factor, or factor VIII. This factor, per se, has no effect 
on quiescent platelets, however the presence of denuded 
endothelium may modify its structure leading to its binding 
to, perhaps glycoprotein Ib on, the platelet membrane. In 
this way it has been postulated that von Willebrands factor 
forms a bridge between the subendothelium and the platelet 
(Berndt & Phillips, I98I). Platelets will also adhere to 
non-physiological surfaces, for example glass, and this is 
facilitated by the presence of fibrinogen.
4.3 Aggregation
Aggregation describes the formation of clumps of activated 
platelets on top of the initial adherent layer at the site 
of vascular damage. This is an interaction specific to platelets 
as it occurs to the virtual exclusion of other blood cell types. 
The development of these aggregates is not fully understood 
although the presence of a complex of glycoproteins Ilb and 
Ilia on the platelet membrane appears to be mandatory as do 
the co-factors Ca^* and fibrinogen. When quiescent platelets 
are challenged with agonists, notably ADP, there is an increase 
in fibrinogen binding sites on the plasma membrane and there 
is indirect evidence that the glycoprotein Ilb/lIIa complex 
may participate in the function of these binding sites (Berndt 
& Phillips, 1981). This bound fibrinogen may then form an 
isthmus between platelets. Calcium is believed to be necessary 
to maintain fibrinogen binding, thereby helping to stabilise 
platelet to platelet interaction. Lectins and various clotting 
factors may also play a pro-aggregatory role in haemostasis.
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Platelet aggregation can be designated as "primaiy", 
where the process is reversible, or "secondary”, 
where the platelets form permanent clumps* The former is 
mediated entirely by the initiating agonist, whereas the latter 
although initiated b^ exogenous agents is propagated by 
endogenous mediators.
4.4 Secretion
Secretion from stimulated platelets can be broadly divided 
into two distinct categories. Firstly there is the selective 
release of storage granule contents, termed degranulation, 
exocytosis or merocrine secretion. The second mechanism 
involves the release of intracellular compounds which are not 
stored in their releasable form, but are synthesised and liberated 
upon activation (MacIntyre, 1977).
The platelet has the capacity to selectively release the 
constituents of one, or more, of its intracellular organelles 
indicating a fine level of control within the cell. The release 
of the dense granular contents occurs readily in response to 
relatively low concentrations of agonist, often in the absence 
of aggregation. In contrast the liberation of lysosomal 
enzymes is only induced by powerful stimuli such as thrombin. 
Release from alpha granules depends upon the concentration of 
the stimulus. Some of the alpha granular contents are liberated 
at lower agonist concentrations than are required for dense 
granule secretion, whereas others necessitate higher concentrat­
ions (Skaer, I98I).
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It has been proposed that platelet stimulation causes 
dense granules to migrate to and fuse with the plasma membrane 
with the resultant liberation of the granule contents. In 
contrast the contents of the alpha granules are expelled into 
the open canalicular system. Furthermore it appears that 
alpha granule secretion depends not only on fusion with the 
open canalicular system but also with some form of platelet 
contraction. Little is known of lysosomal secretion, however 
some liberation of acid hydrolases occurs directly into internal 
phagocytic vacuoles (Lewis ejfc al. , 197^; Skaer, I98I).
The two principal examples of formation and release from 
stimulated platelets are eicosanoids and PAF. Platelets have 
an uptake process for, and are rich in, the eicosanoid precursor 
arachidonic acid (Rittenhouse-Simmons & Deykin, I98I). This 
unsaturated fatty acid is particularly prevalent at position 
2 (sn-2) of the glycerol backbone of various phospholipids 
(Marcus et al., 1969)* The arachidonic acid is released either 
by the action of phospholipase A^, or by the sequential 
activities of phospholipase C and diacylglycerol lipase 
(Broekman e_t aT. , I98O; Bell & Maj erus, I98O; MacIntyre, I98I). 
Regardless of the source of arachidonic acid it is susceptible 
to the action of two pathways, the cyclo-oxygenase and the 
lipoxygenase pathways. When platelets are challenged with 
potent stimuli, the cyclo-oxygenase endoperoxides prostaglandin 
(PG^G^ PGH^, Thromboxane(Tx)A2 and, latterly, the lipoxy­
genase products 12 L hydroxyperoxy- and 12 L hydroxy-5,8,10,14 
eicosatetraenoic acid (HPETE/HETE) are the major eicosanoids 
formed and secreted (Rittenhouse-Simmons & Russell, 1978; 
Rittenhouse-Simmons & Deykin, I98I). Adrenaline and ADP are 
weak agonists in respect of their ability to induce eicosanoid
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release, indeed the release in response to ADP is often 
undetectable (Best al. , I980).
Similarly platelet stimulants such as thrombin, collagen 
and A23I87 but not ADP induce the release of the ether lipid 
1 0 alkyl 2 acetyl sn glycero 3 phosphoryl choline (Platelet 
activating factor; PAF). The precise mechanism is unclear, 
although a phospholipase A^ like enzyme may catalyse the 
déacylation of membrane phospholipid to synthesize lyso-PAF. 
Acétylation of this precursor at glycerol sn-2 would yield PAF 
(Chap ejb ad. , I98I; Chi guard e_t ad., I983; Vargaftig ^t ad.,
1981; Chiguard ad., 1985)*
3. Platelets in vivo
3•1 Physiological functions
The primary function of the platelet is its involvement 
in the maintenance of vascular homeostasis (haemostasis). The 
initial response of the platelet, as outlined earlier, when 
encountering the exposed collagen of a damaged vascular wall 
is to adhere to the sub-endothelial connective tissue with the 
consequent formation of a primary haemostatic plug. In 
addition the platelet is involved in a variety of haemostatic 
mechanisms. The secretion of ADP, 3HT, TxA^ and PAF, all of 
which are pro-aggregatory agents, act as a positive feedback 
stimulus to promote the activation of additional platelets 
with the consequent accumulation on the initial adherent 
layer. This is further enhanced by the release of PF4 and Ca^*. 
Four major adhesive glycoproteins are released from the alpha 
granules of stimulated platelets - fibrinogen, fibronectin, 
von Willebrand Factor and thrombospondin (TSP). The TSP 
released rapidly binds to the platelet surface in the presence
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of Ca (Phillips et al., I980) and is thought to reinforce 
the bridging fibrinogen molecule linking the GP Ilb/lIIa 
complexes on adjacent platelets, leading to an irreversible 
state (Silverstein et al», I986). The role of von Willebrand 
Factor, fibronectin and PF4, each of which are present on the 
surface of stimulated platelets, is unclear although a role 
in the stabilisation of aggregates is not precluded. This 
haemostatic plug is consolidated to form a thrombus by the 
initiation of the coagulation cascade, including the production 
of fibrin strands around the aggregate and the release of the 
powerful aggregatory agent thrombin (Gordon, I98I).
Following this rapid thrombus formation which serves to 
minimise blood loss, platelets are believed to become involved 
in the repair process. Proteins such as PDGF and BTGF are 
released which stimulate proliferation of smooth muscle, 
synthesis of connective tissue and formation of fibroblasts 
(Gordon & Milner, 1977)« The 3HT secreted at the site of injury 
then stimulates these fibroblasts to release collagen (Aalto 
& Kulonen, 1972).
Platelets may also be involved in maintaining the integrity 
of the blood vessel endothelium. They achieve this by becoming 
integrated either at the junctions between endothelial cells 
or within the cells themselves (Johnson, I971).
The possibility of platelets acting as scavengers iri vivo
has been raised as they are capable of pinocytosis and of the
«
ingestion of several small particles. However it is unclear 
whether this is true phagocytosis or indeed if it is physiologic­
ally significant (Gordon & Milner, 1977; Skaer, I98I).
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Platelets have been shown to accumulate at the site of 
tissue damage and it is believed that they play a role in 
the mediation of inflammation via both direct and indirect 
effects on vascular permeability. Directly the release of 
5HT, PGD^ and HETE all have a pronounced effect on vascular 
permeability. Indirectly the secretion from alpha granules 
may cause the degranulation of mast cells thereby releasing 
histamine which increases permeability (Gordon & Milner, 1977)»
5*2 Pathological processes
The contribution of platelets to pathological conditions 
are an extension of their physiological functions.
Platelets play a major role in arterial thrombosis. This 
condition is due, at least in part, to an oversensitivity of 
platelets to pro-aggregatory agents. This results in the 
formation of thrombi either attached to vessel walls in the 
absence of vascular damage, or circulating without any vascular 
contact whatsoever. The consequence of this is that these 
thrombi, or fragments of them, block smaller vessels and so 
deprive tissues of oxygen. This is often fatal if the obstructioi 
occurs in the myocardium or in the brain.
The condition of atherosclerosis is associated with 
cardiac, cerebral or peripheral ischaemia due to localised 
thickening of arterial intima. This thickening is accounted 
for by the formation of mural plaques which consist of fibrous 
tissue and lipid. Platelets may be involved in a variety of 
ways in the development of these plaques. Firstly, by forming
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mural thrombi and being incorporated into the arterial wall? 
this may be particularly important in areas where there is 
disruption of the blood flow. Secondly, platelets may adhere 
to existing atherosclerotic plaques. Thirdly, by secretion 
of granular constituents which result in the proliferation of 
smooth muscle and formation of connective tissue; this is 
believed to be the major contribution that platelets play 
in atherosclerosis (Gordon & Milner, 1977; Bora, 1983)»
Platelets have also been implicated in conditions such 
as pathological inflammation, the rejection of organ transplants 
and migraine.
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CHAPTER II; STIMULUS-RESPONSE COUPLING 
1• General
The response of platelets to changes in their environment 
depends, in common with other cells, upon the interaction of 
external agents with their specific cell surface receptors.
These agents, or agonists, can either inhibit platelet reactivity 
thereby maintaining or prolonging the quiescent state, or 
stimulate platelet reactivity, and hence initiate activation, 
of the platelet. The information is transferred from the 
external stimulus, which can be soluble or particulate, to 
the final cellular response by a process known as stimulus- 
response coupling. The general mechanism involved is shown 
in Figure 2. The agonists bind to their specific receptors 
which are situated on the external surface of the plasma membrane, 
Information generated as a consequence of agonist receptor 
combination is transmitted through the membrane by a trasduction 
process. These transducers are believed to be a family of 
heterotrimer proteins which are inert until they bind guanosine 
triphosphate (GTP) and are therefore termed "G-Proteins" (Rodbell, 
1980). When GTP binds to the G— proteins the complex activates 
an effector, normally an enzyme, on the inner face of the 
membrane. This enzyme amplifies the signal by converting an 
intracellular precursor into an active chemical, or second 
messenger, which may diffuse into the cytoplasm or remain 
within the plasma membrane. The role of this second messenger 
is to stimulate specific intracellular target sites, or 
acceptors, which in turn are responsible for the final cellular 
response. There appears to be only a limited number of naturally 
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See text for details*
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processes are relatively universal (Berridge, 1985)» As a 
result of this» the formation of the same second messenger(s) 
may be the common product of a variety of agonists and therefore 
a similar cellular response can be observed from a plethora 
of external stimulants. The most important second messengers 
so far discovered are cAMP» 1,2 Diacylglycerol (DAG), inositol
1,4,5 trisphosphate (ins(l, 4 , 5 )  and Ca^* (Schramm & Selinger, 
1984; Berridge, 1984). As mentioned above, platelet agonists 
may be either stimulatory or inhibitory. In consequence the 
corresponding second messenger systems also can be designated 
either inhibitory or stimulatory (see Table 1).
2. Inhibition
Platelet inhibition, that is the prevention of function, 
is associated with the activation of adenylate cyclase and 
consequent elevation of the intracellular concentration of 
cAMP. Each of the inhibitory agonists in Table 1 have been 
shown to stimulate cAMP formation (Peinstein et al., I98I; 
Aktories & Jakobs, I985).
2.1 Agonists and receptors 
2 .1 (a) Prostacyclin;
Prostacyclin (PGI^) is synthesised by and secreted from, 
vascular endothelial cells (Moncada & Vane, 1979) and is the 
most potent endogenous anti-aggregatory agent known. It is 
formed by the action of PGI^ synthetase on the PG endoperoxides, 
however it is highly unstable and this has restricted the 

















Thromboxane A^ TP Stimulate
5HT SHTg Stimulate
Table 1. Platelet inhibitory and stimulatory agonists.
A selection of those agonists which either stimulate or inhibit human platelet 
functional responses, together with their receptor sub-types.
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studies have revealed two distinct PGI^ sites on the human 
platelet. The first is a high affinity, low capacity (50 sites/ 
cell, Kd = 10 nM) site which possesses the pharmacological 
properties of the functional receptor and the second is a low 
affinity, high capacity (4000 sites, Kd = 1.6 p,M) site (Siegl, 
1982; "Whittle et al. , I985). The PGT^ receptor conforms to 
the IP class of prostanoid receptor (Kennedy et al., I983).
2.1 (b) Prostaglandin :
Prostaglandin (PG) E^ is an inhibitor of platelet function 
some 30 times less potent than PGI^* Pharmacological studies 
in intact platelets and in lysates have indicated that PGE^ 
is an agonist at the IP receptor. Pre-exposure of the cells 
to PGIg render them insensitive to a subsequent addition of 
either PGI^ or PGE^ and in addition both eicosanoids displace 
-PGE^ from the receptor at comparable concentrations 
(whittle e_fc aT. , I983; MacIntyre e_fc aT. , I986).
2.1 (c) Prostaglandin ;
PGD^ is an anti-aggregatory, vasoconstrictory and anti­
neoplastic agent. It is 10 times less potent than PGI^ in 
respect of anti-aggregatory activity. Radioligand analyses 
have identified a single class of binding site (76O sites/cell). 
Structure activity relationships suggest that this site, 
designated DP, differs from those mediating vasoconstriction 




Adenosine at low concentrations inhibit platelet function. 
The presence of an adenosine uptake process in the platelet 
has until recently hindered binding studies. However, studies 
utilising a novel adenosine analogue indicates that the 
receptor conforms to the A^ class of adenosine receptors (Ukena 
et al., 1986). In addition to this extracellular receptor 
there may be an intracellular receptor, probably a purino- 
receptor, which may be activated at higher concentrations and 
oppose the actions of the extracellular receptor (MacIntyre 
et al., 1986).
2.1 (e) Adrenaline;
As indicated on Table 1, adrenaline can either activate 
or inhibit the platelet depending on which receptor is activated. 
The mediated activation is the dominant response in the 
human platelet, however the specific agonist isoprenaline 
inhibits responses to agonists such as ADP. The use of ligand 
binding studies, selective agonists and antagonists indicate 
that the receptor is of the  ^ subtype and that there are 
25-66 receptors per platelet (Kerry & Scrutton, I985).
2.2 G proteins
The inhibitory compounds, PGI^» PGE^, PGD^» adenosine 
and 1^ 2 specific agonists all exert their activity via the 
stimulation of adenylate cyclase and the consequent production 
of cAMP (Aktories & Jakobs, I985). The transduction process 
mediating adenylate cyclase activity involves a pair of G 
proteins (see Figure 3). The first, termed N^, is associated 











Figure 3. Regulation of cyclic AMP formation by platelets, 
See text for details.
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is responsible for agonist induced inhibition of the enzyme 
(Rodbell> 1980). Each of these G proteins consist of three 
subunits alpha, beta and gamma and in both cases beta and 
gamma are identical.
The binding of an inhibitory agonist to its receptor 
induces a conformational change in the receptor. This change 
is transmitted through to which becomes susceptible to GTP 
which approaches from within the cell. The interaction of GTP 
constitutes the "on reaction" enabling it to activate adenylate 
cyclase (Berridge, 1985)» The precise mechanism is unclear 
although it is believed that some form of inhibition of the act­
ive a subunit is exerted by the beta-gamma complex and this 
inhibition is removed by receptor occupancy (Jacobs aT.,
1986). The activity of the active species of is terminated 
by the hydrolysis of the GTP to GDP by a GTPase inherent in 
the a subunit.
A similar series of events occurs during the inhibition of 
adenylate cyclase by N^. The effect of an inhibition of adenylate 
cyclase would be to decrease the cAMP levels within the cell, 
although the functional significance of this in the platelet 
is controversial.
The alpha subunits are targets for the actions of cholera 
and pertussis toxins. Cholera toxin catalyses the ADP-ribo— 
sylation of the alpha subunit of N^. This has the effect of 
inhibiting the GTPase activity of N^, therefore there is no 
hydrolysis of GTP and so is permanently active increasing 
the cellular cAMP content (Cassel & Selinger, 1977)* Similarly
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pertussis toxin ADP—ribosylates prevents its activation
and so prevents those agonists which would inhibit cellular 
activity having any effect (Jakobs e_fc ad., I986). In fact 
platelets do not contain the appropriate receptor (ganglioside) 
to which the toxins must bind before being internalised and 
therefore neither can be studied in intact platelets, however 
they have been studied in platelet membrane fractions.
2.3 Adenylate cyclase
The effector mediating inhibition in the platelet is 
adenylate cyclase. This is the enzyme (mol.wgt. 150,000) 
which converts a metal-ATP complex, most probably MgATP, into 
the intracellular second messenger cAMP. It appears to be a 
glycoprotein which traverses the plasma membrane, although 
the physiological significance of this is unknown (Pfeuffer 
et al., 1985)* The enzyme can be directly activated by forskolin, 
a diterpine isolated from the Indian plant Coleus forskohlii, 
which elevates cAMP in intact platelets and inhibits platelet 
aggregation (insel _et ad., I982).
2»k Cyclic AMP
The product of stimulated adenylate cyclase activity is 
elevated cytoplasmic levels of cAMP. When synthesised this 
cyclic nucleotide diffuses into the cytoplasm and activates 
a cAMP dependent protein kinase(s) (Krebs & Beavo, 1979)* There 
is evidence however that it is not the total cellular cAMP 
content which is critical for the activity of these kinases 
but the activity of a smaller specific cAMP pool. The specific
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targets for these kinases have not been delineated, however 
the phosphorylation (and any subsequent dephosphorylations) 
are not regarded as simple "on-off" mechanisms. The alterations 
in the levels of protein phosphorylation regulated by the 
kinases serves as a precise method of regulating cellular 
response (Cohen, 1982). The cAMP is metabolised to 5 * AMP by 
the action of a cAMP-specific phosphodiesterase. Non specific 
phosphodiesterase inhibitors, such as isobutyl methyl xanthine 
(iBMX), prevent cAMP metabolism and potentiate the inhibitory 
effects of adenylate cyclase stimulants.
2.5 Site of inhibition
Acting through cAMP dependent protein kinase activities, 
cAMP potentially may mediate inhibition of the platelet 
activation pathway in a variety of ways. The precise site of 
cAMP dependent regulation is unknown but it could be at one 
or more of the following points;-
a) It may interfere with the platelet stimulatory trans­
duction process thereby limiting the production of various 
second messengers. It has been shown to interfere with 
phospholipase C activity (Lapetina ad., 1977) and the 
consequent production of inositol phosphates (Vatson ejt ad. , 1984)
b) It may enhance the removal, or metabolism of stimulatory 
second messengers and so terminate their effects. Cyclic AMP 
inhibits and reverses agonist induced elevation of cytosolic 
Ca^ '*’ levels (Peinstein eJb ad., I983; Zavoico & Peinstein, 1984; 
MacIntyre e_t ad., 1983a). In addition cAMP stimulates the 
active sequestration of Ca^* into purified platelet intracellular
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membrane preparations (Kaser-Glanzmann ejb ad• , 1977)*
c) It may impede protein phosphorylation (or stimulate 
dephosphorylation) or indeed inhibit the activity of those 
phosphorylated proteins required for cellular reactivity.
In support of this PGE^ inhibits the phosphorylation of proteins 
which have been implicated in platelet activation (Lyons et ad.,
1975).
3 * stimulation
The obvious converse to the observation that elevated 
cAMP levels inhibit platelet function, is that a decrease in 
the resting cAMP levels activate the platelet (Salzman, 1972). 
However, no agonist has been shown to have such an effect, 
although adrenaline and ADP both reverse cAMP levels elevated 
by adenylate cyclase stimulants (Mills, 1974). In addition 
thrombin, adrenaline, ADP, vasopressin and TxA^ all inhibit 
adenylate cyclase in platelet membranes (Aktories & Jakobs,
1985; Vanderwel et al., I983; Miller & Gorman, 1976). The 
functional significance of stimulatory agonists on total cAMP 
content is unclear although the possibility that adenylate 
cyclase inhibition is involved in activation must be taken 
into account (Aktories & Jakobs, I985)* Since there are 
distinct compartments of cAMP in platelets (Hashimoto, 1983); 
the possibility exists that regulation of adenylate cyclase 
by agonists may play an important role in cellular reactions 
in the absence of demonstrable changes in the overall level 
of cAMP.
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stimulation of human platelets, in common with other 
secretory cells, has been associated with a rise in the levels 
of cytoplasmic calcium ( [ca^^] ^  ) (Gerrard ejb ad., I98I). In 
1973; Michell related increased |ca^^]^ to the hydrolysis of 
the phospholipid phosphatidylinositoi (Ptd Ins) and hypothesised 
that this phospholipase C catalysed event serves as a trans­
duction process leading to the gating of Ca^ "*" (Michell, 1975)*
It is now accepted that the agonist stimulated hydrolysis of 
a family of inositol phospholipids generates two products 
(d a g  and Ins(l,4,3)P^) both of which may function as second 
messengers in stimulated cells. Ins(l,4,3)P^ seems to act 
by mobilizing intracellular Ca^ "*" stores, whereas DAG stimulates 
protein phosphorylation (Berridge, 1984). Platelet stimulatory 
agonists such as thrombin, PAF, 3HT, TxA^ and vasopressin are 
believed to exert their effects at least in part by such a 
mechanism.
3*1 Agonists and receptors 
3*l(a) ADP;
ADP is a platelet stimulatory agonist which induces the 
whole range of functional responses. Binding studies, using 
stable analogues due to the instability of the parent compound, 
indicate a single class of binding site with 400-1200 sites 
per cell (Macfarlane ejb ad., 1983)* It appears that the 




Platelets remove 3HT from the blood by an avid and 
specific uptake system. In addition this biogenic amine is 
a weak platelet stimulant acting on specific receptors (probably 
260 per cell) which are of the 3HT^ subtype (de Clerk al.> 
1984; de Chaffoy de Courcelles e_t al. , I983).
3 .1 (c) Thromboxane ;
TxA^ is synthesised in and released from stimulated 
platelets (Rittenhouse-Simmons & Deykin, I98I) and acts as a 
pro-aggregatory and vasoconstrictor agent. The effects of TxA^ 
on platelets are shared by the prostaglandin endoperoxides 
PGG^ and PGH^. The instability of these compounds led to the 
synthesis of a battery of stable analogues such as U44o69,
U46619 (Bundy, 1975) and EPI7I (Jones ^  , I985). Although
two binding sites exist on platelet plasma membranes, only 
one (2000 sites per platelet) relates to the phannacological 
characteristics of receptor mediated activation (MacIntyre 
et al., 1986). This receptor is of the TP class of prostanoid
receptor (Kennedy e_t al. , I983) and is linked to inositol
phospholipid hydrolysis.
3 .1 (d) Platelet activating factor;
The biologically active ether lipid, PAE, has dramatic 
cardiovascular and bronchopulmonary effects in experimental 
animals, including hypotension and bronchoconstriction. At 
the cellular level PAF stimulates, amongst others, rat, rabbit 
and human neutrophils and also rabbit and human platelets
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(Roth, 1986). Numerous studies have failed to conclude 
whether there are multiple types of PAF binding sites on 
the platelet plasma membrane. However on the basis of the 
antagonistic effect of kadsurenone, the PAF receptor on the 
human platelet (termed Paf^) differs from that on the macrophage 
(termed Paf^) (Lambrecht & Parnham, I986).
3.1 (e) Vasopressin;
Vasopressin is the most potent endogenous pressor agent 
known and possesses anti diuresis activity. In addition 
vasopressin stimulates the human platelet via a specific 
receptor although the physiological significance of this 
activation is unclear. There are around 9O-I5O sites per 
platelet (Pletscher aT., I985) and, in common with vascular 
smooth muscle, they are the inositol phospholipid linked V^ 
type (Siess ejfc aT., I986; Pollock & MacIntyre, I986).
3 .1 (f) Thrombin;
Thrombin is the most efficacious and potent platelet agonist. 
It is a serine protease with catalytic activity against the 
carboxyl linkage of arginine residues and this activity is a 
pre-requisite for platelet activation. Two classes of binding 
site have been identified on the platelet, a high affinity 
(500 sites, Kd = 10 nM) and a low affinity (50,000 sites,
100 nM). It has been proposed that one of these sites is 
Glycoprotein V which is the only known thrombin substrate on 
the plasma membrane. Although the high affinity site correlates 
in many respects to platelet activation, the functional 
significance of the binding sites has been challenged. It
—  28 —
is possible to remove almost all of the Glycoprotein V without 
impairing thrombin induced platelet activation. Inactive 
thrombin, that is with the active site blocked, as well as 
active thrombin binds to the platelet and thrombin analogues 
can stimulate without detectable binding. This suggests that 
active thrombin modulates the receptor and stimulates the 
platelet without remaining bound to the receptor (Detwiler & 
McGowan, 1983). The discovery of a partial agonist which 
inhibits thrombin induced activation with no effect on its 
proteolytic activity (Ruda aT., I983), perhaps indicates a
twin stimulation via both an agonist receptor interaction and 
a catalytic activity (MacIntyre ejb aT. , I986).
3.1(g) Adrenaline;
The stimulatory effects of adrenaline are mediated by 
the adrenoceptor of which there are around 270 sites per 
platelet (Kerry & Scrutton, I983). Adrenaline causes both 
platelet aggregation itself (O'Brien, I963) and potentiates 
aggregation induced by other agents (Mills & Roberts, 1967). 
However adrenaline induced aggregation differs from other 
agonists as it is not preceded by shape change. In addition, 
adrenaline induced activity is not associated with an increase 
in (MacIntyre ejb ad., 1983b) and the receptor is




The involvement of G proteins as the transduction process 
in the inositol phospholipid mediated activation of platelets 
has not been conclusively demonstrated. In platelets permeabilise 
by high voltage electric charges, Ca^* induces 3HT release and 
this release is greatly potentiated by GTP and its analogues 
(Haslam & Davidson, 1984a). In addition, in these platelets 
there is increased production of DAG in the presence of GTP 
(Haslam & Davidson, 1984b). This suggests that G proteins do 
play a role in platelet stimulation. It is unclear whether 
these G proteins are identical to, or interact with, those 
involved in the regulation of the adenylate cyclase system.
3*3 Calcium
Ringer, in 1883, demonstrated the absolute dependence on
2+Ca for continued contraction of the heart. In further 
classical studies Katz (Katz, I969) and Douglas (Douglas, 1974), 
amongst others, observed that physiological responses required 
extracellular Ca^* and this prompted the proposal that many 
agonist evoked responses involved Ca^* as a second messenger.
Calcium is perhaps the most extensively investigated and 
generally accepted intracellular second messenger in platelets 
(Gerrard et al., I98I). The evidence for a central role for Ca^* 
in platelets is partly circumstantial (by analogy with other 
cells) and partly indirect.' Calcium is clearly a primary 
coupling agent in contractile tissue and secretory cells 
(Rasmussen & Barrett, 1984) and therefore by analogy a role 
has been postulated for it in platelets. Indirect evidence
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for the involvement of stems from the ability of the
ionophore A23187 to activate platelets in a manner similar 
to thrombin (Feinman & Detwiler, 1974; White et al., 1974).
The mechanism of action of A23187 is not clear and is complicated
as A23187 activates platelets equally well in an extracellular
2+ 2+ medium containing 1 mM Ca or 1 mM EGTA, a Ca chelating
agent which renders the bathing medium nominally Ca^^ free
(Feinman & Detwiler, 1974). Further evidence for a role of
Ca^ "*" in platelet activation is provided by the demonstration
that a variety of drugs which have been proposed to block
calmodulin mediated, calcium dependent processes also block
platelet responses to several agonists (Huang & Detwiler, 1986a).
The advent of the fluorescent calcium indicator dye.
Quin 2 (Tsien et al., I982) allowed, for the first time, the 
quantification of both basal and stimulated j^Ca^^ . Rink 
and colleagues concluded that in quiescent platelets the 
resting ^ was about 100 nM. When challenged with thrombin
or ionomycin this rose to 3 P-M, in the presence of 1 mM 
extracellular Ca^*, or to 200-300 nM in its absence (Rink 
et al., 1982). This may suggest that agonists stimulate both 
the influx of Ca^* from the external environment and mobilise 
Ca^* from internal stores (MacIntyre e_fc a^., 1985b). Although 
dense granules, mitochondria, alpha granules and the internal 
surface of the plasma membrane all contain Ca^ "*" (Murer, 1969,
Sato e_t ad., 1973); it is popularly believed that the dense 
tubular system is the source of this mobilised Ca^* (White,
1972). Shape change, dense granular secretion and aggregation
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induced by ionophore was observed to occur at |ca^^j ^  levels 
of 0 .5 » 0.8 and 2 p-M respectively. However this correlation 
was not absolute as thrombin stimulated more secretion than 
an ionophore concentration which elicited a comparable rise 
in |ca^^j . In addition thrombin induced shape change of 
platelets at values below the threshold (0.3 p-M)
described above. This indicates that agonists must evoke 
additional mechanisms or second messengers besides the evoked 
increase in [ca^^j .
The mechanism(s) underlying the agonist induced increase
in ^a^^j have been the subject of numerous studies. The
translocation of Ca^^ from the extracellular space to the
intracellular environment is believed to be achieved by the
opening of specific calcium channels in the plasma membrane
allowing the Ca^* to enter the cell down its concentration
gradient. There are a variety of such channels in biological
tissues. There are voltage operated channels (VOCs) which are
opened by the depolarisation of the cellular membrane. These
VOCs are particularly prevalent in tissues such as smooth
muscle (Bolton, 1979)* The second type of channel are termed
receptor operated (rOCs ) and are opened as a direct consequence
of receptor occupancy. In the case of human platelets,
receptor mediated activation occurs in the absence of any
detectable change in the membrane potential. Consequently
agonist induced Ca^* influx must occur via ROCs (MacIntyre
& Rink, 1982; Doyle & Ruegg, I983)» The mobilisation of 
2+internal Ca stores must depend upon the generation of
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intracellular mediators which cause the liberation of the Ca^* 
from the bound pool. Studies concerned with elucidating 
the mechanism of both Ca^* influx and mobilisation have centered 
on the metabolism of a family of acidic phospholipids, the 
phosphoinositides.
3•^ The phosphoinositide cycle
The original concept expounded by Michell, was that phospho- 
lipase C activity resulted in the hydrolysis of Ptd Ins to form 
DAG and a mixture of two water soluble products inositol 1 
phosphate (ins IP) and inositol 1,2-(cyclic) phosphate (lns(l,2- 
cyc)p). DAG would be rapidly phosphorylated, by DAG kinase, 
to phosphatidic acid (Ptd OH) which, in turn, is converted to 
CDP-DAG by CTP (Ptd OH) cytidyl transferase. This CDP-DAG 
would combine with free inositol, liberated from the inositol 
phosphates by phosphatases, to reform Ptd Ins, under the action 
of CDP-DAG inositol transferase, thereby completing what was 
popularly termed the "Ptd Ins cycle". Michell proposed that 
receptor occupancy accelerated the rate of turnover of this 
cycle and by some mechanism, possibly due to ionophoric actions 
of Ptd OH (or of lyso Ptd OH), this would increase the 
permeability of the cellular membrane to the Ca^* which mediated 
the final response (normally secretion). The intervening 
eleven years has shown that, not only is this system present 
in cells as diverse as brain (Berridge at aT., I983) and insect 
salivary gland (Berridge, 1983)» but also that the process is 
a great deal more complex than outlined above. Figure 4 details
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what has been shown, and what has been proposed, to occur 
in a broad spectra of cells including platelets.
Ptd Ins and its phosphorylated derivatives Ptd Ins 4 
phosphate (PIP) and Ptd Ins 4,3 bisphosphate (PIP^) (Figure 3) 
are relatively minor constituents of the mammalian plasma 
membrane representing about 39^  of the total cellular phospho­
lipid (Marcus at ad., 1969)» Ptd Ins is a typical phospholipid, 
situated primarily on the inner leaflet of the membrane bilayer. 
However it is unusual as it forms two derivatives by a pair 
of apparently futile, rapid turnover cycles. Ptd Ins kinase 
phosphorylates Ptd Ins, at position 4 on the sugar ring, to 
yield PIP which is further phosphorylated at position 3 to form 
PIP^» Conversely these phosphate groups are removed by PIP 
phosphatase and PIP^ phosphatase respectively. Ptd Ins remains 
the major inositol phospholipid representing of the total
phosphoinositide pool. The polyphosphoinositides, especially 
PIP^j have the unique physicochemical property of having a 
very high affinity for Ca^* (greater than that of EDTA)
(Hirasawa & Nishizuka, 1983)»
It has been shown in a variety of cells that the first 
inositol phosphate to be detected after agonist addition is 
Ins(l,4,3)P^ (Figure 6) and not Ins IP (Berridge, I983; Martin, 
1983; Drummond at ad., 1984). In addition when platelets were 
challenged with thrombin this initial accumulation of Ins(l,4,3)P^ 
coincides with decreased levels of PTP^ (Agranoff at ad., 1983)*
As a consequence of such studies it is now believed that it is 
PIP^ which is initially hydrolysed by phospholipase C in response 
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Figure 4. The phoephoinositide cycle.
This representation demonstrates the complex nature of the cycle. 
Receptor mediated phospholipase C activity results in the hydrolysis 
of one or more of the inositol phospholipids with the generation of 
DAG and, possibly a variety of inositol phosphates. The inositol 
phosphates and DAG are then incorporated in cycles leading to the 
resynthesis of the phosphoinositides.
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Figure 5. Structures of the inositol phospholipids.














Ins(l,2-cyc)P Ins(1,2-cyc,4)P2 Ins( l ,2 -cyc,4 ,5)P
Figure 6. Structure of inositol phosphates.
InslP-Inositol 1 phosphate; Ins(l,4)P2-Inositol 4,5 bisphosphate;
Ins(l,4,5)P -Inositol 1,4,5 trisphosphate; Ins 4P-Inositol 4 phosphate; 
Ins(l,3,4)P -Inositol 1,3,4 trisphosphate; Ins(l,3,4 ,5)P^-Inositol
1,3,4,5 tetrakisphosphate; Ins(l,2-cyc)P-Inositol 1,2-Ccyclic) phosphate; 
Ins(l,2-cyc,4)p2-Inositol l,2-(cyclic) 4 bisphosphate; Ins(l,2-cyc, 4,5)Pg- 
Inositol l,2-(cyclic) 4,5 trisphosphate.
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The role of Ptd Ins and of PIP in platelet activation 
is the subject of some controversy. There is a marked decrease 
in the levels of both phospholipids in response to agonist 
stimulation although this occurs significantly later than that 
of PIP^' In addition the formation of Ins(l,4,3)P^ and 
inositol (l,4) bisphosphate (lns(l,4)P2) is followed by increased 
levels of Ins IP and free inositol (Agranoff et al., I983;
Watson et al., 1984; Siess & Binder, 1983)» These observations 
are consistent with one of two possible mechanisms. There may 
be direct hydrolysis of Ptd Ins and PIP, which would liberate 
Ins IP and Ins(l,4)P2 respectively, occurring after the initial 
PIP^ breakdown (Wilson _et ad., 1983c; Majerus e_fc ad., 1983)» 
Alternatively Ptd Ins may act as a phospholipid pool which 
replenishes the PIP^ hydrolysed (Michell e_fc ad., I98I). Thus 
the lower phosphorylated inositol derivatives would be formed 
by déphosphorylation of Ins(l,4,3)P^ (Downes e_t ad., 1982; 
Berridge e;fc ad., 1983)*
The enzymes which convert Ins(l,4)P2 to Ins IP and Ins IP 
to myo—inositol are believed to be inhibited by lithium 
(Hallicher & Sherman, I98O; Huang & Detwiler, 1986b) and this 
blockade would limit the supply of inositol for phospholipid 
resynthesis. However a second metabolic pathway might exist 
which involves the conversion of Ins(l,4)P2 to inositol 4 
phosphate (lns4P) and inositol (Storey ejb ad., 1984) and this 
pathway is believed to be insensitive to lithium although 
the relative importance of each is unknown (Michell, I986).
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The complexity of the system is further indicated by 
reports of the accumulation of the inositol (l,3>4) tris­
phosphate (ins(l,3>4)P^; Figure 6) isomer in stimulated cells 
(Irvine e_k ad. , 1983; Burgess ejfc ad. , I983) although this has 
not, as yet, been demonstrated in platelets. The formation 
of Ins(l,3>4)P^ occurs after that of Ins(l,4,3)P^ as does its 
decline on removal of the stimulus. The source of Ins(l,3>4)P^ 
is now thought to be inositol 1,3>4,3 tetrakisphosphate 
(lns(l,3,4,3)P^; Figure 6). Ins(l,3;4,3)P^ is formed as rapidly
as Ins(l,4,3)P^ in rat cerebral cortical slices challenged 
with muscarinic agonists (Batty e_t ad. , 1983)» There is evidence 
that Ins(1 ,3>4,3)P^ is formed from Ins(l,4,3)P^ by the activity 
of an ATP dependent kinase (Michell, I986). Hence the metabolism 
of Ins(l,4,3)P^ via Ins(l,3»4,3)P^ and Ins(l,3>4)P^ may be 
quantitatively as important as its déphosphorylation to 
Ins(l,4)P^ (Michell, I986). The alternative is that another, 
as yet undetected, inositol phospholipid (PIP^) may exist, 
the hydrolysis of which would directly yield Ins(l,3;4,3)P^
(Batty e_fc ad., I983)*
Until recently the only cyclic phosphate believed to be 
synthesised was Ins(l,2-cyc)P. However in studies using less 
acidic extraction procedures, Majerus and colleagues demonstrated 
the isolation and characterisation of inositol l,2-(cyclic) 
4-bisphosphate (ins(l,2-cyc,4 )P2 ) and inositol 1 ,2- (cyclic)
4 ,3-trisphosphate (lns(l,2-cyc,4,3 )P^), the two cyclic 
phosphate products of PIP and PIP^ respectively (Wilson ^  ,
1983a,b). Indeed it has been proposed that Ins(l,2-cyc,4,3)P^
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is the major product of phosphoinositide metabolism in thrombin 
stimulated platelets (Majerus et al» > I986).
In contrast to the situation involving the formation of 
inositol phosphates (Figure 6), the formation of DAG, Ptd OH 
and CDP-DAG (Figure 7) remains identical to Michell's original 
proposal. The only point of contention is the source of DAG 
as it can be formed by the action of phospholipase C on one 
or all of the inositol phospholipids. DAG is converted by 
DAG kinase to Ptd OH utilising ATP. Ptd OH is, along with 
CTP, then converted to CDP-DAG by CTP (Ptd OH) cytidyl 
transferase which combines with myo-inositol (from whatever 
source) to reform Ptd Ins.
3•5 Phosphatidic acid and lyso phosphatidic acid
Initially the prime candidate for an intracellular mediator
of elevated ^a^^j was Ptd OH. Ptd OH was shown to be a 
Ca^* ionophore (Tyson e_t al. , 1976) and therefore it was 
proposed that it was important in Ca^* mediated cellular 
activation (Michell e_t al. , 1977)* There are however several 
lines of evidence which would challenge this as being the 
sole mechanism involved in the elevation of jca^ '*'j^ . Firstly, 
the formation of Ptd OH may not occur rapidly enough to account 
for the Ca^* influx and secondly it is now debatable whether 
Ptd OH does possess ionophoric activity (Holmes & Yoss, I983) 
or increase Ca^* permeability (Putney, I986 ).
Lyso Ptd OH, which is formed in the platelet by the 
activity of phospholipase A^ on Ptd OH, is a potent pro-
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Figure 7. Structures of diglycerides.
DAG-1,2 Diacylglycerol; Ptd OH-Phosphatidic acid; CDP-DAG- 
Cytidine diphosphate diacylglycerol.
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aggregatory agent and it has been suggested that lyso Ptd OH,
rather than Ptd OH, may be an important intracellular messenger
via an ionophoric activity (Benton , I982). However not
2+otily is lyso Ptd OH unable to translate Ca across liposomes 
(Lapetina & Watson, I985) but they also stimulate platelets 
via a cell surface receptor (Watson e_fc ad., 1983a). It is 
therefore unlikely that lyso Ptd OH is a second messenger in 
agonist induced platelet activation.
3*6 Inositol phosphates
2+The formation of a Ca mobilising second messenger must 
be extremely rapid as, by definition, it must precede the 
increase in |ca^^j . Berridge demonstrated the liberation of 
Ins(1 ,4 ,3)P^ in the blowfly salivary gland within 3 seconds of 
challenge with 3HT (Berridge, I983)* The possibility of a 
second messenger role for Ins(l,4,3)P^ was enhanced when, in 
permeabilised pancreatic acinar cells, Ins(l,4,3)P^ was shown 
to release Ca^* from an intracellular, non mitochondrial store 
(Streb al., I983)* This has subsequently been demonstrated 
in a variety of tissues including hepatocytes (Burgess e_fc ad., 
1984), vascular smooth muscle (Somlyo ejb ad., 1983)» skeletad 
muscle (Vergara ad., I983) and platelets (O'Rourke ejb al.,
1983; Authi & Crawford, I983)*
In addition Ins(l,4,3)P^ induces platelet aggregation 
and 3HT release in a manner similar to thrombin (Authi e_fc ad., 
1986; Watson e_t , I986). These effects, however, were 
abolished by cyclo oxygenase blockade indicating that Ins(l,4,3)P^
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induced Ca^* mobilisation activates phospholipase A^. The
PG endoperoxides and TxA^ generated as a result induce platelet
activation via external receptors.
An intracellular Ins(l,4,3)P^ acceptor has recently been
identified in hepatocytes (Spat et al., I986) and adrenal cortex
(Baukal et al., I986). Although Ins(l,4,5)P^ is the most potent
mobilising compound, other inositol phosphates, Ins(2,4,3)P^
and Tns(4 ,3)P2 * both bind to the acceptor (Spat jet ad., I986)
and mobilise Ca^* (Burgess ^  ^ . , 1984). Ins(l,4 )P2> Ins IP,
Ins(1 ,2-cyc)P and Ins(l,3;4)P^ neither bind to the acceptor
nor mobilise Ca^* thereby strengthening the correlation between
binding and release.
The cyclic phosphate. Ins(l,2-cyc,4,3)P^> which has been
reported to be the major product in thrombin stimulated platelets
(Majerus et al., I986) can also mobilise Ca^* in permeabilised
platelets (Wilson eJb ad., 1983b). Ins (l, 2-cyc, 4, 3 )P^ is the
only cyclic inositol phosphate possessing such activity,
however the characteristics of its binding to the intracellular
Ins(l,4,3)P^ acceptor have not been reported.
Recently Putney suggested a model which proposed an action
of Ins(1 ,4,3)P^ in the agonist stimulated influx of Ca^*. The
"capacative" model proposes that Ins(l,4,3)P^ activates the 
2+discharge of Ca from its intracellular store, situated at
the plasma membrane, into the cytosol. The decrease in the
Ca^* content of this pool relieves an inhibitory constraint on
2+a direct pathway for extracellular Ca to enter the pool. In
2 +
L
into the cytosol down the concentration gradient thereby
the continued presence of Ins (l, 4, 3 )P^> Ca will continue
- 39 -
sustaining Ca^+ entry into the cell (Putney, I986). Ins(l,3 ,
may promote the rapid release of sequestered Ca^* from 
liver plasma membranes (Hansen ^  ad., I986). It is possible 
that it is the formation of Ins(l,3;4,3)P^; involving a 
metabolically expensive process, and not Ins(l,4,5)P^ which is 
responsible for the translocation of Ca^’*’ across the plasma 
membrane of stimulated cells.
3•7 Diacylglycerol
The other major product of phosphoinositide hydrolysis is 
DAG which also has an important second messenger role in that 
it activates protein kinase C with the resultant protein 
phosphorylation which, in turn, has been implicated in platelet 
function (Takai ejfc al. , 1979> 1981a).
DAG is normally absent from membranes, but upon stimulation
by agonists, very rapid increases have been measured in platelets
(Rittenhouse-Simmons, 1979) and other cells (Berridge, 1984).
The activation of protein kinase C by DAG is a complex process
2+that requires Ca and Ptd Ser as co-factors. It appears 
that relatively small amounts of DAG dramatically increases 
the affinity of protein kinase C for Ca^ "*" thereby fully 
activating the enzyme at resting jca^^j (Xishimoto ejb ad.,
1980). In the presence of DAG, protein kinase C becomes 
reversibly attached to membranes where it exerts its enzymatic 
activity. DAG is only transiently produced in membranes due 
both to its phosphorylation to Ptd OH and its degradation to 
liberate arachidonic acid. This transient appearance of DAG 
in membranes is always associated with activation of protein
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kinase C (Huang & Detwiler, 1986a).
The activation of protein kinase C by DAG is mimicked by 
the tumour promoting class of compounds, the phorbol esters 
(Castagna e_fc al., I982). Phorbol esters, such as phorbol 12 
myristate I3 acetate (PMA; 12 0 tetradecanoylphorbol I3 acetate; 
Figure 8), have structural similarities to DAG (Figure 7 ) and 
are capable of causing platelet aggregation (Zucker e_t ad. ,
1974) and release (White et ad., 1974). Like DAG, phorbol esters
increase the affinity of protein kinase 0 for Ca^* resulting
in enzymatic activity and platelet activation without detectable 
mobilisation of Ca^ **’ (Rink £t ^ .  , I983). Once again Ptd Ser 
appears to be a necessary co-factor (Nishizuka, 1984). In 
contrast to the transient nature of DAG accumulation, phorbol 
esters are metabolised very slowly and so activate protein 
kinase C for a prolonged period.
The use of phorbol esters (or of the synthetic DAG, 1 
oleoyl 2 acetyl glycerol, GAG) in concert with Ca^* ionophores 
has demonstrated a marked synergism in their abilities to 
elicit the physiological response (Yamanishi ejb aJ^ . , 1983;
Halenda e_fc ad., I983). The balance of these two synergistic 
pathways, both emanating from phosphoinositide hydrolysis, 
may exert differential control over different processes within 
a single activated cell, such as the agonist selectivity











Figure 8. Structures of phorbol compounds.
Upper-Phorbol 12 myristate 13 acetate (PMA; active compound). 
Lower-4# -Phorbol (inactive analogue).
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3*8 Protein phosphorylation
Stimulation of platelets by thrombin is associated with 
the phosphorylation of a number of proteins. The two most 
readily observed have a of 20,000 and a of 40,000-4?,000,
termed 20K and 40K respectively (Lyons ejb al • , 1975; Haslam & 
Lynham, 1977)* In addition phosphorylation of proteins with 
= 56,000 and 81,000 (Wallace & Bensusan, I98O), of actin 
binding protein (Carrol & Gerrard, I982) and the delayed 
phosphorylation of a protein with of 27>000 (Chambard & 
Pouyssegur, I983) have all been reported. Most attention has, 
however, been given to the 2OK and 4OK proteins, phosphorylation 
of which correlates to secretion but not to aggregation (Haslam 
& Lynham, 1977)*
The 2OK protein has been identified as a light chain of 
myosin and its phosphorylation by a calcium calmodulin dependent 
protein kinase, as a consequence of elevated jca^^j^, enhances 
actin activated myosin ATPase activity (Adelstein & Conti, 1975)* 
The 20K protein regulates the contractility of actomyosin and 
its phosphorylation parallels the association of myosin with 
cytoskeletal proteins in platelets (Huang & Detwiler, 1986a).
The 4OK protein is one of the major substrates of protein 
kinase C and is phosphorylated when the enzyme is activated 
either by endogenous DAG or by phorbol esters (Castagna at ad., 
1982; Nishizuka, 1984). Recently it has been proposed that 
this protein has anti phospholipase A^ activity and its 
phosphorylation removes this inhibitory constraint thereby 
mobilising arachidonic acid (fouqui et al., I986). In addition 
a 4OK protein has been isolated from stimulated platelets which
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lias been demonstrated to bave Ins(lj4,5)P^ phosphatase 
activity (Connolly & Majerus, I986). Therefore, the 4OK 
protein may not be a single moiety, but a combination of a 
number of active species each with a M^ of approximately 4OK 
which have not yet been identified individually* Little is 
known of the functions of the other proteins which are 
phosphorylated in response to stimuli.
3*9 Arachidonic acid
Eicosanoids, such as PGG^, PGH^ and TxA^, are secreted 
from platelets in response to agonists. It has been proposed 
that the agonist dependent hydrolysis of phosphoinositides 
plays a vital role in this release (Bell ejfc al. , 1979» Ritten- 
house, 1982). The fatty acid on position of 2 of the phospho­
inositides is normally arachidonate although oleate and linoleate 
may also be present. However during agonist stimulation 
phospholipase C activity is preferentially directed against 
those phosphoinositides containing arachidonate, such that all 
the DAG and Ptd OH formed has arachidonate in position 2 
(Bell al., 1979)* Several mechanisms for the release of 
arachidonate have been proposed.
i) Direct déacylation of phospholipids by a phospholipase 
A^ type enzyme (McKean ^  al. , I98I; Bills al. , 1977)*
ii) Déacylation by a phospholipase A^ activity followed 
by a lysophospholipase.
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iii) Sequential activation of Ptd Ins specific phospholipase 
C followed by DAG lipase and MAG lipase (Bell ^  , 1979;
Prescott & Majerus, I983).
iv) Sequential activation of Ptd Ins specific phospholipase 
C, DAG kinase and Ptd OH specific phospholipase A^ (Billah et al.; 
I98I; Lapetina, I982).
It is possible that eicosanoids serve as positive feedback 
second messengers in platelet activation particularly as 
cyclooxygenase inhibitors reduce, not only platelet responsiveness 
but also the hydrolysis of Ptd Ins, the formation of DAG induced 
by collagen (Rittenhouse & Allan, I982) and the formation of 
Ptd OH induced by low concentrations of thrombin (Siess at al.,
1983a).
3.10 cGMP
In platelets, in common with other cells (Michell, 1975)» 
agonists which trigger phosphoinositide hydrolysis also stimulate 
guanylate cyclase activity to form cGMP (White ejb aT. , 1973;
Haslam ab ad., I980). The mechanism of this stimulation is 
unclear but seems to depend upon an increase in |ca^^j 
(Berridge, 1984).
Haslam and McClenaghan (1974) proposed a role for cGMP 
in the platelet release reaction. Davies and colleagues 
(Davies ejt ad., 1976) correlated cGMP levels with aggregation 
although probably as a consequence rather than as a cause.
However 5HT and adrenaline elevate cGMP levels with no 
aggregation (Laubscher & Pletscher, I980) and these authors 
suggested that cGMP generation was secondary to platelet
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activation. The function of cGMP in platelet activation is 
I^]^ther complicated by inhibitory effects of the guanylate 
cyclase stimulant sodium nitroprusside on platelet activation 
(Glusa et , 1974; Levin e_fc , I982), elevated [ca^ '*'] ^  
(Kavahara et al., 1984), DAG formation and 4OK phosphorylation 
(Takai e_t ad., 1981b) suggesting perhaps a negative feedback 
role for cGMP.
4. Summarv
Figure 9 summarises the two transduction processes so far
identified in the human platelet.
Stimulatory agonists (A^) such as PAF, vasopressin, 5HT
and TxA^ combine with their specific cell surface receptors
which are linked, possibly via a G protein, to phospholipase C.
Activation of this enzyme results in the hydrolysis of one,
or more, of the inositol phospholipids with the consequent
production of DAG and a plethora of inositol phosphates. DAG,
although produced only transiently, activates a Ptd Ser and Ca^*
dependent enzyme, protein kinase C. Protein kinase C in turn
phosphorylates a protein(s) which has been implicated in platelet
function. IP^ (ins(l,4,5)P^ and/or Ins(l,2-cyc,4 , 5 )  release 
2+Ca from an intracellular, non-mitochondrial store, probably 
in the dense tubular system. This agonist induced increase 
in |ca^^] is enhanced by an influx from the external milieu.
The mechanism of this influx is unknown, although roles for 
Ptd OH, lyso Ptd OH, Ins(l,4,5)P^ and Ins(l,3,4,5)P^ have all 
been proposed. Regardless of the source of this Ca^*, it 
activates a calcium calmodulin dependent protein kinase which
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phosphorylates the light chain of myosin which plays a role 
in platelet stimulation and which may synergise with the 
DAG mediated activation#
The adenylate cyclase system is also active in the platelet, 
Inhibitory agonists (A^), such as PGI^f PGD^ and adenosine, 
acting on their specific receptors, activate adenylate cyclase 
via the stimulatory G protein, . This leads to elevated ' 
cAMP levels which in turn activate a cAMP-dependent protein 
kinase and the resultant protein phosphorylation inhibits 
platelet reactivity#
Whether the converse is true, that is decreased cAMP 
concentrations stimulates platelet function, as has been 
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Figure 9. Transduction processes in the human platelet.
This is a summary of the transduction processes present in the 
human platelet. represents a stimulatory agonist, such as PAF, 
vasopressin or TxA« and A„ represents an inhibitory agonist such 
as PGIg or PGD^.
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CHAPTER III; EXPERIMENTAL INDICES OF PLATELET REACTIVITY
There are a variety of measurements of platelet reactivity 
i-H vitro which allow the correlation to be made between cellular 
(functional) responses and various biochemical reactions.
1• Measurement of platelet functional responses to agonist 
exposure
1.1 Shape change
Platelet shape change vitro is monitored photometrically. 
With the exception of adrenaline, addition of an agonist to 
a stirred suspension of either platelet rich plasma or washed 
platelets causes a decrease in the amount of light transmitted 
in the plane perpendicular to the axis of stirring. This occurs 
as a direct result of the projection of pseudopodia from the 
cell body. Shape change, unlike aggregation, occurs in the 
absence of calcium in the extracellular environment (Zucker & 
Zaccardi, 1964). Born (l970) utilised this differential 
dependency upon divalent cations between these two functions 
to monitor shape change independently of aggregation. Chelating 
agents, such as EDTA, when added to platelet preparations 
prevented the platelet shape change from progressing to 
aggregation, and therefore allowed the former response to 
manifest itself fully.
1.2 Adhesion
Measurement of the adhesive properties of platelets vitro 
can be carried out by using the interaction between platelets 
and a glass surface. These employ a column of glass beads 
through which blood samples are passed and adhesiveness
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estimated by the difference in platelet count before and after 
passage through the column (Hellem, I96O; Salzman, I963). 
However, systems have now been devised which allow the exposure 
of natural vascular surfaces to blood in a controlled fluid 
dynamic environment, and the measurement of platelet adhesion 
by direct morphometric techniques (Baumgartner & Muggli, 1976; 
Sakariassen e_t t I983),
1.3 Aggregation
Aggregation is probably the most commonly measured platelet 
functional response. The standard method is a photometrical 
determination, which is simple and relatively inexpensive. Two 
novel approaches to the measurement of aggregation have been 
reported, both of which can be carried out in whole blood. 
Firstly it is possible to monitor the disappearance of single 
platelets, and secondly aggregation can be evaluated by an 
electronic method.
1 .3 (a) Photometric ;
In 1962 a photometric method was introduced for the 
investigation of the aggregation of platelets (Bom, I962).
A beam of light is directed through a suspension of platelets 
in plasma or in an artificial medium, the optical density of 
which is continuously recorded by measuring the transmitted 
light. The suspension is stirred at a rate sufficiently rapid 
to make the collision rate non limiting but insufficient to 
damage the cells. Agonist induced platelet aggregation causes 
the amount of transmitted light to increase and, conversely, 
when the aggregates disperse light transmission decreases.
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This method has been the most frequently used, however it is 
limited by its sensitivity. It requires the formation of 
relatively large aggregates before platelet activation can be 
detected# It has been estimated that platelets challenged 
with ADP induce the removal of 87^ of single cells with only 
79^  increase in light transmission (Born & Hume, 1967)» In 
addition the modulatory actions of other blood cells, which 
may occur in vivo, cannot be readily monitored using this 
technique. This criticism can also be levelled against other 
methods adopted to monitor platelet aggregation in cell 
suspensions using both optical (Silverstein, 1976) and electronic 
(Gordon, 1973; Reuter & Deters, 1979) techniques,
1 .3 (b) Single cell disappearance;
A novel method for the estimation of single platelet 
disappearance has been reported (Day e_t al., I98O; Lumley & 
Humphrey, I98I). This involves measuring the electrical 
impedance of platelets in whole blood which alters when a single 
platelet is removed (to form an aggregate). This method 
overcomes the limitations on the photometrical determination 
of platelet aggregation such as interaction of other blood 
cells and insensitivity.
1 .3 (c) Electronic measurement of aggregation;
Cardinal and Flower (1980) have also reported a method 
to monitor platelet aggregation in whole blood. A pair of 
electrodes are placed in a sample of blood and a small electric 
current passed between them. Platelets adhere to the electrodes, 
however in the presence of a stimulatory agonist the platelets
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form aggregates around the electrodes and consequently impede 
the conductance. This method of measuring platelet aggregation 
has advantages over photometric determinations for the reasons 
outlined above.
1.4 Release
Secretion from human platelets can occur by two mechanisms. 
Firstly degranulation may occur, that is the selective release 
of storage granule contents. The second mechanism involves 
the synthesis and liberation of eicosanoids, which are not 
stored in their releasable form. The most common techniques 
used to measure the platelet release reaction involve detection 
of the dense granule constituents 3HT and ATP as an index of 
degranulation and measurement of TxA^ formation as an index 
of stimulated synthesis of arachidonate metabolites.
1.4(a) 5HT;
3HT release can be monitored using isotope pre-labelling 
techniques (MacIntyre e_fc al., 1978). Platelets are incubated 
with radiolabelled ( j or ) 3HT for a period of time
which allows active uptake of the amine across the plasma 
membrane and incorporation of the label into the granules.
The platelets are challenged with an agonist, the reaction 
terminated by appropriate means, 3HT re-uptake blocked 
pharmacologically, the platelets pelleted by centrifugation 
and a sample of the cell-free supernatant counted for presence 
of radiolabel. By inclusion of appropriate unstimulated 
controls and measurement of intracellular radiolabel, the extent
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of stimulus—induced release of 5HT can be assessed.
1.4(b) ATP;
ATP release is routinely monitored using luciferin 
luciferase luminescence. The principle underlying this method 
is the interaction of the released ATP with synthetic luciferin 
and luciferase extracted from firefly tails to emit a luminescence 
signal (Detwiler & Peinman, 1973)* This signal can be readily 
detected by means of a Photomultiplier Tube. The release of 
ATP can be quantified using standards or compared in extent to 
release elicited by a powerful agonist (e.g. lU/ml thrombin).
The extent of ATP secretion evoked by this agonist is defined 
as 100^ of maximum releasable ATP. In addition this method 
allows for simultaneous measurement of agonist induced ATP 
release and aggregation. However evidence suggests that 
luciferin-luciferase may inhibit agonist induced aggregation 
(Thompson & Scrutton, 1985).
1.4(c) Thromboxane A^ :
Thromboxane A^, the major eicosanoid produced by stimulated 
platelets, is extremely unstable and consequently it is quantified 
as the formation of its stable metabolite, TxB^. Multiple ion 
analysis, bioassay, radioimmunoassay, gas chromatography/mass 
spectrography, HPLC and thin layer chromatography have all been 
used to measure TxB^. In addition stimulation of platelets 
preincubated with radio labelled arachidonic acid, can be used 
as an estimation of cyclo oxygenase activity.
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Measurement of platelet biochemical responses; Monitoring 
intracellular calcium levels
It is well accepted that calcium plays a pivotal role in 
the stimulation of platelets by a number of agonists (Gerrard 
Gt al., 1981), Although agonist induced calcium fluxes have 
been readily monitored using a direct measurement of
intracellular free calcium concentration ( [ca^ j^j . ) and changes 
[ca2+],
possible until relatively recently.
in jC  that result from exposure to agonists have not been
2.1 Quin 2
jca^^j^ can be measured fluorimetrically using the Ca^*
indicator dye, 2 methyl 6 methoxy 8 nitroquinoline (Quin 2),
trapped in the cytosol (Tsien, I98I). Quin 2 itself does not
readily cross cellular membranes although the esterified form.
Quin 2 acetoxy methylester (Quin 2 AM) is membrane permeant.
Consequently incubation of cells with Quin 2 AM results in
incorporation into intact cells, cleavage by cytoplasmic
esterases to the parent Quin 2 which is effectively trapped
in the cytosol. Such a procedure does not involve disruption
of the cellular membrane. Quin 2 is a calcium chelator which
in the presence of free Ca^* displays a fluorescence peak at
492 nm emission when excited at 339 Tun. The measured fluorescence
levels can be calibrated for [ca^^] ^  by exposing the dye to 
2+known Ca concentrations at the end of each experiment. This 
is normally achieved by lysing the cells and titrating the 
Ca^* in the lysate with the familiar chelator EGTA (Tsien at ad., 
1934). Quin 2 has a dissociation constant (II5 oM) comparable
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to typical resting i values near 100 nM and so is highly
sensitive to variations near those levels. Quin 2 has three 
major drawbacks;
i) Quin 2 itself is a calcium chelating agent and so may 
mask the small, and underestimate the larger, jca^^j^ changes 
which may occur in unloaded cells. This problem is exacerbated 
as intracellular concentrations of Quin 2 must be in the milli— 
molar range (Tsien et ^ . , 1984).
ii) The suggested Kd for calmodulin is 2.5 P<M (Rasmussen 
& Barrett, 1984), however Quin 2 is relatively insensitive to
|ca^’*'j ^  at this concentration level.
iii) Quin 2 reports the spatial average |ca^^j in the 
cell cytosol and thus is insensitive to small localised changes 
in specific intracellular calcium pools (Johnson e_t ad., 1985)*
Tsien and colleagues have recently developed a novel 
fluorescent indicator dye, Pura 2. The principle underlying 
Pura 2 is stimilar to that of its predecessor, however it 
exhibits a much greater fluorescence than Quin 2, undergoes a 
shift of emission maximum upon Ca^* binding and may be used 
at lower (]iM) loading concentrations in the cell (Grynkiewicz 
et al., 1985).
2.2 Aequorin
The use of large, calcium sensitive photoproteins, such 
as aequorin, in platelets was, until recently, impossible as 
they required to be administered to cells by micro-injection. 
However a technique has been developed which apparently allows 
platelets to be permeabilised, aequorin introduced into their
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cytoplasm and then resealed (Johnson et al*, 1985)* The 
range of sensitivity of aequorin is 100 hM to 1 mM and its Kd 
is 3 P-M, approximately the same as that of calmodulin (Salzman 
Gt al•, 1985)» In addition, there is evidence that aequorin 
is distributed inhomogeneously within cells. Consequently 
aequorin signals may represent local elevations in jca^^j^, 
such as might be expected to occur in the early stages of a 
response to an agonist. This may also account for changes 
in |ca^ "*’j ^  being monitored in platelets challenged with 
adrenaline or phorbol esters in studies using aequorin but not 
Quin 2 (Salzman e_fc al. , 1985)*
3* Measurement of platelet biochemical responses; Monitoring 
the phosphoinositide cycle
The hydrolysis of the inositol phospholipids plays a 
central role in the activation of platelets by stimulatory 
agonists. A variety of techniques have evolved which permit 
the metabolic pathways involved to be studied. In general, 
two methods exist, firstly the use of radioactive tracers and, 
secondly the direct measurement of the moieties involved in 
the phosphoinositide cycle. The benefits and limitations 
inherent in each method are discussed below.
3*1 Radioactive labelling
Protocols adopted for the labelling of the inositol 
containing constituents in platelets have to be a balance 
between conditions of maximum incorporation of the isotope 
and those which are conducive to the survival of the cells 
in vitroi In the former case optimal labelling conditions
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involves the suspension of the platelets in a physiological 
buffering solution and incubation with the isotope for a 
period of time to allow the label to be incorporated into the 
appropriate intracellular constituent to be examined. In the 
latter case, platelets outwith the corporeal circulation have 
a limited life-span, even when conditions are propitious to 
their survival. Specifically, agonist induced phosphoinositide 
hydrolysis can be monitored by measuring;—
1) a decrease in the levels of the parent inositol 
phospholipid; Ptd Ins, PIP or PIP^.
2) the formation of the products of hydrolysis; DAG or 
inositol phosphates.
3 ) an increase in the turnover of the phosphoinositide 
cycle as a whole.
3 .1 (a) ^^P incorporation;
The incorporation of ] orthophosphate (P\) into Ptd Ins
and Ptd OH remains the most widely used, indirect method of 
monitoring phosphoinositide turnover. Ptd Ins labels with 
j^^^ P j P^ rapidly as, unlike other phosphatidate esters (e.g.
Ptd Cho), the phosphate group is derived directly from Ptd OH 
(Figure lO). Ptd OH in turn gains the ^^P label from the 
gamma, or terminal, phosphate group of cellular ATP. When 
short term labelling conditions (l-2 hours) are employed, 
after which excess label is removed, the pool of [^^P ] Ptd OH 
is in isotopic equilibrium with the cellular ATP (Holmsen
et al., 1984) and so changes in label reflect changes in Ptd OH 























Figure 10. Incorporation of radiolabels into phosphoinositide cycle.
The radio-labels which are routinely used to monitor inositol 
phospholipid hydrolysis are indicated by *.
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cellular content: of Ptd Ins, it would require several hours 
incubation with P ] P^  ^ to label j^ ^^P j Ptd Ins to equilibrium 
with the P j ATP* Although this can readily be achieved 
using cells grown in culture, it is impossible to achieve 
such an equilibrium without radically impairing the functional 
viability of platelets.
The polyphosphoinositides, PIP and PIP^, are derived from 
Ptd Ins and their 4- and 3-phnsphate groups, which turn over 
extremely rapidly (Hawthorn & Pickard, 1979); are donated 
directly from the pool of ATP (Figure lO). In addition to 
this rapid turnover, the polyphosphoinositides are present 
in minimal amounts and so the 4- and 3-phosphate groups quickly 
achieve an equilibrated state with the cellular j^^^P j ATP.
Agonist receptor interaction results in the phospholipase 
C mediated hydrolysis of the inositol phospholipids, resulting 
in the formation of DAG which is rapidly phosphorylated to 
Ptd OH by DAG kinase. In labelled platelets, where j Ptd
OH is at equilibrium with [^^P ] ATP, this manifests itself 
initially as an increase in ] Ptd OH. In addition [^^P ] Ptd
Ins levels are also increased due to conversion of [^^P j Ptd 
OH produced to [^^P] Ptdlns. These increased levels of [^^p] - 
Ptd OH and -Ptd Ins have been assumed to be indicative of an 
accelerated turnover of the phosphoinositide cycle.
There are however limitations on studies involving [^^P ] P^ 
labelling (Irvine _et aT. , I982).
i) The increase in [^^P ] -Ptd OH and -Ptd Ins levels are 
both secondary effects following the initial hydrolysis of
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inositol phospholipids. Ptd OH formation is dependent upon 
DAG formation, and in turn Ptd OH is the precursor of Ptd Ins.
ii) Although phospholipase C activity, via the formation 
of DAG, is believed to be the major source of Ptd OH, another 
two minor mechanisms may affect [^^P ] Ptd OH formation independent 
of the phosphoinositide cycle. Stimulation of triglyceride 
lipase will also elicit DAG formation (from TAG), however this 
enzyme is reportedly absent from human platelets (Lote & Lowery, 
1979)» De novo synthesis of Ptd OH can also occur by the
acylation of glycero 3 phosphate to lyso Ptd OH. This is a
relatively slow pathway (Neufield & Majerus, I983) and so is
not believed to influence the early accumulation of [^^pj Ptd OH
which follows agonist-induced platelet activation.
It is assumed therefore that increased [^^P ] Ptd OH levels 
reflect an increased Ptd OH mass and that stimulation of [^^P]
-Ptd OH and -Ptd Ins are indicative of activation of phospho­
inositide hydrolysis.
3 .1 (b) Glycerol labelling;
Glycerol is incorporated into the backbone of phospholipids 
by its conversion to glycerol 3 phosphate which is the common 
precursor for all phospholipids (Figure lO). [^h] glycerol 
labelling has been extensively used to monitor the phospho­
inositide cycle and allows the measurement of the initial 
hydrolysis of [^h] inositol phospholipids without rapidly 
altering their specific activity. Such changes can be monitored 
when the isotopic labelling has not reached equilibrium, 
however the large amounts of endogenous DAG and Ptd OH formed 1
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may mask the corresponding increases in pli] -DAG and -Ptd OH. 
f H J glycerol labelling is often used to verify studies using 
P ] however such studies are compromised by the differing 
rates of incorporation of the labels (irvine e_fc , I982).
3 .1 (c) Fatty acid labelling;
Radioactive fatty acids are also used to label the backbone 
of phospholipids as they are esterified in position 1 and 2 of 
the glycerol backbone (Figure lO). [^h] or [^^c] arachidonic 
acid is preferentially used as it specifically reacylates the 
phosphoinositides at position 2. This label has three principal 
limitations (irvine e_fc ad. , I982).
i) Stimulated phospholipase A^ activity causes the liberation 
of labelled arachidonic acid metabolites. Such activity may
lead to an over estimation of Ptd Ins breakdown and an under 
estimation of the levels of DAG and Ptd OH formed in response 
to agonists.
ii) DAG lipase activity removes arachidonic acid from 
DAG with the resultant decrease in the observed levels of 
labelled Ptd OH.
iii) Specific reacylation may occur, which results in
a change in the specific activity of the lipids. This change 
would not reflect changes in the mass of the lipids and so 
would complicate such studies.
3 .1 (d) Inositol labelling;
^^h J inositol can be used to measure activation of the 
phosphoinositide cycle by both indirect and direct methods. 
Indirectly phosphoinositide turnover is measured by an increased
—  38 —
incorporation into the phospholipids in a manner similar to
labelling and so is subject to similar restrictions. 
Inositol labelling allows the agonist induced accumulation of 
Puj inositol phosphates to be monitored directly (Figure lO). 
These water soluble compounds can be readily separated (e.g. 
on Dowex columns; Berridge et al.> I983) and effectively allows 
simultaneous measurement of inositol lipid hydrolysis and 
inositol phosphate production.
The tissue inositol content is in excess of the extracellular 
levels (Dawson & Freinkel, I961) and hence passive uptake of 
inositol is limited. Therefore under conditions where 
the viability of the platelet is maintained, unless prohibitively 
expensive quantities of inositol are utilised (Watson
et al., 1984, 1983b) there is insufficient labelling to ensure 
phosphoinositide hydrolysis can be accurately measured.
3.2 Measurement of phosphoinositide amounts
The artifacts associated with labelling studies to 
monitor phosphoinositide metabolism can be avoided by direct 
measurement of the various constituents of the phosphoinositide 
cycle. This can be achieved either by measuring the amount 
of phospholipid present, normally by the chemical analysis of 
the inorganic phosphorous (P\) present, or by monitoring the 
formation of the inositol phosphates, either by HPLC or by 
gas chromatography.
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3.2(a) Inorganic phosphorous assays;
A large number of assays for the determination of 
have been reported and a selection are shown on Table 2 along 
with the level of detection claimed by the authors. Each assay 
depends upon the release of P^ from the phospholipid, normally 
achieved by digesting the lipid with an acid, such as perchloric. 
The basis of each of the assays is a reaction between the 
released P^ and ammonium molybdate to liberate phosphomolybdic 
acid which in turn is reduced and the product quantified 
spectrophotometrically. The method of Bartlett (1959) was the 
method of choice for a large number of studies and has been 
modified and the sensitivity improved (Usher, I963; Christie, 
1982). This method utilises a mixture of sodium bisulphite, 
sodium sulphite and 1 amino 2 napthol 4 sulphonic acid as a 
reducing agent. Bartlett claimed that the original method 
was sensitive enough to measure I50 nmoles of P^. Usher* s 
version measured I6 nmoles and Christie claimed that his 
protocol was more sensitive without quoting the limits of the 
assay. The methods of Itaya and Ui (1966), Hess and Derr (1975) 
and Bowyer and King (1977) reduced the phosphomolybdic acid 
using malachite green and had sensitivities of 1 .6, 1.0 and 
1.6 nmoles of P^ respectively. Bowyer and King detailed their 
protocol specifically for the measurement of the P^ content 
of phospholipids separated by thin layer chromatography.
Similarly Rouser and his colleagues (1969) reported a method 
of measuring mass amounts of phospholipid by quantification 
of their P^ content. The reducing agent in this case was 





Itaya & Ui (1966) 1.6
Hess & Derr (1975) 1.0
Bowyer & King (1977) 1.6
Rouser et al. (1970) 0.1
Table 2. Assays for the measurement of inorganic phosphorous levels.
A list of assays which have been used to measure inorganic phosphorous 
levels and the resolution claimed by the authors (nmoles of inorganic 
phosphorous).
N.D. - not determined.
- 6o -
to be 0.1 nmoles P^, by far the most sensitive assay of 
those listed.
There are, of course, several drawbacks using P^ assays 
to measure levels of phospholipids. Firstly, assays for P^ 
are tedious, time consuming and difficult to perform accurately. 
Secondly, there is relatively little P^ associated with 
phospholipids, and so the technique employed is required to 
be highly sensitive to avoid large tissue samples being necessary. 
Thirdly, the methods for the determination of P^ are subject 
to contamination which interferes with the assay. Such 
contamination can be overcome, however this requires measures 
which are expensive in terms of both time and cost.
3 .2(b) Inositol phosphate assays;
Inositol phosphates, isolated in acidic conditions can be 
monitored by HPLC (irvine e_t aJL. , I985) and by using a combination 
of ion exchange and capillary gas chromatography (Rittenhouse 
and Sasson, 1983).
These procedures are advantageous over those involving [ 
inositol prelabelling as they overcome the various labelling 
artifacts involved. In addition both can be readily used for 
cells, including platelets, where the incorporation of inositol 
is limited. Although various isomers of the inositol phosphates 
can be readily identified, these methods, in common with 
prelabelling studies, involve an acidic extraction procedure 
and so any cyclic phosphates formed would be hydrolysed to 
the linear form.
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CHAPTER IV; DESENSITISATION AND POTENTIATION
1 • Desensitisation
It is well known that many cells possess mechanisms which 
allow them to regulate their responses to external stimuli. 
Desensitisation (also described as tachyphalaxis, tolerance, 
fade, refractoriness, subsensitivity) is the loss of cellular 
sensitivity during, or subsequent to, the initial action of 
a drug (Triggle, I980). This desensitisation is an ubiquitous 
occurrence in systems as diverse as bacterial organisms and 
mammalian tissues and suggests that this phenomenon represents 
an important regulatory component of the homeostatic capacity 
of the cellular recognition process. Two distinct types of 
desensitisation have been recognised. The term "homologous" 
desensitisation was applied to designate the type of desensitis­
ation observed when cells were rechallenged with the same 
agonist used in the initial exposure; "heterologous" desensitis­
ation referred to the situation where re-exposure was to an 
alternative agonist (Su ^  ^ .  , 1976). The mechanism (s) 
underlying both forms of desensitisation have been the subject 
of much speculation. A variety of potential mechanisms, 
including alterations in receptor structure and number, in the 
membrane lipid environment and the inhibition of* uncoupling 
of transduction processes, have been postulated and several 
of these are discussed below.
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1*1 Platelet desensitisation
Platelet functional responses, normally aggregation, 
display the phenomenon of homologous desensitisation. ADP 
(0*Brien, I966; Evans & Gordon, 1974; Ruggles & Scrutton,
1979); 5HT (Baumgartner & Born, I968; Evans & Gordon, 1974; 
Ruggles & Scrutton, 1979); vasopressin (Ruggles & Scrutton,
1979); thrombin (Ruggles & Scrutton, 1979; McGowan & Detwiler,
1983); adrenaline (Motulsky et al., I986) and TxA^, using stable 
analogues (MacIntyre, I98I), all exhibit this phenomenon. The 
possibility of heterologous desensitisation is unclear. Prior 
exposure of platelets to ADP renders them less responsive to 
collagen (Evans & Gordon, 1974; Ruggles & Scrutton, 1979) but 
those responses to adrenaline (O'Brien, I966), 5HT (Baumgartner 
& Born, 1968), thrombin and vasopressin (Ruggles & Scrutton,
1979) are unaffected. Addition of 3HT has been reported to 
desensitise platelets to ADP and adrenaline (Baumgartner & Born, 
1968) although this has been disputed (Evans & Gordon, 1974; 
Ruggles & Scrutton, 1979)» In addition Ruggles and Scrutton 
reported that platelets challenged with 3HT and thrombin become 
refractory to collagen and in the case of thrombin also to 
vasopressin and arachidonic acid (Ruggles and Scrutton, I979). 
With the exception of the above cases, ADP, adrenaline, thrombin, 
5HT and vasopressin have been reported to be ineffective at 
inducing heterologous desensitisation (Ruggles & Scrutton,
1979; Motulsky _et , I986). Partial agonists at the ADP 
or a-adreno receptors do not induce significant desensitisation 
to the subsequent addition of a full agonist (Ruggles & Scrutton,
1979).
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Studies into the role of second messengers in the 
development of platelet desensitisation have been limited 
to the adenylate cyclase system. Adrenaline induces homologous 
desensitisation without affecting the ability of the receptor: 
to inhibit adenylate cyclase (Motulsky ^  al,9 I986). The 
platelet inhibitory agonists PGI^ and PGD^ cause homologous 
but not heterologous desensitisation of adenylate cyclase 
(Miller & Gorman, 1979)» In contrast to platelets, a large 
number of studies in a variety of other cell types have 
addressed the role of various transduction processes in the 
mechanisms underlying desensitisation. The vast majority of 
these reports have involved an investigation of desensitisation 
in the adenylate cyclase system.
1.2 Adenylate cyclase
The  ^ adrenergic' receptor linked adenylate cyclase system 
has provided a model system for the study of the mechanisms 
underlying desensitisation. Kakiuchi and Rail (1968) were 
first to demonstrate that following the exposure of a tissue 
(rabbit brain slices) to an agonist (adrenaline or histamine) 
there would be a reduction in the accumulation of the second 
messenger (cAMP) with time. In this study, desensitisation 
was limited to the agent used in the first exposure. Perkins 
and colleagues (Su ^  ^ . , 1976) extended these findings in 
human astrocytoma cells, where short term incubations with 
either catecholamines or PGE^ resulted in desensitisation 
to a subsequent addition of the same agonist. In contrast, 
if the cells were incubated for an extended period with a
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catecholamine, there was a diminished response to PGE^, and 
vice versa. Therefore Perkins proposed the two distinct forms 
of desensitisation now accepted. Heterologous desensitisation 
was slower occurring and less extensive than homologous 
desensitisation. Furthermore this heterologous desensitisation 
correlated to cAMP formation and it was proposed to occur 
through a cAMP mediated reduction in adenylate cyclase activity. 
Homologous desensitisation was thought to be comprised of both 
the cAMP mediated phenomenon that occurs during heterologous 
desensitisation and an agonist specific phenomenon that is 
unrelated to the elevation of cAMP (Harden, 1983). Antagonists 
can block homologous but not heterologous desensitisation.
In addition a good correlation is observed between efficacy 
for adenylate cyclase stimulation and the extent of desensitis­
ation induced, i.e. partial agonists induce "partial desensitis­
ation". This is presumably indicative of an intimate relation­
ship between receptor occupancy, and therefore activation of 
the transduction process and formation of second messengers, 
and the generation of desensitisation.
1 .2(a) Heterologous desensitisation;
Investigation into the mechanism of heterologous de­
sensitisation of the adenylate cyclase system has centered on 
the post receptor events. In a variety of adenylate cyclase 
mediated cells, the role of cAMP in desensitisation has been 
supported by the use of cAMP analogues (Terasaki et ^ . , 1978), 
cholera toxin (Nickols & Brooker, I980) and phosphodiesterase
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inhibitors (Terasaki et al.> 1978) all of which induce 
desensitisation. To date the component or process in the 
adenylate cyclase system regulatory cycle that is modified 
during the process of desensitisation is unclear. However 
several possible mediators have been ruled out;-
1 ) Destruction of the agonist during stimulation
2) Increased egress of cAMP into the extracellular medium
3 ) Increased phosphodiesterase activity.
Desensitisation is unaffected by protein synthesis
inhibitors, with the exception of rat glioma cells. In this 
tissue desensitisation is markedly reduced in the absence of 
protein synthesis and, a so far unidentified, mediator of 
desensitisation has been proposed. Likewise, fat cells are 
unique during the development of desensitisation. Stimulation 
by adrenaline, ACTH or glucagon all cause cellular desensitisatio 
accompanied by the formation of an inhibitor of agonist action. 
The appearance of this "feedback regulator" correlation to 
cAMP formation and is also stimulated by dibutyrl cAMP.
Studies in red blood cells, of various species, demonstrated 
that in these cells desensitisation is stable to cell lysis 
and likely involves a covalent modification of the G proteins 
(Harden, I983). This modification could result in G proteins 
being less efficient promoters of catalytic activity, as 
proposed for fibroblasts (Kassis & Fishman, I982), and/or an 
alteration in the rate of exchange of GTP for GDP on the G 
proteins, as proposed for pigeon erythrocytes (Hudson & Johnson,
1981). In general however heterologous desensitisation is
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not observed in membrane preparations and so may involve a 
process dependent on cellular integrity (Triggle, I98O).
Therefore there is probably no universal mechanism for hetero­
logous desensitisation of the adenylate cyclase system.
1 .2 (b) Homologous desensitisation;
In contrast to heterologous desensitisation, in all systems 
studied the phenomena of homologous desensitisation has been 
attributed to a common mechanism.
In frog cells, the desensitising action of catecholamines 
can be blocked, or reversed, by propranolol. This indicates 
that desensitisation is caused by a reduction in the number of 
functional receptors, termed down regulation. It is likely 
that chronic occupancy, rather than active loss of the receptors, 
is responsible as receptor number and adenylate cyclase activity 
is unaffected by protein synthesis inhibitors (Mukherjee ejfc al., 
1976). Labelling studies, in erythrocytes, demonstrated that 
agonists dissociate from receptors much slower than antagonists 
and this dissociation is accelerated by guanyl nucleotides 
(williams & Lefkowitz, 1977)» Antagonists are ineffective at 
inducing, and guanyl nucleotides reverse, desensitisation 
(Mukherjee & Lefkowtiz, I976), and this is further evidence 
for prolonged receptor occupancy mediating acute desensitisation. 
In studies involving erythrocytes. Shear and colleagues (Shear 
et al., 1976) concluded that this receptor occupancy alone or 
occupancy in the presence of elevated cAMP levels was insufficient 
for the agonist induced down regulation of receptors. Several 
studies have demonstrated that for receptor down regulation 
to occur, agonist induced coupling of the receptor to G proteins
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is mandatory although the presence of adenylate cyclase, or 
the formation of cAMP, is not (Harden, 1983). It is now 
believed that during desensitisation the G proteins remain 
unaltered and it is the receptor subunit which is modified 
(lyengar et al., I98I). The nature of this alteration in the 
1^ adrenoceptor is unknown although phosphorylation/dephosphoryl­
ation, disulphide-sulphydryl exchange, methylation/demethylation 
or receptor proteolysis have all been proposed to occur in a 
variety of cells (Hollenberg, 1985a). The chronic effects of 
receptor occupancy may well be the clustering and internalisation 
of the receptors with the concomitant loss of receptors over 
a period of hours (Su ejb aT. , 1979; I980). Thus a pathway for 
homologous desensitisation would involve the interaction of 
an agonist with its cell surface receptor and the resultant 
activation of adenylate cyclase via a G protein. This receptor 
is then rapidly converted to a form no longer coupled to the 
G proteins. These desensitised, uncoupled receptors are then 
rapidly clustered and internalised and become undetectable 
to radioligand binding.
1.3 Calcium mediated systems
Complex patterns of desensitisation can also be observed 
in non adenylate cyclase linked systems. However the mechanisms 
involved in such systems are less well documented.
The rat parotid gland is one of the few tissues in which 
desensitisation of the Ca^* signalling system has been studied. 
Homologous desensitisation of a adrenergic induced potassium 
release (Strittmatter et ^ . , 1977) and a-amylase secretion
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(Harper & Brooker, 1978) has been observed and attributed 
to an effect at the receptor level. However Putney demonstrated 
that not only does the efflux stimulated by carbachol or 
substance P fade with time, but a subsequent addition of an 
agonist, either the same or different to the original, fails 
to produce a response (i.e. heterologous desensitisation) 
(Putney, 1978). It was further suggested that this desensitis­
ation was mediated by a Ca^* influx and may be due to a 
development of insensitivity of the channel for activation
by elevated |ca^^] , rather than an effect at either the
receptor or Ca^^ channel.
Studies in guinea pig pancreatic acinar cells have shed 
light upon the role of interactions between second messenger 
systems in the development of desensitisation. In this tissue 
both increased cAMP levels and elevated [ca^^]^ cause enzyme 
secretion. Heterologous desensitisation is observed when 
maximal concentrations of secretagogues that both elevate |ca^^] i 
or both stimulate cAMP are used. This phenomena is not observed 
if two secretagogues with differing modes of action are used 
(Gardner & Jensen, I980).
2+Desensitisation of Ca gating has been observed in 3HT 
stimulated blowfly salivary glands (Berridge & Fain, 1979).
This effect was attributed to a depletion of the phospho­
inositides, which serve as the transduction process. The 
agonist was reported not only to stimulate the hydrolysis, but 
also inhibit the resynthesis, of the phospholipids. The 
possibility was also entertained that clustering of desensitised
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receptors would limit their access to the remaining inositol 
phospholipids in the membrane. The addition of inositol, but 
not of choline or ethanolamine, to desensitised cells led to a 
complete recovery of responsiveness (Fain & Berridge, 1979)*
The guinea pig ileum responds to a variety of smooth muscle 
stimulants, including acetylcholine, histamine and substance P, 
to generate a mechanical contraction mediated by an apparently 
common influx of Ca^^ from the extracellular space. Both 
homologous and heterologous desensitisation can be observed 
in this tissue. A major component to heterologous desensitisatioi 
is probably the hyperpolarisation of the cellular membrane 
caused by electrogenic pumping of the Na"*" ions that enter the 
smooth muscle cells during the stimulation. This hyperpolaris­
ation will increase the threshold for cellular excitation and 
render the cell less sensitive to stimulation (Triggle, I980).
2. Potentiation
The second receptor mediated alteration which allows cells 
to regulate their response to the external environment is 
termed potentiation. The definition of potentiation (also 
called synergism) is often not clear although, in general 
terms, it is that situation where the response to the co-addition 
of two agonists is greater than the sum of the responses induced 
by either agonist acting alone. Potentiation has been less 
extensively studied than desensitisation.
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2.1 Platelet potentiation
The potentiation of platelet aggregation has been widely 
reported. ADP synergises with collagen (O’Brien, 1964), 
thrombin (Niewiarowski & Thomas, I966), adrenaline (O'Brien,
1964; Ardlie ^  , I966; Mills & Roberts, I967) and 5HT
(O'Brien, 1964; Baumgartner & Born, I968; Michal & Motamed,
1976). In addition adrenaline potentiates responses elicited 
by collagen (Mills & Roberts, I967); thrombin (O'Brien, 1964; 
Thomas, I967; Steen & Holmsen, I985); 5HT (Baumgartner & Born, 
1968; Mills & Roberts, I967) and PAP (Pouque & Vargaftig,
1984). The underlying biochemical mechanism of these 
potentiation effects have not been addressed in any of these 
studies.
2.2 Second messenger potentiation
Few studies have been reported which specifically investigate 
the potentiation of the production of second messengers. As 
outlined earlier, in guinea pig pancreatic acinar cells 
stimulated formation of cAMP and elevation of ^ both
elicit enzyme secretion. If the cells are challenged with two 
agonists which have the same mode of action then the enzyme 
secretion is equal to that of the more effective secretagogue.
In contrast however if an adenylate cyclase stimulant and a 
calcium mediated agonist are combined then there is a marked 
synergism in the effect of the agonist (Gardner & Jensen, I980).
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3• Pharmacology of desensitisation and potentiation
Many pharmacological effects can manifest themselves as 
changes in the position of the agonist concentration response 
curves. However there is an increasing reluctance to relate 
these changes to events at the molecular level. In general, 
receptor down-régulâtion will lead to a rightward shift of 
the concentration response curve. Since prolonged receptor 
occupation leads to down-regulation it may be anticipated that 
the curve will continuously shift to the right with time 
(Hollenberg, 1983b).
Desensitisation, following repeated administration of 
the agonist is indicated not only by a shift to the right in 
the concentration response curve (due to receptor down-regulation) 
but also by a reduction in the maximal obtainable response 
(Hollenberg, 1983b). The reverse, that is a leftward shift 
and increased maximal response, occurs when either agonists 
are potentiated or the cells are hypersensitive (Hollenberg,
1983b).
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CHAPTER V; OBJECTIVES AND BACKGROUND OF STUDY
The general objectives of the study can be summarised as 
follows
i) To investigate the function, if any, of phosphoinositide 
hydrolysis in the mechanism of action of agonists which, hitherto, 
had not been studied.
ii) To employ new techniques to verify phosphoinositide 
hydrolysis as the mechanism of action of agonists.
iii) To further study the pharmacological profile of agonists 
such as the TxA^ analogues and thrombin.
iv) To study possible biochemical mechanisms underlying 
the phenomenon of desensitisation.
v) To examine the role, if any, of phosphoinositide hydrolysis 
in the potentiation by ADP and adrenaline of platelet responses.
1. Effects of agonist on phosphoinositide hydrolysis
It is now generally accepted that the hydrolysis of one 
or more of the inositol phospholipids, with the consequent 
production of DAG and elevation of jca^^j , serves as a 
transduction process in the stimulation of human platelets 
(Rink & Hallam, 1984). A variety of techniques have been 
employed to monitor phosphoinositide hydrolysis and have been 
used to elucidate the mode of action of a number of agonists. 
Thrombin, PAF, collagen, arachidonic acid, vasopressin, 5HT 
and TxA^ (u44o69) have all been shown to cause the breakdown 
of the phosphoinositides in human platelets (Agranoff e_t al. ,
1983; MacIntyre & Pollock, 1983; Watson ejfc ^ .  , 1985b; Siess
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^  , 1983b, 1986; Pollock, 1984; Pollock et aly, 1984).
Previous studies in the laboratory have contributed to, and 
extended, these findings and allowed the correlation between 
[^^P] Ptd OH formation and elevation of |ca^^j ^  to be made.
Figures 11 and 12 summarise these observations. PAF, U44o69> 
vasopressin and 3HT, but not adrenaline, stimulate the formation 
of Ptd OH and elevation of The first objective of
this study was to complete this correlation by examining the 
effects of thrombin and ADP, both of which elevate [ca^^j , 
on [^^p] phosphoinositide levels. In addition the novel TxA^ 
mimetic EPI7I, reputedly the most potent such compound 
(Jones et aJ., 1985)» was examined, as was the phorbol ester 
and protein kinase C stimulant, PMA (Castagna e_fc ad., I982).
In each case the levels of [^^P ] -PIP^» -PIP and -Ptd OH was 
monitored in ] P^ prelabelled human platelets.
2. Further analysis of U44069 and thrombin induced phosphoinositide 
hydrolysis
Thrombin is the most frequently used platelet agonist and 
is the most potent and efficacious stimulant of platelet 
functional and biochemical responses. Thrombin has been reported 
to decrease levels of the phosphoinositides (Broekman ejb aT. ,
I98O; Agranoff ejfc , I983; Rendu et , I983) and correspond­
ingly increase DAG (Rittenhouse-Simmons, 1979)» Ptd OH (Broekman 
et al., 1980) and the inositol phosphates (Agranoff ^  al.,
1983; Siess & Binder, I983; Rittenhouse & Sasson, I983). However, 
although a high affinity thrombin binding site on the platelet 
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Figure 11. Agonist induced elevation of in human platelets.
Agonists, at the concentration indicated, were added to Quin 2 labelled
suspended in a medium of external free Ca^"*" = 1 mM. Changes
. were calculated from the observed changes in dye fluorescence 
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Figure 12. Agonist induced [^^p] Ptd OH formation in human platelets.
fsTi "Agonists, at the concentration indicated, were added to \_ P j pre-labelled 
platelets. Levels of [^ P^] Ptd OH were measured 30s after the addition 
of PAF, vasopressin, U44069 and adrenaline and 60s after addition of 5HT. 
Results are expressed as "fold stimulation" of the basal value (= l) 
(Figure 5 in MacIntyre et al., 1985b).
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the possibility exists that thrombin induced platelet activation 
is not solely as a consequence of this binding. As thrombin 
has proteolytic activity, the possibility of this contributing 
to its mode of action was investigated.
TxAg mimetics such as '\Jk■h06  ^ and EP1?1 are routinely used 
to investigate the effects and mechanisms of action of the 
natural agonist on platelets and other TxA^ sensitive tissues. 
However, which agent most closely mimics the actions of TxA^ 
remains to be determined. For example, it has been shown that 
U44o69 acts as a partial agonist at the thromboxane receptor 
(TP type) on airway and vascular smooth muscle (jones et al.,
1982). Although widely used to probe the sequelae of platelet 
TP receptor occupancy, it remains to be proven whether U44o69 
also acts as a partial agonist in this system. Indeed, u44o69 
and TxA^ reportedly differ in their effects on inhibition of 
platelet adenylate cyclase (Gorman ejb ad., 1978; Best e_t al., 
1979)* Besides this inhibition of adenylate cyclase, platelet 
TP receptors are coupled to inositol phospholipid hydrolysis 
and elevation of jca^^j ^  (Pollock et al., 1984). Therefore 
the possibility that U44069 acts as a partial agonist at the 
platelet TP receptor was investigated.
3. Desensitisation
Platelet activation, which is a reversible process, exhibits 
the phenomenon of desensitisation. However, the underlying 
biochemical mechanism has not been widely investigated. The 
possibility exists that inhibitory second messengers may play 
a role in terminating, limiting or desensitising platelet
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reactivity. Specifically the effects of several putative 
"negative feedback regulators" of agonist induced inositol 
phospholipid hydrolysis and elevation of |ca^ j^| were examined.
3•1 Adenylate cyclase stimulants
Agents such as PGI^» PGE^ and PGD^ which stimulate 
adenylate cyclase, have been shown to be inhibitors of platelet 
activation (Feinstein e_t ad., 1983)» Therefore, if an endogenous 
mediator of desensitisation exists, then it is possible that 
it may be cAMP. However there is no evidence that cAMP levels 
are elevated following exposure of platelets to stimulatory 
agonists or in desensitised platelets, although changes may 
occur in cAMP compartments in the absence of a demonstrable 
elevation in the total cellular cAMP. There is evidence that 
adenylate cyclase activation has a pronounced inhibitoiy action 
on platelet phosphoinositide hydrolysis (Lapetina, 1984) and 
jca^^J^, and this was further investigated in the present 
study. In addition this study would help clarify possible 
interactions between platelet second messengers.
3.2 Guanylate cyclase stimulants
The potent guanylate cyclase stimulant NaNP has been shown 
to inhibit agonist induced platelet activation (Glusa et al., 
1974; Haslam et al., I980), phosphoinositide hydrolysis 
(Takai ^t aT. , 1981b) and elevated jca^^j ^  (Kawahara ejt al.,
1984). In addition elevated intracellular cGMP levels have 
been reported in response to several agonists (White ejt al.,
1973) and so cGMP is a prime candidate as a putative endogenous
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regulator of platelet reactivity.
3•3 Protein kinase C stimulants
The phorbol esters have been shown to stimulate platelet 
reactivity (Zucker , 1974; White ^  , 1974), presumably
by mimicking endogenous DAG and stimulating protein kinase C 
(Castagna e_t ad., 1982) and hence bypassing receptor mediated 
phosphoinositide hydrolysis. The phorbol esters however have 
been shown to influence agonist induced elevation of jca^^j 
in neutrophils (Serhan e_fc aT. , I983; Gennaro e_t al. , 1984). 
Consequently, the effect of these agents on inositol phospho­
lipid and |ca^ '*’j ^  in resting and stimulated platelets were 
investigated.
4. Potentiation
The actions of adrenaline and ADP to potentiate the effects 
of other agonists are well documented. However the mechanism(s) 
of this potentiation is/are unknown. The possibility that 
this occurs by activity at the level of phosphoinositide 
hydrolysis was examined.
5• New techniques
The limitations of ^^^P J P^ prelabelled platelets to 
monitor inositol phospholipid hydrolysis have been discussed 
earlier. This study was involved with the development of two 
techniques which would help to confirm findings from such 
labelling studies.
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5•1 Inorganic phosphorous assays
Inorganic phosphorous assays have been widely used to 
monitor phosphoinositide hydrolysis. It was hoped to adapt 
such an assay to be used to monitor the effects of a variety 
of agonists on PIP^, PIP, Ptd Ins and Ptd OH levels in the 
human platelet.
5*2 Platelet permeabilisation
The use of [^hJ inositol labelling and pertussis and 
cholera toxins pretreatment in human platelets have been 
precluded due to the inability of each of these compounds to 
cross the cellular membrane. The possibility of the 
permeabilisation technique, adapted for the incorporation of 
aequorin into the platelet (Johnson et al., I985)» being 





CHAPTER VI; MATERIALS AND METHODS
1. Preparation of platelets
1.1 Preparation of platelet rich plasma
Blood was taken from the antecubital vein of apparently 
healthy human volunteers who denied taking any drugs known 
to affect platelet function. The blood was collected in 
disposable plastic centrifuge tubes containing 10^ (v/v) sodium 
citrate (3*8% in GDW) as an anti-coagulant and centrifuged 
at 800g for 3 minutes. The supernatant (platelet rich plasma, 
PRP) was aspirated into other disposable centrifuge tubes.
The remainder, red blood cells and leucocytes, was discarded.
All experiments were completed within four hours of the removal 
of blood to maximise platelet viability (MacIntyre & Pollock,
1983).
1.2 Platelet washing procedures 
1.2(a) Method I ;
The platelets were pelleted by centrifugation of PRP at 
800g for 10 minutes in the presence of an adenylate cyclase 
stimulant, either prostacyclin (lOO ng/ml) or a mixture of PGE^/ 
6-keto-PGE^ (lOO ng/ml), to prevent platelet activation (Moncada 
et al., 1982). The ^upernatant was aspirated and discarded 
and the pellet was resuspended in the relevant buffer (MacIntyre 
& Pollock, 1983).
1 .2(b) Method II;
A column of Sepharose 2B was equilibrated with the relevant 
buffer. The PRP was then washed through with additional buffer 
separating the platelets from the plasma (Pollock ejfc ^ .  , 1984).
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1.3 Buffers
1 .3 (a) Buffer 1-Phosph.ate-free, calcium-free Hepes buffer; 
130 mM-sodium chloride; 3 mM-Hepes
4 mM—potassium chloride; 10 mM-dextrose
1 mM-magnesium chloride; 0.3^^boviue serum albumin 
(The pH was adjusted to 7*4).
1 .3 (b) Buffer II-Hepes-buffered Tyrodes* solution;
129 mM-sodium chloride; O.33?^bovine serum albumin
10.9 mM-trisodium citrate; 2.4 mM-calcium chloride
8.9 mM-sodium bicarbonate; O .36 mM-dextrose
2.8 mM-potassium chloride; 3 mM-Hepes
0.8 mM-potassium phosphate; 0.84 mM-magnesium chloride
(The pH was adjusted to 7*4).
1 .3 (c) Buffer III-Hepes buffered solution;
129 mM-sodium chloride; 1 mM-calcium chloride
8.9 mM-sodium bicarbonate; 10 mM-Hepes
2.8 mM-potassium chloride; 3*6 mM-dextrose
0.8 mM-potassium phosphate; 0.8 mM-magnesium chloride
(The pH was adjusted to 7*4).
1 .3 (d) Buffer IV-Permeabilisation buffer;
130 mM-sodium chloride; 3 mM-ATP
3 mM-Hepes; 1 ^M-PGE^




-arachidonic acid (2 p,Ci/ml) was dried down at 23°C 
in a disposable centrifuge tube under a stream of oxygen free 
nitrogen. The PRP was then added and incubated at 37°C for 
60 minutes. The PRP was washed by Method I and the platelets 
were resuspended in phosphate-free, calcium-free Hepes buffer 
(buffer: PRP; 1:2).
2. 2 ^H -inositol
The relative impermeability of the platelet plasma membrane 
to inositol makes incubation of the platelets with [^hJ -inositol 
alone an unviable proposition. The platelets therefore have 
to be permeabilised. The only method which would permeabilise 
and reseal the plasma membrane was that of Salzman and colleagues 
(Johnson aL., I983).
PRP (13-18 ml) was washed by Method I and the platelets 
resuspended in 1 ml of Hepes buffered solution (4°C). The 
platelets were immediately centrifuged (4000g; 20 seconds) and 
the supernatant aspirated and discarded. The platelets were 
resuspended in 1 ml of the permeabilisation buffer containing 
magnesium chloride (2 mM), EGTA (lO mM) and [^H] -inositol 
(20 pCi) and incubated at 4^C for 60 minutes. The platelets 
were re-centrifuged (4000g; 20 seconds) and the supernatant 
aspirated and discarded. The platelets were resuspended in 
1 ml of the permeabilisation buffer containing magnesium chloride 
(10 mM) and EGTA (O.l mM) and incubated at 4°C for 60 minutes.
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Three aliquots (l p,l ) of permeabilisation buffer containing 
magnesium chloride (lO mM), EGTA (O.l mM) and calcium chloride 
(lOO mM) were added 5 minutes apart and the platelets were 
gently re-warmed to 22°C. The platelets were then re-washed 
by Method II and resuspended in Hepes buffered solution 
containing calcium chloride (l mM) (Buffer;PRP; 2:3). These 
platelets were then tested in a platelet aggregometer for 
functional viability and were found to respond to high 
concentrations of agonists.
In order to assess the success of the permeabilisation 
procedure samples of these platelets were added to scintillation 
fluid and counted in a Liquid Scintillation Counter. It was
3
found that there was no significant difference in the H levels 
in these samples when compared to parallel platelets which had 
been prepared as above except that the incubations at 4°C were 
carried out in Hepes buffered solution containing EGTA (lOOmM) 
and PGEj^ (lOO ]ig/ml) • Therefore it appears either that the 
platelets have not undergone the permeabilisation procedure 
or the intracellular inositol levels were too high for the 
-inositol to enter down its concentration gradient.
"32,
2.3 -orthophosphate
2 .3 (a) Prelabelling for Ptd Ins and Ptd OH:
PRP was washed by Method I, the platelets resuspended in 
phosphate-free, calcium-free Hepes buffer (PRP:buffer; 5îl) 
and 25 p.Ci/ml [^^P ] -orthophosphate was added. The cells were 
then incubated at 37^0 for 90 minutes. The platelets were
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re-washed by Method I, which removed the excess label, 
resuspended in phosphate-free, calcium-free Hepes buffer 
(pRP;buffer; 3:2) and allowed to equilibrate for 3 minutes 
prior to the start of the experiment (MacIntyre & Pollock, I983). 
In selected experiments the cyclo-oxygenase inhibitor flurbiprofen 
(10 tjlM) was added in order to abolish the effects of thromboxane 
release. Under these conditions the labelling of Ptd OH had 
reached equilibrium with [^^P ] -ATP and therefore changes in 
Ptd OH label reflect changes in Ptd OH mass (Holmsen et al.,
1984). In addition the platelets remained functionally viable 
as indicated by aggregation studies.
2.3 (b) Pulse chase labelling for PIP and PIP^;
PRP was washed by Method I, the platelets were resuspended 
in phosphate-free, calcium-free Hepes buffer (PRP:buffer; 3:l) 
and incubated at 37°C for 43 minutes in the presence of [^^p] - 
orthophosphate (23 ]iCi/ml). This procedure labelled all 
three inositol phospholipids and Ptd OH. In order to enhance 
the possibility of observing agonist-induced changes in PIP 
and PIP^ it was necessary to prevent the specific activity of 
the phosphoinositides from increasing. This was achieved by 
rewashing the cells by Method I and resuspending in fresh 
buffer (PRP:buffer; 3:2) containing KH^PO^ (lOO p,M) and 
incubating at 37°C for a further 43 minutes. This had the 
effect of chasing the label from the ATP pool with a resulting 
decrease in the specific activity of Ptd Ins (Pollock, 1984).
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3* Experimental procedures
Measurement of '32p' -Ptd OH and '32p' -Ptd Ins
a) Experimental :
Aliquots (0.4 ml) of prelabelled platelets were dispensed 
into 3 ml plastic tubes in a 37°C water bath and allowed to 
stand for 5 minutes. Reactions were initiated by the addition 
of the drug(s) (or vehicle) in a 4 p,l volume. At the appropriate 
time after addition, the reaction was terminated by transferring 
the entire sample to a glass test-tube containing 2 ml of 
chloroform:methanol!ION hydrochloric acid (25:30:4; v:v:v) and 
vortexing thoroughly. Each experiment contained a maximum of 
24 samples, including vehicle controls at the start and end 
of the experiment, and protocols were designed to minimise the 
duration of each experiment.
3#l(b) Extraction of phospholipids:
The phospholipids were extracted by Method B of Lloyd ejb al. 
(1972). This involved the addition of O.623 ml of chloroform 
and 0.623 ml of GDW and vortexing thoroughly. The samples 
were centrifuged (lOOOg, 3 minutes) which caused a partition 
into two distinct phases and a protein interface. The lower, 
organic, phase was removed by Pasteur pipette to a drying 
bottle and the upper, aqueous, phase and protein interface 
were discarded. The phospholipids were dried down at 43°C 
under a constant stream of oxygen free nitrogen. The drying 
bottle was then sealed and stored at -20°C for a maximum 
of 3 days.
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3 .1 (c) Separation of phospholipids;
The phospholipids were separated by two dimensional thin 
layer chromatography (t.l.c.) (Yavin & Zutra, 1977)* Silica- 
gel t.l.c. plates (lO cm x 10 cm) were marked 2 cm x 2 cm from 
the lower left edge and 3 lig of carrier Ptd OH was spotted.
The phospholipids were redissolved in 75 P-1 of chloroform; 
methanol (9 :1 ; v:v) and were then spotted onto the t.l.c. plate. 
The plates were then inin in the first dimension in a solvent 
system of chloroform:methanol:40^  ^methylamine (26:1 2 :3 ; v:v:v).
The plates were removed when the solvent front had reached 
1-2 cm from the top of the plate. The basic nature of this 
system meant that the acidic phospholipids, such as Ptd Ins 
and Ptd OH, were retarded. The t.l.c. plates were dried under 
a stream of warm air, subjected to hydrochloric acid fumes to 
neutralise the methylamine and dried initially under warm air 
and then cool air. The plates were then subjected to an acidic 
wash in the second dimension in a solvent system of diethyl 
ether: acetic acid (l9 :l) and dried under a stream of cool air.
The lipids were separated in the second dimension in a solvent 
system of chloroform:acetone:methanol: acetic acid: GDW (10:4:2:3:1 
The solvent front in this dimension was allowed to run no further 
than that of the acidic wash. All solvents were renewed after 
each group of 24 plates and allowed 60 minutes to equilibrate.
The plates were placed in iodine vapour which allowed the 
identification of Ptd Ins, Ptd OH, Ptd Oho, Ptd Eth, Ptd Ser, 
lyso-Ptd Eth and sphingomyelin. However under the labelling 
conditions employed only Ptd Ins, Ptd OH and Ptd Oho became
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labelled to a significant extent (Figure 13). The spots 
corresponding to Ptd Ins and Ptd OH were scraped into a 
scintillation vial and counted in a Liquid Scintillation Counter.
3•2 Measurement of I Pi -PIP and 32p
3 .2 (a) Experimental;
Aliquots (0.4 ml) of pulse chase labelled platelets were 
dispensed into 3 ml plastic tubes and allowed to stand at 37°C 
for 3 minutes prior to use. Reactions were initiated by the 
addition of drug(s) (or vehicle) in a volume of 4 p,l. At the 
appropriate time the reactions were terminated by transferring 
the entire sample to a glass test tube containing 1.2 ml of 
chloroform;methanol (l:2) and vortexing thoroughly. Each 
experiment contained a maximum of 24 samples, including vehicle 
controls at the beginning and end of the experiment, and were 
designed to be of minimum duration.
3 .2 (b) Extraction of phospholipids:
The phospholipids were extracted by the addition of 2.4N 
hydrochloric acid (0.4 ml) and chloroform (0.4 ml) and then 
vortexing. The sample was partitioned into two phases by 
centrifugation (lOOOg; 3 minutes) and the lower, organic phase 
was removed to another glass test tube by Pasteur pipette and 
stored at 4°C. The aqueous phase was rewashed by mixing with 
chloroform (0.8 ml) and centrifugation (lOOOg; 3 minutes) to 
separate phases. The upper, aqueous phase was removed by 
Pasteur pipette and discarded and the organic phases combined.
P - L P E
S P M  
+ L P E
Figure 13. Diagramatic representation of phospholipid separation 
by method of Yavin and Zutra (1977).
Phospholipids identified by iodine staining are indicated and the hatched 
spots represent those phospholipids which are significantly labelled 
following preincubation with P  P] P^ -
PI - phosphatidylinositol; PS - phosphatidylserina; PA-phosphatidic acid; 
LPE-lyso phosphatidylethanolamine; SPM-sphyngomyelin; PC-phosphatidylcholine; 
PE-phosphatidylethanolamine; P-LPE-plasmalogen lyso phosphatidylethanolamine; 
NL-neutral lipids.
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The organic phases were washed by the addition of 1.6 ml of 
methanol : IN hydrochloric acid (l:l), centrifuged (lOOOg;
3 minutes) and the lower, organic phase removed, by Pasteur 
pipette, to a drying bottle. The phospholipids were dried down 
at 43°C under a stream of oxygen free nitrogen, the bottle 
sealed and stored at -20°C for a maximum of 3 days (Schacht, 
1981).
3*2(c) Separation of phospholipids;
High performance t.l.c. plates (lO cm x 20 cm) were 
impregnated with potassium oxalate (l^ in methanol;GDW (2:3)) 
and activated by heating at llO^C for at least 10 minutes. The 
phospholipids were resuspended in 75 of chloroform:methanol : 
GDW (75:25:2) and spotted in 1.5 cm bands 2 cm from the edge 
of the plate. The plates were then placed in a solvent system 
of chloroform:acetone:methanol: acetic acid:GDW (40:15:13:12:8) 
and allowed to run until the solvent front reached the top 
edge of the plate (Jolies et ^ .  , I98I). Fresh solvents were 
used for each experiment and allowed 60 minutes to equilibrate. 
The plates were dried and then autoradiographed on X-Omat S 
X-ray film (Kodak). This allowed the identification of PIP^» 
PIP, Ptd Ins and Ptd OH. Spots corresponding to PIP^ and PIP 
were scraped into a scintillation vial and counted in a Liquid 
Scintillation Counter.
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3*3 Measurement of I -arachidonate release
Platelets prelabelled with [^h] -arachidonic acid were 
dispensed (0.2 ml) into disposable 1.5 ml plastic tubes at 
37^C. Reactions were initiated by the addition of drug(s)
(or vehicle), in a volume of 4 )il, and terminated by the addition 
of ice cold EDTA/saline and removing the entire tube onto ice.
The samples were then centrifuged (2000g; 4 minutes ; 4°C) to 
pellet the platelets and an aliquot of supernatant was counted 
in a Liquid Scintillation Counter.
3*4 Direct measurement of phospholipid mass
The measurement of the cellular content of phospholipid 
by the use of radiolabel have several deficiencies. Therefore 
the direct measurement of the mass of lipid present has been 
used in some studies. These studies have utilised the many 
assays which have been developed to estimate the content of 
inorganic phosphorous and several have been discussed earlier.
The phospholipids were separated by t.l.c. and the spots 
scraped into Pasteur pipettes which had been plugged with glass 
wool and washed thoroughly with chrorisic acid. The phospholipids 
were eluted from the silica by passing 5 ml of chloroform: 
methanol:ION hydrochloric acid (25:50:4) through the pipette.
The eluant was collected and dried down (45^C) under a stream 
of oxygen free nitrogen. The phospholipids were digested 
to release the inorganic phosphorous by adding 0.1 ml of 
perchloric acid and heating (l70-l80°C; 60 minutes), taking 
care to avoid loss of the perchloric acid fumes. The samples 
were then cooled. On each occasion a standard curve was
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constructed by using either potassium dihydrogen phosphate, 
or a known amount of phospholipid, usually Ptd Cho.
3.4(a) Method of Bartlett (l959) (modified by Christie (1982));
A solution of ammonium molybdate (2.4 ml) was added, 
followed by a reducing agent (2.4 ml). The samples were 
thoroughly mixed, placed in a boiling water bath (lO minutes) 
and the extinction at 83O nm read in a standard Cecil spectro­
photometer. The ammonium molybdate solution consisted of 4.4g 
of ammonium molybdate in ^00 ml of GDW, l4 ml of concentrated 
sulphuric acid was added and the solution was made up to 1 litre 
with GDW. The reducing agent was sodium(meta)bisulphite (2.5g); 
sodium sulphite (0.5s) and 1 amino 2 naphol 4 sulphonic acid 
(0.042 g) dissolved in 25O ml of GDW and allowed to stand in 
the dark for several hours. The solution was filtered and 
stored at 4°C.
A typical standard curve using this method is shown in 
Figure l4. The inorganic phosphorous content of Ptd Ins was 
estimated using this technique. The mean content (- SEM) was 
12.5 (- 4.4) nmoles phosphorous per sample, which converted 
to 57.9 (- 20.4) nmoles per 3 x 10^ platelets. This, although 
the error involved was large, is consistent with the published 
values of 61.35 nmoles per 5 x 10^ platelets (Broekman e_t al., 
1980). Thrombin (l U/ml) caused a decrease in the amount of 
phosphorous to 33*9 (- 4.4) nmoles of phosphorous per 5 x 10^ 
platelets, however this effect was at the limit of sensitivity 
of this assay. It also proved impossible to quantify the 







Figure 14. Measurement of inorganic phoephoroua by the method of 
Bartlett (l959) as modified by Christie (*1982).
Typical standard curve using the procedure outlined in Materials and
Methods (3.4a).
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3.4(b) Method of Bovryer and King (l977):
The samples were vortexed with 0.3 ml of GDW and centrifuged 
(lOOOg; 3 minutes). A standard aliquot (0.3 ml) was removed, 
thoroughly shaken with 1.3 ml of the "colour reagent" and the 
extinction read at 66O nm. The "colour reagent" was a mixture 
of 1 volume of ammonium molybdate (4.2^ in 3N hydrochloric acid) 
and 3 volumes of malachite green (0.2^ in GDW). The mixture 
is allowed to stand for 30 minutes and filtered before use.
A typical standard curve using this procedure is shown 
in Figure 13» It can be readily seen that it was impossible 
to obtain the sensitivity to measure the mass of phosphorous 
in the phospholipids.
3«4(c) Method of Rouser et al. (1969):
The following reagent were added rapidly and in order to 
the samples which were thoroughly vortexed after each addition; 
(i) 0.92 ml of GDW; (ii) 0.4 ml of ammonium molybdate (l.23^ 
in GDW); (iii) 0.4 ml of ascorbic acid (3^ in GDW). The 
samples were incubated in a boiling water bath for 3 minutes 
and the extinction read at 797 nm.
A typical standard curve is shown in Figure I6. This 
technique indicated a phosphorous content of Ptd Ins of only
9.7 nmoles per 3 x 10^ platelets and the effects of thrombin 
and the basal levels of Ptd OH were undetectable.
3 .4 (d) Conclusions :
Each of the above assays were relatively insensitive to 
the measurement of basal Ptd OH levels and the effects of an 
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Figure 15. Measurement of inorganic phosphorous by the method of 
Bowyer and Kino (1977)1






















Figure 16. Measurement of inorganic phosphorous by the method of 
Rouser et al. (l969).
Typical standard curve using the procedure outlined in Materials and
Methods (3.4c).
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encountered during the measurement of Ptd OH was the fact 
that there is so little Ptd OH present in the cell that it is 
not readily seen on a t.l.c. plate without the use of.carrier.
The use of such a carrier in the measurement of the mass of 
Ptd OH was impossible as it would affect the resultant 
calculation and so the position of Ptd OH on the plate had to 
be estimated using values. These problems of insensitivity 
could, of course, be overcome by increasing the platelet 
count per sample, which could be achieved by either increasing 
the amount of blood drawn from a single donor or by pooling 
blood. The former proposition was ruled out due to the fact 
that there was only a limited supply of regular donors and 
large volumes of blood could not be donated on a routine basis. 
The pooling of blood was excluded as it too would necessitate 
the use of large amounts of blood if quantitative observations 
were to be made. Therefore these experiments were discontinued 
on the grounds that they were time consuming, insensitive, 
expensive in terms of blood and alternative approaches were 
available.
3.3 Measurement of intracellular calcium concentrations
Intracellular calcium levels were monitored by using the 
fluorescent calcium dye Quin 2 (Tsein et al. , 1982; Pollock jet al, 
1984). PRP was incubated with Quin 2 acetoxymethyl ester 
(10 pM; 37°C; 30 minutes) after which the platelets were washed 
by Method II using the Hepes—buffered Tyrodes* solution. The 
Quin 2 content of the platelets using this technique was 1 mmole
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per litre of cell water. The external free calcium concentration 
was adjusted to 1 mM immediately before use by the addition
of calcium chloride. Platelet samples (2 ml; approximately
7 \ '5 X 10 platelets per ml} were placed in 1 cm square quartz
curvettes at 37^0 and the fluorescence monitored (Perkin-Elmer
LS3 Fluorescence Spectrometer) with standard monochromator
settings of 339 run (excitation) and 300 nm (emission). During
the course of each experiment at least one sample was treated
with digitonin (30 p.M) to lyse the platelets thereby releasing
all cellular calcium. This indicated the maximum calcium levels
present. This sample was then treated with EGTA (20 mM) which
bound all calcium present and so gave a theoretical minimum
calcium level. The intracellular calcium concentration was
obtained using the following equation;-




F = measured fluorescence
F . = measured fluorescence in presence of digitonin
and EGTA
F = measured fluorescence in presence of digitonin
max
A typical representative trace of the fluorescence record 















Figure 17. Diagramatic representation of fluorescence record in Quin 2 
labelled platelets.
Typical representative trace of fluorescence in Quin 2 labelled platelets. 
Agonist addition elicits an increase in fluorescence w^ich can be readily 
calibrated for fca ^].. F (theoretical maximum [ca j. )obtained by the 
addition of digitonin. F T^^(theoretical minimum [Ca 1. )was obtained 
by subsequent addition of^^^ EGTA.
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3* 6 Measurement of platelet functions 
3.6(a) Aggregation;
Platelet aggregation was measured using platelets washed 
by Method I and resuspended in Phosphate free, calcium free 
Hepes buffer. A platelet sample (0.6 ml) was placed in a 
standard Malin aggregometer. The agonist (6 p,l) was added 
and the resultant aggregation compared to buffer alone (0.6 ml).
3.6(b) ATP release;
ATP release, an index of dense granular secretion, was 
measured directly by use of Lucifern-luciferase luminescence 
in platelets washed by Method I and resuspended in Phosphate 
free, calcium free Hepes buffer. Lucifern-Luciferase (l5 V-1 ) 
was added to a platelet sample (0.5 ml) in a Chronolog Corp. 
luminescence aggregometer, the agonist was added and aggregation 
and ATP secretion were measured simultaneously.
3.7 Quantification of radioactivity
All radioactive samples to be analysed were added to 5-10 ml 
of either scintillator-299 (Packard) or ecoscint (National 
Diagnostics) in polythene vials and counted (5 minutes) for 
their radioactive content in a liquid scintillation counter 
(Packard Tri Garb).
4. Calculation of results
Simple statistical analysis was carried out on results 
obtained from the liquid scintillation counter to give mean, 
standard deviation (SD) and standard error of mean (SEM).
Vehicle controls were carried out at the beginning and the end 
of each experiment and the test values were expressed as a
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percentage of these controls. Statistical significance was 
assessed using Student*s t-test; only values of p < O.O3 
were taken to indicate statistical significance and the level 
of significance is indicated at each experiment.
3• Materials 
3*1 Drugs
Saline (0 .9% in GDW) was used to dissolve, dilute and 
used as vehicle control for the following drugs 
Bovine thrombin (Sigma), 8-arginine vasopressin (Sigma), 
adrenaline tartrate (Koch-Light Laboratories (U.K.), adenosine 
3 *-diphosphate (ADP, Sigma), sodium nitroprusside (NaNP,
Hopkins & Williams), 8-bromoadenosine 3*3*cyclic monophosphate 
(8-bromo cAMP, Sigma), 8-bromoguanosine 3 ’5 ’ cyclic mono- 
phosphoric acid (8-bromo cGMP, Sigma), bovine trypsin (Sigma), 
leupeptin (Sigma), flurbiprofen (Boots), EP I7I (Dr. R.L. Jones, 
University of Edinburgh) and the ”PG mixture" of PGEj^/6-keto- 
PGE^.
Phorbol 12 myristate 13 acetate (PMA, Sigma), 4-F-phorbol 
(Sigma), phorbol 12,13 dibutyrate (PDBu, Sigma) were dissolved 
in dimethyl sulphoxide (DMSO, Sigma) which was also used, at 
concentrations of less than 1%, as the vehicle control.
The stock (I.8 mM) platelet activating factor (PAE,
Bachem, Babbendorf, Switzerland) was dissolved in iso-osmotic 
saline containing bovine serum albumin (0,237°) • Subsequent 
dilutions of this stock were made up in saline which was also 
used as the vehicle control.
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Prostacyclin (Dr J .E. Pike, Upjohn Co.) was dissolved 
(l mg/ml stock), and dilutions made, in Tris buffer (30 mM 
in GDW, pH > 9 ).
PGD^ (Dr J.E. Pike, Upjohn) was dissolved initially in 
ethanol and diluted to a 3»3 mM stock by addition of 9 volumes 
of sodium carbonate (3 mM in GDW). All subsequent dilutions 
of this stock were in saline.
3.2 Phospholipid standards
Phosphatidylinositoi (Sigma) was dissolved in chloroform: 
methanol (2:l), phosphatidic acid (Sigma) in chloroform:methanol 
(l:l) and phosphatidylcholine (Sigma) in chloroform.
3•3 T.l.c. plates
Merck Silica Gel 60 high performance t.l.c. plates (lO cm x 
20 cm) and Macherey-Nagel precoated t.l.c. plates SIL G-23 
(20 cm X 20 cm) were purchased (MacFarlane Robson Ltd., Glasgow) 
The latter being cut into four smaller plates (lO cm x 10 cm) 
prior to use.
3*4 Radiochemicals
Carrier free ] -orthophosphate was provided by the
Regional Isotope Dispensary (Western Infirmary, Glasgow). 
3,6,8 ,11,12,14,13- [^h] arachidonic acid and myo- [2-^h] 
inositol were purchased from Amersham International.
3.3 Others
Bovine serum albumin, Hepes, ethylene diamine tetra-acetic
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acid (EDTA) and ethylene
glycol bis (F—amino ethyl ether) tetra-acetic acid (EGTA) 
were purchased from Sigma, perchloric acid (70^ *) from BDH Ltd. 
(Poole), Quin 2 acetoxymethylester from Lancaster Synthesis 
(Morecambe) and all solvents and laboratory reagents were of 






Although previous studies (Rittenhouse-Simmons, 1979; 
Broekman el al., 1980; Bell & Majerus, I98O; MacIntyre & Pollock, 
1983; Agranoff ejk al. , I983; Pollock ejb al. , 1984) have examined 
the effects of agonists on human platelet phosphoinositide 
metabolism, characterisation of these effects is by no means 
complete. Accordingly this section is concerned with investigat­
ing the effects of several agonists, including ADP, EP 171» 
trypsin and PMA, to ascertain whether phosphoinositide hydrolysis 
serves as the/a transduction process by which these agents 
generate second messenger molecules to influence human platelet 
function. In so doing, I examined the possibility that U44o69 
acts as a partial agonist at the platelet TxA^ (TP) receptor.
In addition I attempted to elucidate whether thrombin exerts 
its effects via both proteolytic and receptor-directed activities, 
In all cases the data, expressed as a percentage of the relevant 
control, are the mean - SEM of triplicate determinations and in 
each case are typical of 2 to 4 similar experiments.
1.1 Effect of ADP on platelet phosphoinositide metabolism
If phosphoinositide hydrolysis plays a role in ADP induced 
platelet activation, it follows that those concentrations of 
the agonist which stimulate the cell should also elicit 
significant formation of [^^p] Ptd OH. Preliminary studies 
established that platelets prepared under conditions of 
radio-labelling retained responsiveness (i.e. aggregation) to
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ADP. Figure 18 depicts the concentration response relationship 
for ADP on platelet [^^p] Ptd OH, the formation of which is 
the most sensitive index of inositol phospholipid metabolism 
in human platelets. In unstimulated platelets the levels of 
j^^^P J Ptd OH did not change significantly. When challenged 
with 0.1 — 100 p,M ADP for 30s there was no significant formation 
of j^ ^^ P ] Ptd OH by platelets at any concentration of ADP.
It is possible that the time course of ADP stimulated 
phosphoinositide metabolism differs from that reported in 
response to other agonists (MacIntyre & Pollock, I983; Pollock 
et al., 1984; Pollock & MacIntyre, I986). Therefore platelets 
were challenged with a supramaximal (in terms of functional 
response) concentration of ADP (lOO p,M) for 10 - 300s and the 
effects on Ptd OH levels are shown in Figure 19» Once
again there was no significant alteration in Ptd OH
levels at any time.
The final index of ADP induced phosphoinositide metabolism 
monitored was the effect of the agonist on j^ ^^ P j -PIP^ and -PIP 
levels and the results are shown on Figure 20. The level of 
neither phospholipid was significantly affected by the presence 
of ADP (100 >iM; 10 - 300s).
These observations indicate that ADP is unique amongst 
those agonists which have been reported to elevate |ca^^j ^  
in human platelets (MacIntyre et al., 1983b) and are in contrast 
to reports in rabbit (Lloyd et al., 1972, 1973a; Vickers et al., 
1982; Leung £t , 1983), rat (MacIntyre & MacMillan, I983)
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Figure 18. Concentration response curve for ADP-induced stimulation of 
P^P I Ptd OH formation
Ï32 10.4 ml samples of [ Pj P. prelabelled platelets were exposed to ADP at 
the concentrations indicated. [^^PJ Ptd OH levels were measured 30s after 
agonist addition. The results are means - SEM of triplicate determinations. 
The experiment shown is typical of 5 similar experiments.
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Figure 19. Time course of ADP-induced stimulation of Ptd OH formation.
0.4 ml samoles of [^^p] P. prelabelled platelets were exposed to 100 pM ADP 
and the [ P] Ptd OH levels measured at the times indicated. The results 
are means - SEM of triplicate determinations. The experiment shown is typical 
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chase labelled platelets were exposed totse .w— ———————— I------ — _ — I- -
 ^PJ PIPg (upper trace) and P  Pj PIP flower
0.4 ml samples of [ PJ P. pu.
100 vlM ADP and the levels of [ . j ... 
trace) were measured at the times indicated. The results are means - SEM 
of triplicate determinations. The experiment shown is typical of 3 similar 
experiments.
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studies ADP was shown to stimulate phosphoinositide metabolism
as monitored by Ptd OH formation and PIP^ loss, measured in 
32
both mass and P labelling studies. However in support of 
my observations, Fisher and colleagues (1985) subsequently 
confirmed that in human platelets, ADP does not affect ^^^pj 
-Ptd OH, —Ptd Ins, -PIP^ and -PIP levels or the formation of
inositol phosphates.
1.2 Effect of EP 171 ou platelet phosphoinositide metabolism
It has been previously shown, using the stable analogue 
U44o69 (9 ,11-epoxy methano PGH^), that agonist occupancy of 
platelet TP receptors is coupled to phosphoinositide hydrolysis 
(Pollock ejb al. , 1984). However studies on vascular tissue 
indicate that U44o69 may be a partial agonist (Jones ejfc al. ,
1982).
EP 171 is the most potent TxA^ mimetic known; in platelets 
it induces shape change, aggregation, secretion and elevates 
^Ca^^j (Jones ejfc a^. , 1983)» I therefore compared the effects 
of EP 171, U44o69 and a known partial agonist at the TP 
receptor. Et PGH^ (9;ll-ethano PGH^), alone and in combination 
on phosphoinositide metabolism in order to assess whether 
U44o69 is a full or partial agonist. EP 171 (l uM — 623 uM; 
120s) elicited a concentration dependent formation of [^^PJ Ptd 
OH (Figure 21). The maximal stimulation was 8OO - 20% of 
control with an EC-„ of 9 - 3  uM.30
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Using a high concentration of EP 171 the time course of 
changes in [^^P ] Ptd OH was also measured (Figure 22). EP I7I 
(625 nJM) induced a rapid increase in [^^P ] Ptd OH which plateaued 
at 120 - 300s (602 - 19% of control) and thereafter declined 
to 4-02 - 19% at 600s. As this time course does not rapidly 
reach its maximum level it is consistent with the relatively 
slow onset of functional responses observed (Jones et al., 1983)» 
In addition EP 171> like U44o69> maintained elevated levels 
of [^^P ] Ptd OH until at least 600s following agonist stimulation 
(Pollock e^;t ad., 1984).
The effects of EP I7I (623 hM) on [^^p] -PIP^ and -PIP 
levels is shown in Figure 23« The agonist caused an initial 
decrease (by approximately 12 - 1%) in the levels of PTP^ 
followed by an increase (ll2 - 4% at 600s). In contrast EP 171 
caused no decrease in PIP but the subsequent increase was much 
larger than that of PIP^ (315 - 20% at 600s). These observations 
are further evidence that the effects of the platelet Tx 
receptor are mediated by phosphoinositide hydrolysis.
1.3 Comparison of the effects of u44o69> Et PGH  ^ and EP 171
alone and in combination on 32p Ptd OH formation and ATP
secretion
The possibility that U44o69 was a partial agonist at the 
human platelet Tx receptor was investigated by examining the 
effects of U44o69> EP I7I and the known partial agonist Et PGH^ 
alone and in combination on platelet phosphoinositide metabolism. 














Figure 21. Concentration-reeponse curve for EP 171-induced stimulation of
Ptd OH formation.
0.4 ml samples of j^ p^l P. prelabelled platelets were exposed to EP 171 
at the concentrations indicated. [32p] ptd OH levels were measured 120s 
after agonist addition. The results are means - SEM of triplicate 
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Figure 22. Time course of EP 171-induced stimulation of
formation.
32P Ptd OH
0.4 ml samples of [^^p] P^ pMlabelled platelets were exposed to 625 nM
EP 171 and the levels gf Ptd OH measured at the times indicated.
The results are means - SEM of triplicate determinations, 
shown is typical of 2 similar experiments.
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Figure 23. Time course of EP 171-induced changes in levels of poly
phoephoinositides. L J
0.4 ml samples of L Pj P. pulse chase labelled platelets uera exposed to 
625 nM EP 171 and the levels of [^^Pj PIPg (upper trace) and L  PJ PIP 
flower trace) were measured at the times indicated. The results are means 
- SEM of triplicate determinations. The experiment shown is typical of 2 
similar experiments. Analysis of data: *P < 0.05; **P< 0.01; ***P<0.001.
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Ptd OH formation induced by the three analogues. The
rank order of potency is EP 1?1 > U44o69 > Et PGH«» with EC_^*s2 30
of 9 54 nM and approximately 1 )iM respectively. As outlined
in Figure 23, EP 1?1 (lOO nM; 120s), U44069 (3 )iM; 120s) and 
Et PGH^ (30 p,M; 120s) elicited [^^p] Ptd OH formation of 
840 — 30^, 350 - 23% and 179 — 3^^ of the saline control 
respectively. However both u44o69 and Et PGH^ attenuated the 
EP 171 induced ] Ptd OH formation to 4o4 - 21% and 333 ± 76%
respectively. When agonist induced ATP secretion, expressed 
as a percentage of the maximum releasable ATP, is monitored 
(Figure 26), the order of potency is EP I7I > U44o69 > Et PGH^
(= 0 ). In addition, U44o69 and Et PGH^ inhibit EP I7I induced 
release of ATP from human platelets (Figure 27). These 
observations would perhaps be best explained were U44069, like 
Et PGH^, to act as a partial agonist and EP 171 to act as a 
full agonist at the platelet Tx receptor.
1.4 Effect of thrombin on platelet phosphoinositide metabolism 
Thrombin is probably the most widely studied platelet 
stimulatory agonist. It has been shown to elevate DAG
(Rittenhouse-Simmons, 1979), decrease [^^p] PIP2 (Agranoff e_t al. , 
1983; Rendu e_t aT. , I983), stimulate the formation of inositol 
phosphates (Siess & Binder, I983), increase the amount of Ptd OH 
and decrease the amount of Ptd Ins (Broekman ejb al. , I98O).
The concentration response relationship for thrombin on Ptd OH 
in [^^P ] pre-labelled platelets is shown in Figure 28. Thrombin 
(0.01 - 3 U/ml (0.3 - 130 nM); 30s) elicited a concentration 
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0.4 ml samples of [ p] P. prelabelled platelets were exposed to EP 171, 
U44069 or Et PGHg at the concentrations indicated. [ Pj Ptd OH levels 
were measured 120s after agonist addition. (U44069 curve from MacIntyre 
et al., 1985).














^ S al i n e 
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U44069 (3;jM) 
[Et PGH 2 (30|jM)
'U44069 (3>jM)
Et PGH 2 (30>jM)
on EP 171-induced [32p- Ptd OHFigure 25. Effects of U44069 and Et PGH. 
formation.
0.4 ml samples of [^ p^] P. prelabelled platelets were incubated with 
combinations of either saline or EP 171 (100 nM) and either saline^ EP 171, 
U44069 or Et PGHL at the concentrations indicated. The levels of L PJ Ptd 
OH were measured 120s after the addition of the agonists. The results are 
means - SEM of triplicate determinations. The experiment is typical of 3 
similar experiments. Analysis of data (comparison with saline/EP 171);
















Figure 26. Concentration response curves for EP 171, U44069 and Et PGH, 
induced ATP release.
0.5 ml platelet samples were exposed to EP 171, U44069 or Et PGH^ at the
concentrations indicated. ATP release was measured by Lucifern-luciferase
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Figure 27. Effects of U44069 and Et PGH_ on EP 171-induced ATP release.
0.5 ml platelet samples were challenged with EP 171 at the concentrations 
indicated and either saline (circles), 3 U44G59 (triangles) or 30^M
Et PGHg (squares). ATP release was measured by Lucifern-luciferase 
luminescence and expressed as a percentage of the maximum releasable ATP.
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of thrombin used was 3 U/ml and as the curve was still rising 
at this point it is impossible to assign a maximum level of 
stimulation and the can only be estimated to be > 0.1 U/ml
(> 3 TiM).
The maximum ^  Ptd OH levels in response to thrombin
(l u/ml (30 nM))was achieved at 120s (2333 -  121^ of saline 
control) and this did not decline at 600s (Figure 29)* This 
finding is relatively consistent with that of Agranoff, who 
demonstrated that the levels of [ ] Ptd OH were still rising
at 120s, which was the latest time point he measured (Agranoff 
et al., 1983)* The time course of the effects of thrombin 
(1 u/ml (30nM)) on [^^pj -PTP^ and -PIP levels in human platelets 
(Figure 30) shows a decrease in PTP^ levels (to - 1% of the 
saline control) followed by an increase (to 128 - 3^ at 600s). 
There was a time dependent increase in the levels of PIP which 
reached 339 - 11% at 600s following agonist addition.
1.3 Effect of agonists alone and in combination on 32p Ptd OH
formation
Results in Figure 28 and Figure 29 demonstrate that thrombin 
is by far the most efficacious and potent platelet stimulatory 
agonist at inducing [^^P] Ptd OH formation. In order to 
investigate this further, thrombin induced [^^P j Ptd OH was 
compared to that of a variety of compounds which may function 
as endogenous platelet agonists or mimics of endogenous platelet 
agonists vivo. The platelets were challenged with high 
concentrations of the agonists both alone and when combined 













Figure 28. Concentration response curve for thrombin-induced stimulation 
of Ptd OH formation.
0.4 ml eamplea of 32, prelab^lle 
at the concentrations indicated
.abel d
I.
platelets were exposed to thrombin 
Ptig OH levels measured 30s after 
agonist addition. The results are means - SEW of triplicate determinations. 
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Figure 29. Time course of thrombin-induced stimulation of Ptd OH
formation. L
0.4 ml samples of [ p] P, prelabelled platelets were exposed to lU/ml 
(50 nM) thrombin and the levels of [32pj ptd OH measured at the times 
indicated. The results are means - SEM of triplicate determinations. 
The experiment is typical of 2 similar experiments.
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Figure 30. Time course of thrombin-induced changes in levels of
poly phosphoinosotidee. L J
0.4 ml samples of
f
pulse chased labelled platelets were exposed
o lU/ml (50 nM) thrombin^and the levels of [^^PJ PIPg (upper trace) and 
32pj PIP (lower trace) measured at the times indicated. The results are 
means i SEM of triplicate determinations. The experiment is typical of 3 
similar experiments. Analysis of data; *P <0.05; **P < 0.01; ***p< 0.001.







Figure 31. Effects of agonists alone and in combination on T^P Ptd OH 
formation ^
0.4 ml samples of [^ p^] P. prelabelled platelets were exposed to either 
saline, ADP (IpM), PAF (Ï80 nM), 5HT (I0)i M) all for 30s, EP 171 (100 nM) 
for 120s, a cocktail containing the same concentrations of above agonists 
for the times indicated or thrombin (lU/ml; 50 nM) foj 120s and the levels 
of [32p]ptd OH were measured. The results are means - SEM of triplicate 
determinations. The experiment is typical of 4 similar experiments.
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however PAT (l80 nM; 30s), 3HT (lO >iM; 30s) and EP 171 (lOO nM; 
120s) stimulated 356 ± 9^, l49 - 2fo and 607 - 6fo of the saline 
control respectively. The cocktail containing the same supra 
maximal agonist concentrations elicited a response of 663 - 27^ 
which is marginally more than the individual agonists alone 
elicit but considerably less than the 1529 - ll4^ stimulation 
of ] Ptd OH evoked by thrombin (l U/ml; 120s). Two possible
explanations for this effect are that thrombin stimulates 
platelets via a proteolytic action and that some form of 
heterologous desensitisation occurs to prevent the cocktail of 
endogenous agonists from having an additive effect.
1.6 Effect of trypsin on platelet phosphoinositide metabolism 
Trypsin, like thrombin, is a serine protease which has 
been shown to initiate the platelet functional response (Oavey 
& Luscher, 1967)» Comparison of thrombin and trypsin has shown 
that their enzyme saturating concentrations are 83 uM and 85O nM 
respectively (Martin ejb ad., 1975)»
Trypsin was used to examine the extent of the contribution 
that proteolytic activity made to the action of thrombin.
Figure 32 shows the concentration response relationship for 
trypsin (lO nM - 10 p,M; 120s) induced formation of ] Ptd OH.
The maximal stimulation of [^^P ] Ptd OH formation is 3002 - JOJo 
and the estimated EC^^ is 107 - 39 Thus proteases have
the capacity to stimulate the formation of [^^P ] Ptd OH formation 
to a much greater extent than the classical receptor directed 
agonists. Whether such an effect is due solely to proteolytic 
activity or is mediated in part by some form of receptor-
3 0 0 0 -
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Figure 32. Concentration response curve for trypsin-induced stimulation of 
t^2p| Ptd OH formationl
r 22 1
0.4 ml samples of Pj P. prelabelled platelets were exposed to trypsin 
at the concentration indicated. [ 32pj ptd OH Igvels were measured 120s 
after agonist addition. The results are means - SEM of triplicate 
determinations. The experiment is typical of 3 similar experiments.
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activated process cannot be estimated on the available evidence.
1*7 Effect of trypsin and EP 171 on platelet phosphoinositide 
metabolism
To examine possible additive effects of protease and 
receptor mediated phosphoinositide hydrolysis, trypsin and EP I7I 
were co-added to platelets. The extent of ] Ptd OH formation
evoked by trypsin (l pM; 120s) alone is 3058 - 76^  ^and by EP I7I 
(100 nM; 120s) alone 722 - 2^. In both cases data is expressed 
relative to the saline control. When these agonists were 
combined the resultant extent of [^^p] Ptd OH formation increased 
to 3600 - 55% of the saline control. Thus the combination is 
significantly more effective than either trypsin or EP I7I alone: 
indeed the potentiation appears to be almost exactly additive 
(Figure 33)* This suggests that mechanistically it is possible 
for a dual stimulation of human platelets via both a receptor- 
activated (typified by EP 171) and a protease (typified by 
trypsin). Pretreatment with the protease inhibitor leupeptin 
(100 %g/ml; 60s), inhibits the trypsin-induced formation of 
[^^P ] Ptd OH both alone and in combination with EP 171 (Figure 
34). It is therefore possible that proteases stimulate 
platelets by acting by a different process from other types 
of agonists, although its precise mechanism of action cannot be 
elucidated from this data. The proteases (thrombin and trypsin) 
clearly differ qualitatively and quantitatively from other 
agonists in their coupling mechanism to phospholipase 0 
catalysed phosphoinositide hydrolysis.
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Figure 33. EP 171 and trypsin stimulation of
0.4 ml samples of
P i
Ptd OH formation.
pp. P. prelabelled platelets were exposed to either 
saline, EP 171 (100 nM' , trypsin (IV-M), or a combination of EP 171 (100 nM) 
and trypsin (ipM). [32pj Ptd OH levels were measured 120s after addition 
of the agonist(s). The results are means - SEM of triplicate determinations 
The experiment is typical of 3 similar experiments. Analysis of data:
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Figure 34. Effects of leupeptin on EP 171 and trypsin-induced stimulation
of p p j Ptd OH formation.
r 3 2 10.4 ml samples of [ Pj P. prelabelled platelets were pre-incubated for 
60s with either saline (open bars) or 100 ^ g/ml leupeptin (hatched bars), 
prior to the addition of either saline, EP 171 (100 nM), trypsin (ipM) 
or a combination of EP 171 (100 nM) and trypsin (1 p-M). [ Pj Ptd OH
levels were measured 120s after addition of agonist(s). The results are 
means - SEM of triplicate determinations. The experiment is typical of 
2 similar experiments. Analysis of data; *p < 0.01; **p < 0.001.
— 10 6 —
1.8 Effect of PMA on platelet phosphoinositide metabolism
The phorbol ester class of compound have been shown to 
stimulate human platelets by a direct activation of protein 
kinase C and therefore should bypass receptor mediated phospho- 
inositide hydrolysis. Figure 33 demonstrates the effects of 
the phorbol ester PMA on -Ptd OH and -Ptd Ins levels.
PMA (lOO nM) evoked no alteration in the labelling of Ptd OH 
up to 600s following its addition. This suggests that, as 
expected, PMA does not stimulate phospholipase C activity.
In contrast however 120s to 600s after challenge, PMA caused 
a decrease in the levels of [^^P ] Ptd Ins when compared to the 
DMSO control indicative of some effect by PMA on phosphoinositide 
metabolism.
To further investigate this, the effect of PMA on [^^P ] 
-PIP^ and -PIP were examined. PMA (lOO nM) did not elicit an 
initial decrease in the levels of PIP^? as for example EP 171 
(Figure 23) and thrombin (Figure 30) do, but did stimulate 
increased levels of both [^^P ] -PIP^ a^ id -PIP (Figure 36).
This increase in the levels of the poly phosphoinositides occurs 
late in response to PMA (60s for PIP; 120s for PIP^) unlike 
the corresponding increase in response to receptor directed 
agonists such as EP 171 (Figure 23) and thrombin (Figure 30)•
1.9 Summary
These results demonstrate that thrombin, EP 171 and trypsin 
but not ADP and PMA induced stimulation of the human platelet 
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Figure 35. Time course of PMA-induced stimulation of Ptd OH formation
0.4 ml samples of [_ Pj- P.-.prelabelled platelets were exposed to 100 nM 
PMA and the levels of "[^^fjPtd OH measured at the times indicated. The 
results are means - SEM of triplicate determinations. The experiment is 
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L P_LP.-prelabelled platelets were exposed to 100 nM
of PIPg (upper trace) and [^^Pj PIP flower trac
0.4 ml samples of
PMA and the levels J e) 
were measured at the times indicated. The results are means - SEM of 
triplicate determinations. The experiment is typical of 3 similar experiments, 
Analysis of data; *p < 0.05; **p < 0.01.
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EP 171 is a more potent agonist at the platelet Tx 
receptor than, the previously reported, J^hhoG^  (Pollock ejfc ,
1984). Indeed it appears that EP I7I is a full agonis't and
U44o 69 a partial agonist at this receptor.
Thrombin is the most potent and efficacious agonist so 
far examined. There are at least two possible explanations 
for the inability of combinations of other agonists to match 
the level of thrombin induced [^^P ] Ptd OH formation. Firstly 
thrombin may stimulate platelets by both receptor mediated 
and proteolytic mechanisms, and the effects of trypsin indicate 
that proteases can stimulate [^^P ] Ptd OH formation. Secondly 
there may be some form of desensitisation amongst the other 
agonists.
2. Mechanisms underlying desensitisation
In this section I examine the inter-relationships between 
phosphoinosi tide metabolism and elevation of In
particular the regulation of [ca^^j by agonist concentration, 
by adenylate and guanylate cyclase stimulants and by phorbol 
esters is compared to the effects of the same processes on 
platelet phosphoinositide metabolism. In addition the possibility 
that certain endogenous agents can act as mediators of de­
sensitisation was examined.
2.1 Effect of agonist concentration on platelet Ca2 +
When an agonist is added to platelets pre-incubated with 
Quin 2 it elicits a concentration dependent increase in 
fluorescence which is readily calibrated to report jca^^j ^
— 108 —
and increases in |ca^^j . The resting [ca^^] in human platelets 
is 90 - 3 uM (mean - SEM). A typical experimental fluorescence 
record for PAF (I.8 - 180 nM) is shown in Figure 37* As the 
agonist concentration increased, the rate and extent of the 
resultant fluorescence (and so ^a^^j ^ ) also increased until a 
maximum value (400 — 700 nM in different experiments) was 
attained. Thereafter the fluorescence declined towards the 
resting value. The rate of decline of the signal also varied 
with the agonist concentration; the response elicited by the 
high concentration decayed more rapidly than that elicited by 
the lower concentrations.
2.2 Effect of agonist concentration on platelet phosphoinositide 
metabolism
Inositol phospholipid hydrolysis mechanistically is believed 
to underlie elevated jca^^j . Consequently the effects of agonist 
concentration on the profile of the time course of agonist- 
induced [^^P ] Ptd OH formation was examined. The time courses 
of supra maximal (I.8 ]iM) and threshold (l8 nM) PAF at eliciting 
the formation of j^ ^^ P j Ptd OH are compared in Figure 3 8, The 
supra maximal PAF concentration displays a rapid elevation of 
Ptd OH which plateaus at 30 - 60s and this was followed by a 
rapid decrease. In contrast 18 nM PAF stimulated a much slower 
rise and fall in Ptd OH levels which was significantly elevated 
at 120 - 300s only. This mirrors the situation observed when 
the time course of agonist-induced elevation of [ca^^] is 
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Fiqure 37. Effect of concentration on PAF-induced elevation of ^]i
2.0 ml samples of Quin 2 labelled platelets were exposed to PAF at the 
concentrations indicated. Fluorescence ç^sponses were monitored after 
agonist addition and the appropriate fca J. calibration scale is shown 
on the right of the fluorescence record. me experiment shown is typical
of 3 similar experiments.
* * *
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Figure 38. Effect of concentration on PAF-induced stimulation of 
Ptd OH formation.
K ] .8 U
Ptd
0.4 ml samples of L"^P J P. prelabelled platelets were exposed to 1,
PAF (upper trace) or to lè nM PAF (lower trace) and the levels of 
OH measured at the times indicated. The results are means - SEM of 
triplicate determinations. The experiment is typical of 2 similar experiments 
at each concentration. Analysis of data: *p < 0.05; **p<0.01; ***p ^ 0.001
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2*3 Effect of second addition of agonist on platelet ph.osph.o~ 
inositide metabolism
To further investigate possible desensitisation in phospho­
inositide response, a supra maximal PAF concentration (l.8 p,M) 
was added to ] pre-labelled platelets and this elevated
the Ptd OH levels to 476 - 145% of the saline control
at 30s (Figure 39). The platelets were subsequently challenged 
with PAF (l.8 p,M; 30s) and this second addition failed to 
elicit further formation of Ptd OH. However were vasopressin 
added as the second agonist then further Ptd OH formation results 
when compared to the time matched saline control. The amount 
of vasopressin induced Ptd OH formation is less than that formed 
when this agonist is added alone, and is much less than that 
elicited by thrombin (Figure 39)» This is perhaps indicative 
of heterologous desensitisation and clearly suggests that 
desensitisation is not due to limited levels of inositol 
phospholipids.
As desensitisation is not due to the substrate availability, 
I examined the possibility that endogenous compounds exist 
which act as mediators of desensitisation. Putative candidates 
for such a function are the cyclic nucleotides, cAMP and cGMP 
as elevated levels of both compounds have been shown to inhibit 
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Figure 39. Desensitisation of agonist-induced Ptd OH formation
32,0.4 ml samples of [ Pj P. ^ relabelled platelets were exposed to 1.8p,n 
PAF and the levels of [^2^ j ptd OH measured at the times indicated. At 
30s the platelets were again challenged with either saline (open circles),
1.B^M PAF (open triangles) or 1 M vasopressin (closed circles) and the 
levels of [32pJ Ptd OH measured at 60s. Vasopressin (1 p,M) and thrombin 
(lU/ml (50 nM))controls, which are not desensitised, are depicted for 
comparison. The results are means - SEM of triplicate determinations.
The experiment is typical of 3 similar experiments.
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2.4 Effects of agents that influence cyclic nucleotides on
2+1platelet Ca
In order to examine possible mechanisms of desengitisation 
the effects of cyclic nucleotides, which are potent inhibitors 
of platelet function, on ^ were investigated. The
adenylate cyclase stimulants PGI^ and PGD^ (both < 1 )iM; 120s), 
the guanylate cyclase stimulant NaNP (< 10 p,M; 120s) and the 
stable cyclic nucleotide analogues 8Br cAMP and 8Br cGMP (both
< 1 mM; 300s) were added to Quin 2 labelled platelets prior to
challenge with sub-maximal PAT (lO - 100 nM). Each agent 
inhibited, in a concentration dependent manner, the agonist 
induced elevation of [oa^^j ^  (Figure 40) although none of the 
compounds altered basal |ca^^j .
2.5 Effect of agents that influence cyclic nucleotides on 
platelet phosphoinositide metabolism 
Similar studies were carried out on platelet phospho­
inositide metabolism. PGD^» NaNP (both < 1 pM; 90s) and the
stable cyclic nucleotide analogues 8Br cAMP and 8Br cGMP (both
1 mM; 300s) had no effect on basal [^^p] Ptd OH levels 
(Figure 4l). In contrast PGD^ (3 - 300 nM; 90s) inhibits PAF 
(l8 nM; 30s; Figure 42) and vasopressin (lOO nM; 30s; Figure 
43) induced formation of [^^p] Ptd OH with 1^^ values of around 
10 nM and 30 nM respectively. Similarly NaNP (0.3 riM - 3 
90s) inhibits PAF (l8 nM; 30s) induced [^^p] Ptd OH formation 
in a concentration dependent manner with an 1^^ of around 
30 nM (Figure 44). Were cAMP and/or cGMP to be produced by 
platelets following challenge with stimulatory agonists, then 
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Figure 40. Effects of agents which influence cyclic nucleotides on
PAF-induced elevation of FT
2.0 ml of Quin 2 labelled platelets were pre-incubated with PGI^# PGD^» 
NaNP, 8 Br cAMP, 8 Br cGMP or the appropriate vehicle at the concentration 
indicated prior to the addition of a sub-maximal concentration of PAF 
(10_- 100 nM). Fluorescence responses were monitored, calibrated for 
fca and are expressed as inhibition of the PAF (+ vehicle) control.
















Figure 41. Effects of agents which influence cyclic nucleotides on 32,
Ptd OH levels.
[::p]0.4 ml samples of L““PJ P. prelabelled platelets were exposed either to 
PGD„ or NaNP for 90s or to 8 Br cAMP or cGMP for 300s at the concentrations 
indicated. [32pj Ptd OH levels were measured at the appropriate times.
The results are means - SEM of triplicate determinations. The experiment 
is typical of 2-4 similar experiments.
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Figure 42. Effect of PGDg on PAF-induced stimulation of 32, Ptd OH formation.
0.4 ml samples of L"^PJ P. prelabelled platelets were pre-incubated for 90s 
with POOL, at the concentrations indicated, or with the saline control. 
Samples were then challenged with 18 nM PAF andT^^Pj Ptd OH measured 30s 
after agonist addition. The results are means - SEM of 2 similar experiments 
each performed in triplicate. Analysis of data (expressed as inhibition of 
PAF (+ saline) response): *p <0.05; **p <0.01; ***p < o.OOlr
100-1
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Figure 43. Effect of PGD_ on vasopressin-induced stimulation of 
OH formation.
32, Ptd
[='p] prelabelled platelets were pre-incubated for 90s0.4 ml samples of
with POOL, at the concentrations indicated, or with the saline control.
Samples were then challenged with 100 nM vasopressin and [32pj ptd OH 
measured 30s after agonist addition. The results are means - SEM of 3 similar 
experiments each performed in triplicate. Analysis of data (expressed as 
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Figure 44. Effect of NaNP on PAF-induced stimulation of 32, Ptd OH formation,
0.4 ml samples of [ p] P. prelabelled platelets were pre-incubated for 
90s with NaNP, at the concentrations indicated, or with the saline control. 
Samples were then challenged with 18 nM PAF and Ptd OH levels measured
30s after agonist addition. The results are means - SEM of 3 similar 
experiments each performed in triplicate. Analysis of data (expressed as 
inhibition PAF (+ saline) response): *p < 0.05; **p <0.001.
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Studies in neutrophils have indicated that the protein 
kinase C stimulants, the phorbol esters, activate an ATP- 
dependent calcium extrusion process (Mottola & Romeo, *1982) 
and attenuate an agonist-induced elevation in jca^^j . The 
phorbol esters PMA and PDBu were used to examine whether 
protein kinase C activation in human platelets have similar 
pronounced inhibitory effect on the stimulatory transduction 
process. The inactive phorbol analogue, 4Pphorbol, which is 
structurally similar to phorbol esters but does not activate 
protein kinase C (Castagna ejt aT. , I982), was used as the 
negative control in these studies.
2.6 Effect of phorbol esters on agonist induced elevation of
Ca2+
Using Quin 2 labelled platelets thrombin (0.023U/ml (I.23 uM) 
vasopressin (30 nM) and PAF (lO nM) caused an elevation of 
|ca^’*^j ^  from a resting value of 90 - 3 TtM to a maximum of 
310 - 180 nM, 420 - 80 nM and 480 - 100 nM respectively. When 
incubated with platelets for 120s, neither PMA nor 4Pphorbol 
(both < 1.6 p,M) altered resting [pa^^j^. However PMA (16 - 
160 nM) but not 4Pphorbol inhibited in a concentration dependent 
manner the elevation of ^ induced by all three agonists
(Figure 43).
2.7 Effect of phorbol esters on agonist induced platelet 
phosphoinositide metabolism 
PMA (1.6 )iM; 120s) had no effect on platelet [^^p] Ptd OH 
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Figure 45; Effect of PMA on agonist-induced elevation of M r
2.0 ml of Quin 2 labelled platelets were pre-incubated for 120s with 
DMSO (vehicle), 4 P phorbol or PMA at the concentrations indicated. 
Fluorescence responses were monitored following the addition of 
thrombin (0.025U/ml (1.25 nM)), vasgpressin (50 nM) or PAF (10 nM) and 
the appropriate calibration for [Ca is shown to the right of the 
fluorescence records. The experiment shown is typical of 3 similar 
experiments.
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phorbol analogue, 4Pphorbol (l.6 p,M; 120s). In contrast 
PMA (1.6 y,M; 120s) did cause a significant decrease in the 
levels of Ptd Ins (Figures 35 & 46).
Figure 47 depicts the effect of PMA on PAF induced [^^P J 
Ptd OH formation. In this experiment PAF ( l O  nM; 30s) elicited 
a 523 - 11^ response following preincubation with 4Pphorbol 
(1.6 )iM; 120s). This was attenuated, in a concentration 
dependent manner, by preincubation with PMA (16 nM - 1.6 p,M; 
120s). Moreover PMA preincubation ( l O O  nM; 120s) suppressed 
the response to PAF at all concentrations of the agonist 
tested (1 - 100 nM; 30s) (Figure 48). Preincubation with PMA 
(16 nM - 1.6 |tM; 120s) also attenuated thrombin (o.iu/ml 
(5ttM); 30s) induced [^^p] Ptd OH formation in a concentration 
dependent manner (Figure 49) and 100 nM PMA for 120s caused 
an apparent rightward shift in the thrombin concentration 
response curve (Figure 50). Vasopressin ( l O O  nM; 30s) induced 
338 - 48% of the control level of [^^P ] Ptd OH following 
preincubation with 4Pphorbol (I.6 p-M; 120s). This stimulation 
was inhibited in a concentration dependent manner by pre­
incubation with PMA (16 nM - 1.6 p,M; 120s) as seen in Figure 
31. EP 171 (10 nM; 120s) elicited an increase to 257 - 24% 
of the basal [^^p] Ptd OH levels. This was not significantly 
altered by 120s preincubation with DMSO (228 — 10% of control). 
In contrast the addition of PMA ( l O O  nM; 120s) prior to 
challenge with EP 171 ( l O  nM; 120s) truncated the formation of 
[^^Pj Ptd OH to 126 - 7% of control (Figure 52). In addition
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PMA (lOO nM; 120s) markedly suppressed the response (Ptd OH 
formation) elicited by all concentrations of EP 1?1 tested 
(Figure 53)• Similar effects were observed when platelets were 
preincubated with PDBu (200 nM; 120s) prior to challenge with 
PAF (lO nM; 30s), thrombin (o.lU/ml (5 nM); 30s) or vasopressin 
(100 nM; 30s) (Figure 5^)»
To examine the effects of protein kinase 0 activation 
on agonist-induced poly-phosphoinositide metabolism thrombin 
was used as it is the most efficacious agonist available.
PMA (100 nM; 120s) induced a significant increase in ^^^p] -PIP. 
and -PIP levels (l2? - 1% and 177 - of DMSO control 
respectively). Thrombin (lU/ml (50 nM); 10s) caused a decrease 
in PIP^ (86 - h^ o of saline control) but did not alter PIP 
levels (101 - 2^). Preincubation with PMA (lOO nM; 120s) 
inhibited the thrombin induced decrease in ] PIP^ levels
to 123 - 3% which was not significantly different from PMA 
alone (l27 - 1%) (Figure 55)*
Therefore phorbol esters presumably by activation of 
protein kinase C have a pronounced effect on the human platelet 
phosphoinositide cycle. PMA decreases [^^P ] Ptd Ins levels, 
increases both [^^P ] PIP^ and [^^P ] PIP (PIP > PIPg) and 
apparently inhibits the thrombin induced hydrolysis of PIP^*
In addition PMA inhibits agonist-induced formation of [^^p]
Ptd OH with no effect on the basal Ptd OH levels. As phorbol 
esters effectively act as DAG mimetics, it is possible that 
DAG (via activation of protein kinase C) plays not only a 
















Figure 46. Effect of PMA on
salir
N
W Ptd OH and
32, Ptd Ins levels.
P. prelabelled platelets were expos 
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are means - SEM of triplicate determinations, 
of 8 similar experiments. Analysis of data:
The experiment is typical 
*p < 0.005.
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Figure 47. Effect of PMA on PAF-induced stimulation of 32, Ptd OH formation.
0.4 ml samples of [ p] P. prelabelled platelets were pre-incubated for 
120s with either saline (closed bars) 4 Pphorbol (hatched bars) or PMA (open 
bars) at the concentration indicated. Reactions were initiated by the 
addition of either saline (control) or 10 nM PAF. F^^PJ Ptd OH levels 
were measured 30s after agonist addition. The results are means - SEM of 






















Figure 48. Effect of PMA on 
stimulation of
[''p]
 concentration response curve for PAF-induced
Ptd OH formationi
0.4 ml samples of J P. prelabelled platelets wsre pre-incubated for 120s 
with either DMSO (closed circles) or 100 nM PMA (open circles). Reactions 
were initiated by the addition of PAF at the concentrations indicated. [ Pj 
Ptd OH levels were measured 30s after agonist addition. The results are means 
- SEM of triplicate determinations. The experiment is typical of 2 similar 
experiments.
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Figure 49» Effect of PMA on thrombin-induced stimulation of I^ P^I Ptd OH 
formation.
0.4 ml samples of [^ p^] P. prelabslled platelets were pre-incubated for 120s 
with either saline (closeà bars), 4 P phorbol (hatched bars) or PMA (open 
bars) at the concentrations indicated. Reactions were initiated bkLtbe 
addition of either saline (control) or O.OlU/ml (5 nM) thrombin. [ Pj Ptd ^ 
OH levels were measured 30s after agonist addition. The results are means - 
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Figure 50. Effect of PMA on the concentration response curve for thrombin- 
induced stimulation of I P t d  OH formation. "[ ]
0.4 ml samplee of [ PJ P. prelabelled platelets were incubated for 120s 
with either DMSO (closed circles) or 100 nM PMA (open circles). Reactions
Ï ere initiated by the addition of thrombin at the concentrations indicated. 32pJ ptd pH levels were measured 30s after agonist addition. The results 
are means - SEM of triplicate determinations. The experiment is typical of 
2 similar experiments.
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Figure 51. Effect of PMA on vasopressin-induced stimulation of
OH formation.
32P Ptd
P. prelabelled platelets were pre-incubated for 120s0.4 ml samples of
with either saline (closeà bars), 4P phorbol (hatched bars) or PMA (open 
bars) at the concentrations indicated. Reactions were initiated by the 
addition of either saline or 100 nM vasopressin. [32pj ptd Og levels were 
measured 30s after agonist addition. The results are means - SEM of 
triplicate determinations. The experiment is typical of 2 similar experiments,
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Figure 52. Effect of PMA on EP 171-induced stimulation of 32P Ptd OH
formation.
0.4 ml samples of [^^pj P. prelabelled platelets were pre-incubated for 120s 
with either saline (closeà bars), DMSO (hatched bars) or 100 nM PMA (open 
bars). Reactions were initiated by the addition of either saline or 10 nM 
EP 171. r32pj Ptd OH levels were measured 120s after agonist addition. The 
results are means - SEM of triplicate determinations. The experiment is 













Figure 53. Effects of PMA on the concentration response curve for EP 171- 
stimulation of Ptd OH formation.
0.4 ml samples of N P. prelabelled platelets were pre-incubated with
either DMSO (closed circles) or 100 nM PMA (open circles). Reactions were 
initiated by the addition of EP 171 at the concentration indicated,
Ptd OH levels were measured 120s after agonist addition. The results are 
means - SEM of triplicate determinations. The experiment is typical of 2 
similar experiments.
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Figure 54. Effects of PDBu on agonist-induced stimulation of [32pl Ptd OH
formation. ■ m
0.4 ml samples of [ P ] P. prelabelled platelets were pre-incubated for 
120s with either saline (closed bar), 4 P phorbol (hatched bars) or 200 nM 
PDBu (open bars). Reactions were initiated by the addition of either saline, 
10 nM PAF or 100 nM vasopressin or O.lU/ml (5 nM) thrombin. P | Ptd Oljj 
levels were measured 30s after agonist addition. The results are means - 
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Figure 55. Effects of PMA on thrombin-induced changes in levels of I
poly phosphoinositides.  ^ -*
0.4 ml samples of P. pulse chase labelled platelets were pre-incubated
for 120s with either DMSO^or 100 nM PMA as depicted above. Reactions were^g -i
initiated with either salina or lU/ml (50 nM) thrombin and the levels of [ P J
PIP (upper trace) and [32pjPIP (lower trace) were measured 10s after agonist 
addition. The results are means - SEM of triplicate determinations. The
experiment is typical of 2 similar experiments.
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role on the transduction processes that are initiated by- 
occupancy of platelet receptors for stimulatory agonists.
Having established that prior exposure of platelets to 
agents that elevate cA24P> cGMP or activate protein kinase C 
can impair transduction processes activated by subsequent 
challenge with agonists, I next investigated whether the same 
agents could reverse the transduction process once initiated.
2.8 Reversal of agonist induced elevation of platelet
The possible role of endogenous cyclic nucleotides and 
DAG in mediating the reversal of agonist induced elevation of 
C^a^ '*’J ^  was investigated. A sub-maximal PAP concentration 
(50 nM) elicits an increase in fluorescence in Quin 2 labelled 
platelets which is followed by a decline in the signal. As 
depicted in Figure ^6, PGI^ (lO nM - 1 pM), NaNP (l - 10 pM) 
and PMA (50 - 100 nM) added at the peak of the fluorescence 
signal all accelerated, in a concentration dependent manner, 
the rate of this decline. This suggests that cAMP, cGMP and 
DAG may play a role in limiting or terminating the agonist 
induced response.
2.9 Reversal of agonist induced platelet phosphoinositide 
metabolism
To further investigate the ability of cAMP, cGMP and DAG 
to modulate the platelet transduction process, the ability of 
agents which influence their activity to terminate agonist 
induced phosphoinositide hydrolysis was examined. The agonist 














Figure 56. Reversal of PAF-induced elevation of Ca2+ by PGI_, NaNP and PMA.
2.0 ml of Quin 2 labelled platelets were challenged with 50 nM PAF, PGIg, 
NaNP or PMA, at the concentrations indicated, or the appropriats vehicj^ 
was added at the peak of the resultant fluorescence signal and the |^ Ca J ^  
calibrated from the observed changes. The experiment shown is typical 
of at least 4 experiments for each agent.
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in this section. This was because an agonist was required 
which, at sub-maximal concentrations, stimulates j Ptd OH
formation to a prolonged elevated level which is large enough 
to observe the possible inhibitory effects of NaNP, PGD^ and 
PMA. The formation of ] Ptd OH by 18 nM PAF, although well
maintained, would be insufficient to monitor inhibitory actions 
(Figure 38).
A sub-maximal EP 171 concentration (lO nM) stimulated the 
formation of |^^^P j Ptd OH which reached a peak at 120s and 
remained at this elevated level at 600s (Figure 57)* The profile 
of this curve is similar to that of the submaximal PAF 
concentration (Figure 38). The curve was prolonged at a level 
which allowed the effect of the subsequent addition of a 
compound to be observed.
The addition of PGD^ ( l O O  nM - 1 p,M) or NaNP ( l O O  nM - 1 p,M) 
30s after EP 171 ( l O  nM) suppressed the Ptd OH formation (when 
compared to the saline controls) monitored 60s later (Figures 
58 & 59)' At the concentrations used, PGD^ stimulates both 
adenylate and guanylate cyclases whereas NaNP specifically 
elevates cGMP levels (MacIntyre e^ al., 1985a). Thus this 
result does not differentiate between the effects of PGD^ on 
Ptd OH formation being mediated by cAMP and/or cGMP. This 
point was clarified by examining the effects of the stable 
cyclic nucleotide analogues 8 Br cAMP and 8 Br cGMP on EP I7I 
elevated levels of j^ ^^ P j Ptd OH. In this experiment the extent 
of [^^P ] Ptd OH formation induced by EP 171 (lO nM) within
— 116 —
30s was 263 — 419  ^of control. This increased to 76O — 139^  
of pre-^stimulus level after the addition of saline for a 
further 300s (i.e. 330s after EP l?l). 8 Br cAMP (l mM)
added 30s after EP I7I had no effect (743 — l6^) on the level 
of Ptd OH observed at 330s, however it was significantly reduced 
to 423 - 56% by the addition at 30s of 8 Br cGMP (l mM) for 
a further 300s (Figure 60). This suggests that cGMP is more 
effective than cAMP at reversing agonist induced formation of 
[^^p] Ptd OH. It is possible that the PGD^-induced reversal 
of Ptd OH formation is mediated by a non-specific stimulation 
of guanylate cyclase and not due to its activation of adenylate 
cyclase. The effect of PMA on elevated [^^P ] Ptd OH levels 
induced by EP I7I is shown in Figure 6l . EP 171 (lO nM) for 
30s elevated ] Ptd OH to 466 - 6^ of the pre-stimulus control.
PMA (100 nM - 1 p-M) or DMSO the vehicle control were added 
30s after EP I7I and the levels of [^^P ] Ptd OH were monitored 
60s later. Both concentrations of PMA reduced the Ptd OH 
(to 246 - I8J0 & 226 - 18^ respectively of the pre-stimulus level) 
levels to below that of DMSO (6o4 - 10^).
Hence PGD^j NaNP and PMA, all of which inhibit agonist 
induced elevation of [ca^^] and [^^p] Ptd OH formation and 
reverse an agonist evoked calcium signal, also all reverse an 
agonist stimulated [^^P ] Ptd OH levels.
2.10 Effect of PMA on thrombin induced arachidonate release
Having established that phosphoinositide hydrolysis and Ca^* 
flux could be attenuated by agents that activate protein kinase 









Figure 57, Time course of low 
Ptd OH formation.
EP 171 concentration-induced stimulation of
0.4 ml samples of U“‘’Pi P. prelabelled platelets were exposed to 10 nM EP 171 
and the levels of P^Pj Ptd OH measured at the times indicated. The results 


















Figure 58. Reversal of EP 171-induced stimulation of
by PGP
32, Ptd OH formation
0.4 ml samples of P. prelabelled platelets were exposed to 10 nM EP 171
and 30s after agonist addition either saline (closed circle), (open
triangle) or Ip M (open circle) POOL was added. The levels oj jT PJ Ptd OH 
were measured at the times indicated. The results are means - SEM of 
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Fiqure 59. Reversal of EP 171-induced stimulation of |32pl Ptd OH formation
by NaNP. L J
0.4 ml samples of [ p] P. prelabelled platelets were exposed to 10 nM 
EP 171 and 30s after agonist addition either saline (closed circle), 
100_nM (ppen triangle) or Ip-M (open circle) NaNP was added. The levels 
of f PjPtd OH were measured at the times indicated. The results are 
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Fiqure 60. Reversal of EP 171-induced stimulation of Ptd OH formation
by 8 Br cAMP and 8 Br cGMP. -
0.4 ml samples of 32p] P. prelabelled platelets were exposed to 10 nM EP 171 
and 30s after agonist addition either saline (closed circle), 1 mM 8 Br cAMB. -, 
(open circle) or 1 mM 8 Br cGMP (open triangle) was added. The levels of PJ 
Ptd OH were measured at the times indicated. The results are means - SEM 
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Fiqure 61. Reversal of EP 171-induced stimulation of [32pl Ptd OH formation
^  PMA.
0.4 ml samples of 32P P.w -T UM. w, rj r  prslabslled platelets were exposed to 10 nM EP 171
and 30s after agon:!^ st addition either DMSO (closed circle), 100 oM (open 
triangle) or 1 )iM (open circle) PMA was added. The levels of^^ Pj Ptd OH 
were measured at the times indicated. The results are means - SEM of 
triplicate determinations. The experiment is typical of 2 similar experiments
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on the liberation of arachidonic acid. This liberation of
arachidonic acid from phospholipids is believed to be mediated
‘•2by a Ca^*-activated acyl-hydrolase (phospholipase ) (Wong
& Cheung, 1979).
PMA (lOO nM - 1 )iM; 120s) did not cause the release of
arachidonate when compared to the DMSO control. Thrombin 
(lu/ml (50 nM); 120s) stimulated release of arachidonate
which was unaffected by preincubation of PMA (lOO nM - 1 p,M;
120s) (Figure 62). It appears therefore that although PMA 
has pronounced effects on the platelet transduction process 
it does not alter agonist induced arachidonate release.
2.11 Summary
The observation that increasing agonist concentration 
accelerates the decline in levels of stimulatory second messengers 
(either by impairing formation or stimulating catabolism) is 
perhaps indicative of some negative feedback system in the 
platelet. The most obvious endogenous candidates to mediate 
this feedback would be cAMP, cGMP and DAG. Agents which mimic, 
or stimulate the formation of each of these compounds inhibit 
the formation of, and enhance the rate of decline of, both 
[ca^^j ^  mnd ^^^p] Ptd OH. As cGMP and DAG reportedly are 
formed in platelets challenged with agonists, these findings 
suggest that either of these may play a role as endogenous 
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Figure 62. Effects of PMA on thrombin-induced release of arachidonate.
0.2 ml of [ h] arachidonic acid prelabelled platelets were pre-incubated for 
120s with either DMSO or PMA at the concentrations indicated. Thrombin (l.OU/ml 
(50 nM) was subsequently added for 120s and the [ Hj arachidonate release 
monitored. The results are means - SEM of triplicate determinations. The 
experiment is typical of 7 similar experiments.
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3• Mechanisms underlying potentiation
ADP, but not adrenaline, induces an increase in [ca^^J^ 
(MacIntyre e_fc ad., 1983b), however neither stimulate Ptd
OH formation (Figures 18, I9 & 20; MacIntyre ^  , 1983b).
Both of these agents are capable of potentiating the platelet 
functional response evoked by other agonists. The mechanism 
underlying this effect is unclear, although both ADP and 
adrenaline are linked to the inhibition of adenylate cyclase, 
suggesting perhaps some function for decreased cAMP levels 
in this phenomenon. The possibility of an augmentation of 
phosphoinositide metabolism (possibly via inhibition of adenylate 
cyclase) mediating this potentiation has not been investigated. 
Consequently I investigated the effects of adrenaline and ADP 
on agonist induced phosphoinositide hydrolysis.
3•1 Effect of ADP on agonist induced platelet phosphoinositide 
metabolism
ADP per se does not stimulate Ptd OH formation (Figures 
18 & 19)» However, when added to platelets pre-incubated with 
flurbiprofen (lO ixM) , ADP (lO p,M; 60s) resulted in a shift in 
the concentration response curves for [^^P ] Ptd OH stimulated 
by PAF (1.8 - 180 nM; 30s) and by vasopressin (3 - 300 nM; 30s). 
The maximum responses were increased from 213 - 139^  to 238 - 18^  ^
and from I98 - 79^  to 233 - 79^  respectively (Figures 63 & 64).
The presence of flurbiprofen indicates that this potentiation 
is not dependent on platelet cycle oxygenase activity, and 















Figure 63. Effect of ADP on the concentration response ourve for PAF-induced
stimulation of [ I Ptd OH formation.
\z2 10.4 ml samples of [ PJ P. prelabelled, flurbiprofen pretreated platelets 
were pre-incubated for 60s with either saline (closed circles) or lO^M 
ADP (open circles), prior to the addition of PAF at the concentrations 
indicated. [32pj Ptd OH levels were measured 30s after PAF addition.
The results are means - SEM of 3 experiments each with triplicate determinations,
















Figure 64. Effect of ADP on the concentration response curve for vasopressin- 
induced stimulation of | p t d  OH formation.
f s T l  ^ ^0.4 ml samples of [_ Pj P. prelabelled, flurbiprofen pretreated platelets were 
pre-incubated for 60s witn either saline (closed circles) or lO^M ADP (open 
circles), prior to the addition of vasopressin at the concentrations indicated. 
r^Zpl ptd OH levels were measured 30s after vasopressin addition. The results 
are means - SEM of 3 experiments each with triplicate determinations. Analysis 
of data: *p <0.01; **p <0.005.
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3*2 Effect of adrenaline on agonist induced platelet 
phosphoinositide metabolism
The effects of adrenaline on PAF> vasopressin and thrombin 
induced formation of j Ptd OH was investigated in platelets
pretreated with flurbiprofen (lO p,M). PAF (l.8 - 180 nM; 30s) 
induced a concentration dependent formation of Ptd OH (Figure 
63)* Adrenaline (3 pM; 60s) preincubation caused a significant 
potentiation of the sub-maximal PAF responses (I.8 - 18 nM) 
but not of the maximum PAF concentration (18O nM). Similarly, 
adrenaline potentiated thrombin (O.Ol - lU/ml (0.3 - 30 nM);
30s) induced Ptd OH formation when elicited by low (o.Ol - O.IU/ 
ml) but not by high thrombin concentrations (Figure 66). In 
identical conditions adrenaline potentiated vasopressin (lO - 
300 nM; 30s) induced Ptd OH formation at all concentrations 
(Figure 67).
ADP fails to evoke phosphoinositide metabolism monitored 
by changes in Ptd OH (Figures 18 & I9 )» PIP or PTP^ (Figure 20) 
in [^^P] P^ prelabelled platelets. It is possible that these 
assays are not sufficiently sensitive to detect ADP induced 
phosphoinosiitide hydrolysis. Were this to be the case, 
adrenaline might potentiate the response to a detectable level. 
Figure 68 depicts the (non) effects of ADP on [^^P] Ptd OH 
levels and the consequence of prior addition of adrenaline to 
platelets pre-treated with flurbiprofen (lO p,M). ADP (O.l - 
10 p,M; 30s), either alone or when pre-treated with adrenaline 
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Figure 65. Effect of adrenaline on the concentration response curve for 
PAF-induced stimulation of I j  Ptd OH formation.
[ ]
0.4 ml samples of [ Pj P, prelabelled, flurbiprofen pretreated platelets 
were pre-incubated for 60s with either saline (closed circles) or 5pM 
adrenaline (open circles), prior to the addition of PAF at the concentrations 
indicated. [32p] Ptd OH levels were measured 30s after PAF addition. The 
results are means - S.E.M. of triplicate determinations. The experiment is 
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Figure 66. Effect of adrenaline on the concentration response curve for 
thrombin-induced stimulation of Ptd OH formation.
0.4 ml samples of [ p] P. prelabelled, flurbiprofen platelets were pre- 
incubated for 60s with either saline (closed circles) or 5 adrenaline 
(open circles), prior to the addition of thrombin at the concentrations 
indicated. [3^p] Ptd OH levels were measured 30s after thrombin addition. 
The results are means - SEM of triplicate determinations. The experiment 



















Fiqure 67. Effect of adrenaline on the concentration response curve for 
vasopressin-induced stimulation of l^^pl ptd OH formation.
P32 1
0.4 ml samples of [ PjPi prelabelled, flurbiprofen pre-treated platelets 
were preincubated for 60s with either saline (closed circles) or 5 
adrenaline (open circles), oriot to the addition of vasopressin at the 
concentrations indicated. P  Pj Ptd OH level^ were measured 30s after 
vasopressin addition. The results are means - SEM of triplicate determinations, 
The experiment is typical of 3 similar experiments. Analysis of data;
*p <0.05; **p <0.01.
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Figure 68. Effect of adrenaline on the concentration response curve for 
ADP-induced stimulation of I Ptd OH formation,j—  [ 3
0.4 ml samples of L Pj P, prelabelled flurbiprofen pretreated platelets 
were pre-incubated for 60s with either saline (closed circles) or 5 p.r'l 
adrenaline (ppsn circles) prior to the addition of ADP at the concentrations 
indicated. [32p] Ptd OH levels were measured 30s after ADP addition. The 
results are means - SEW of triplicate determinations. The experiment is 
typical of 2 similar experiments.
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Adrenaline is known to inhibit adenylate cyclase in 
intact platelets as it decreases the cellular content of cAMP 
which has been previously elevated by an adenylate cyclase 
stimulant. In order to investigate the role of decreased 
cAMP levels in adrenaline induced potentiation of phospho­
inosi tide hydrolysis, I examined the effect of agents which 
elevate cAMP on this potentiation.
3*3 Effects of adenylate cyclase stimulants on adrenaline
induced potentiation of platelet phosphoinositide metabolism 
As adenylate cyclase stimulants inhibit (Figures 42 & 43) 
and adrenaline potentiates (Figures 65» 66 & 67) agonist induced
phosphoinositide hydrolysis it is possible that these agents 
exert mutually antagonistic effects. This possibility was 
addressed by examining the effects of adrenaline and adenylate
cyclase stimulants (PGD^j PGI^) in combination on [^^P ] Ptd OH 
formation induced by PAF and vasopressin. Neither of these 
agonists affect adenylate cyclase activity in intact platelets 
(Aktories & Jakobs, 1983)» PAF (l8 nM) elevates the level of 
[^^p] Ptd OH to 293 - 139  ^of the saline control within 30s. 
This was decreased to 243 - 6^ of the pre-stimulus level by 
pre-incubation with 3 P-M adrenaline for 60s. PGD^ added prior 
to adrenaline blocks the latter's capability to potentiate 
the PAF induced response to a level (29O - h^ o of the saline 
control) which is significantly more than that induced by PAF 
alone (Figure 69). In a similar fashion, PGI^ (3 uM; 90s) 
inhibits adrenaline (3 P-M; 60s) induced potentiation of 
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Figure 69. Effect of PGD_ on adrenaline-induced potentiation of PAF-induced 
stimulation or Ptd OH formation.
f32 10#4 fnl ssfnplss of PJ P. prGlsbGllsd* i o j.ooj.««www ww
were sequentially challenged with either saline or 30 nM PGO^ for 30s, 
followed by either saline or Sp-M adrenaline for 60s Godgflnally followed 
by either saline or 18 nM PAF for 3gs. The levels of [ PJ Ptd OH were 
measured and the results are means - SEM of triplicate determinations.
The experiment is typical of 2 similar experiments.
[32p]_ptd OH; % of control
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Figure 70. Effect of PGI_ on adrenaline-induced potentiation of vasopressin- 
induced stimulation of ptd OH formation.
0.4 ml samples of [ p] P, prelabelled, flurbiprofen pretreated platelets 
were sequentially challenged with either Tris buffer or 3 nM PGIg for 30s, 
followed by either saline or 5 p. M adrenaline and finally by either
saline or vasopressin for 30s. The levels of [ Pj Ptd OH were measured 
and the results are means - SEM of triplicate determinations. The experiment 
is typical of 2 similar experiments.
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In each case the agonist induced ] Ptd OH formation
was potentiated by adrenaline pre-treatment and inhibited by 
adenylate cyclase activation. However pre-incubation with a 
combination of adrenaline and an adenylate cyclase stimulant 
had no significant effect on agonist-induced [^^p] Ptd OH 
formation. This suggests that inhibition of adenylate cyclase 
activity might play a role in adrenaline-induced potentiation 
of platelet activation by another agonist.
3.4 Summary
Adrenaline and ADP both potentiate agonist induced formation 
of [^^p] Ptd OH. As both agents also potentiate agonist induced 
platelet functional responses, this effect on platelet phospho— 
inositide metabolism may underlie the observed effects on 
functional responses. This potentiation is observed in the 
presence of flurbiprofen, thus is independent of the formation 
of PGrG^y PGH^ or TxA^» Adrenaline in combination with ADP 
failed to stimulate formation of [^^p] Ptd OH to a detectable 
level. The adrenaline induced potentiation of agonist induced 







The importance of phosphoinositide hydrolysis as a 
coupling mechanism whereby external stimuli can initiate 
activation of a variety of cells, including human platelets, 
has become increasingly apparent in the last decade. The 
agonist-induced hydrolysis of the inositol phospholipids serves 
as the/a transduction process by which agonist-receptor 
interaction at the plasma membrane results in the activation 
of two distinct second messenger systems; the so-called Ca^* 
dependent system, utilising Ins(l,4,5)P^ and Ca^^, and the Ca^*
independent system, involving DAG. In platelets this stimulation
2+ 2+ of cellular reactivity elicited by the Ca -dependent and Ca -
independent systems is abrogated by activation of the adenylate
cyclase system which leads to the inhibition of cellular
reactivity.
This study addressed, not only the role of phosphoinositide 
hydrolysis in agonist induced platelet stimulation, but also 
the possibility that putative endogenous regulators could inter­
fere with this hydrolysis. Hence in the following discussion 
my results will be viewed in the context of current knowledge 
of the actions and interactions of transduction processes.
2. Mechanism of action of ADP
ADP was the first agonist to be studied with respect to
its effects on phosphoinositide hydrolysis in platelets. Several 
studies, using rabbit platelets, indicated that ADP induced 
an increased turnover of the inositol phospholipids (Lloyd al.,
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1972, 1973a) which was related to shape change rather than to 
aggregation (Lloyd al., 1973h). These observations, several
years prior to Michell's hypothesis relating this phenomenon to 
Ca^* gating (Michell, 1973); have been supported in studies 
monitoring PIP^ hydrolysis in rabbit platelets challenged with 
ADP ( Vickers e_fc aT. , 1982; Leung £_t aT. , 1983)* lu addition 
the same group reported increased phosphoinositide turnover 
in ADP stimulated human platelets ( Vickers ejb aT. , 1983)* 
Obviously such observations are at variance with those in this 
study (Figures 18, 19; 20). However, Fisher and colleagues 
have reported that, in human platelets, ADP causes an elevation 
in ^ in the absence of PTP^ hydrolysis and inositol
phosphate formation (Fisher e_t aT. » I983)* ADP-indueed platelet 
activation is associated with the phosphorylation of the 2OK 
but not 4OK protein (Daniel aT* > 1984). These results 
apparently contradict the hypothesis that agonist induced 
elevation of |ca^^] occurs as a direct result of the Ins (l, 4,5)P-i 
from phosphoinositide hydrolysis.There are several possible 
explanations for these discrepancies.
i) It is possible that the techniques employed were 
insufficiently sensitive to monitor small amounts of ADP induced 
phosphoinositide hydrolysis in human platelets. This is unlikely 
however, as agonists which are equally as effective as ADP at 
stimulating platelets, such as PAF and 5HT (Huang & Detwiler, 
1986a), can elicit detectable [^^p] Ptd OH formation (MacIntyre 
et al., 1983b). Moreover the experimental conditions employed 
in this study were based on those of Lloyd (Lloyd e_fc al., 1972, 
1973a,b).
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il) The ADP receptor may become desensitised during the 
prelabelling period as a consequence of the release of endogenous 
ADP. However, when desensitisation was prevented by the addition 
of apyrase during the prelabelling period, ADP remained in­
effective at stimulating [^^P ] Ptd OH formation. Furthermore, 
under the prelabelling conditions employed, ADP retained the 
capacity to elicit both an elevation in [ca^^j ^  and functional 
responses, indicating that the ADP receptor and its transduction 
processes are intact and that the platelet remains functionally 
viable.
iii) With a single exception ( Vickers e_t aT. , 19&3); ADP 
induced phosphoinositide hydrolysis has been observed in non­
human platelets. Therefore the discrepancy may be due to a 
species variation, especially as the reported phosphoinositide 
hydrolysis in rat platelets (MacIntyre & MacMillan, I985) 
utilised identical techniques to those of this study.
iv) Kinetic analysis of the effects of ADP and thrombin 
in Fura 2 loaded platelets has indicated that these agonists 
elevate |ca^^j by different mechanisms (Sage & Rink, I986).
In the case of ADP this mechanism may involve the removal of 
PIPg from the plasma membrane and as a consequence the removal 
of the stimulatory action of PIP^ on a plasma membrane Ca^*- 
ATPase (Choquette e_b al. , 1984; Resink e_t al. , I986). Vickers 
and colleagues recently demonstrated that, in rabbit platelets, 
the observed ADP stimulated decrease in PTP^ levels is not 
primarily due to phospholipase C activity but to a shift in 
the equilibrium between PIP^ and PIP leading to elevated PIP 
(and Ptd Ins) but decreased PIP^ levels (Vickers ejt al. , I986),
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presumably by either activation of PIP^ phosphatase or inhibition 
of PIP kinase. Although this would serve as a putative 
mechanism whereby can be elevated in the absence of
either Ptd OH or Ins(l, 4 , 5 formation, several anomalies 
remain. Firstly, neither Fisher e_fc al. (I985) nor this study 
could monitor decreased levels of PIP^* It should be noted 
that the assay technique I used in this study may not be 
sufficiently sensitive to monitor a small degree of PIP^ 
breakdown evoked by "weak" agonists, e.g. PAF, 5HT (Pollock, 
1984). Secondly, Vickers e_fc al. (1986) suggested that there is 
phospholipase C activity directed specifically at Ptd Ins or 
PIP which results in Ptd OH formation, again contrary to the 
findings of Fisher eJb al. (1985) and this study.
v) It is possible that ADP stimulates platelets by an 
alternative mechanism, independently of the elevation in |ca^^] .
The ADP receptor has been reported to be linked to N^, the G 
protein regulating inhibition of adenylate cyclase. Indeed, 
in intact platelets ADP reverses the increment in cAMP levels 
induced by adenylate cyclase stimulants (Mills, 1974).
Adrenaline is also believed to be linked to N.. N. in turn
X  X
is linked to inhibition of adenylate cyclase and such an 
inhibition would result in a decreased intracellular cAMP 
concentration. Although decreased cAMP levels would, in theory, 
cause platelet activation (Salzman, 1972), no agonist has been 
shown to produce such an effect. However distinct compartments 
of cAMP have been reported in platelets (Hashimoto, I983) and 
it is possible that ADP and adrenaline alter the levels of
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cAMP within these specific pools, in the absence of changes 
in the overall cAMP content. It is also possible that the two 
agonists share an, as yet, unknown mode of action.
Whatever the reason for the observed discrepancies, ADP 
remains an anomaly amongst stimulatory agonists and further 
emphasises the complexities and multiplicity of mechanisms 
underlying platelet activation. Indeed such complexity is not 
confined to platelets as similar observations have been made 
in rabbit (Volpi ejb al. , 1984) and human (MacIntyre & Rossi,
1983) neutrophils challenged with leukotriene where elevated 
jca^^j^ appears unrelated to phosphoinositide hydrolysis.
3• Mechanism of action of thromboxane A^
Endogenous TxA^ and its precursors, the prostaglandin 
endoperoxides PGG^ and PGH^, are believed to play a significant 
pro-aggregatory role in the secondary phase of platelet 
activation. The natural agonists are highly unstable and/or are 
converted to other active metabolites. For this reason 
a large number of stable analogues that mimic the effects of the 
natural agonists have been utilised to probe their mechanisms 
of action. The use of one such compound, U44o69 (9>11 epoxy- 
methano PGH^), demonstrated that the human piatelet-Tx receptor 
is linked to inositol phospholipid hydrolysis and elevation of 
|ca^^] ^  (Pollock e_fc aT. , 1984). However there is evidence from 
other tissues that u44o69 is a partial agonist at the Tx 
receptor (jones e_fc al. , I982).
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The novel Tx mimetic, EP 171» stimulated Ptd OH
formation (Figure 21) and ATP secretion (Figure 26) and in 
both respects was more potent and efficacious than U44o69.
In addition, EP 171 elicited a much slower stimulation of ^^^Pj 
Ptd OH formation (Figure 22) and activation of platelets (jones 
et al., 1985) than U44o69 (Pollock et al., 1984). This slow 
activation has been attributed to the agonist slowly reaching 
equilibrium occupation of the receptors as may be expected 
when a high affinity lipophilic agonist is present at low 
concentrations. The effects of EP I7I on ] -PIP^; -PIP and
-Ptd OH levels are further evidence that human platelet Tx 
receptors are coupled to phospholipase C activity.
The comparable effects of U44o69 and the known partial 
agonist. Et PGH^ ( 9 > H ethano PGH^), in their ability to attenuate 
the EP 171 induced [^^P ] Ptd OH formation (Figure 23) and ATP 
secretion (Figure 27) indicate that, in common with other tissues, 
U44o69 is a partial agonist at the platelet Tx receptor.
This would suggest that EP I7I is a better, i.e. more 
efficacious or "full", agonist with which to investigate the 
effects of stimulation of the platelet TxA^ receptor. However, 
whether either analogue mimics in all respects the effects of 
the natural compounds remains to be proven. TxA^ and PGH^ 
have been reported to inhibit platelet adenylate cyclase activity 
(Miller e_t al. , 1977) whereas U44o69 is devoid of this activity 
(Best e_t al. , 1979)* PGH^ may require to be converted to TxA^» 
by Tx synthetase, prior to exhibiting this effect. In contrast, 
the endoperoxide analogue U44o69 is not a substrate for this
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enzyme, therefore no TxA^ would be formed, explaining why 
U44o 69 does not inhibit adenylate cyclase (Best e_t al. , 1979)*
EP 171 does inhibit adenylate cyclase in the platelet, however 
this is prevented by apyrase, suggesting such an effect is 
mediated by the release of ADP (MacIntyre & Murdoch, unpublished 
observations). Whether the effects of endogenous TxA^ on 
platelet adenylate cyclase are, likewise, mediated by ADP 
generation is unclear.
4. Mechanism of action of thrombin
Thrombin is the most efficacious and potent platelet 
stimulatory agonist and indeed is the archetypical example of 
a "strong" platelet agonist (Huang & Detwiler, 1986a). It has 
been shown to instigate the whole range of platelet responses 
and, as a consequence, has been widely used to probe the 
stimulatory transduction process present within the cell. In 
human platelets thrombin has been shown to stimulate
i) an elevation of jca^^j
ii) decreased levels of Ptd Ins, monitored using both
prelabelling (Rittenhouse-Simmons, 1979) and mass 
(Broekman et al., I98O) techniques,
iii) the formation of [ ] DAG (Rittenhouse-Simmons, 1979)»
iv) increased mass of Ptd OH (Broekman e_t al. , I98O) and, 
in this study, increased levels of [^^pj Ptd OH 
(Figures 28, 29),
v) the hydrolysis of PIP^ (and possibly PIP) (Agranoff 
et al., 1983; Rendu ejfc al. , 1983; Figure 30).
vi) the formation of various inositol phosphates (Agranoff
et al. , 1983; Watson e_b , 1984; Rittenhouse & Sasson, 
Majerus ejb aT. , I986),
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vil) the phosphorylation of a number of proteins, including 
the 4OK and 20K, which have been implicated in 
platelet activation (Lyons ejb ad., 1975)*
These observations strongly suggest a role for receptor 
mediated phosphoinositide hydrolysis in thrombin stimulated 
platelet activation. However, the nature of the initial inter­
action between thrombin and the platelet which triggers this 
range of responses remains elusive. The functional significance 
of the thrombin binding site on the platelet plasma membrane 
has been questioned and a role for proteolysis in thrombin 
induced platelet activation widely proposed (Martin ejb ad., 1975)* 
Comparison of the concentration response relationships for 
the formation of Ptd OH induced by thrombin (Figure 28)
and by the other agonists (Figure 12) clearly demonstrates that 
thrombin is, by far, the most powerful agonist in this respect.
The disparity between the effects of thrombin and other agonists 
is even more marked when those agonists, which are believed to 
be functionally significant in activating platelets dn vivo, 
are added in combination and their effects compared to that 
of thrombin (Figure 31)* Thus, it would appear that the thrombin 
response, which, at the concentrations used in this study, is 
unaffected by cyclo oxygenase inhibition (Siess e_b ad * , 1983a), 
is not merely the result of the activity of a variety of 
endogenous mediators (ADP, PAF, 5HT, TxA^)*
The observation that trypsin, apparently in the absence of 
a specific cell surface receptor, can induce platelet activation 
(Davey & Luscher, I967) and formation of [^^P ] Ptd OH (Figure
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32), suggests that platelets can be stimulated by certain 
proteolytic enzymes. The serine protease inhibitor leupeptin 
inhibits thrombin and trypsin induced functional responses, 
protein phosphorylation and [^^p] Ptd OH formation (Ruggiero 
& Lapetina, 1985; Figure 34) but has no effect on ] Ptd OH
levels elevated by a non-proteolytic agonist, EP 171 (Figure 34). 
In contrast to receptor specific agonists (e.g. ADP, PAF, 5HT; 
Figure 31)» trypsin can potentiate the formation of ] Ptd OH
elicited by supramaximal concentrations of TxA^ (ergo EP 171; 
Figure 33) and this potentiation is inhibited by leupeptin 
(Figure 34). This may reflect the situation in thrombin activated 
platelets, as it demonstrates that it is mechanistically possible 
to have a twin stimulation via both receptor specific and 
proteolytic actions. In addition this may help illuminate the 
vexed question of which inositol phospholipid is hydrolysed 
during platelet activation. In cells other than platelets 
there appears to be a consensus that it is PIP^ which is 
preferentially hydrolysed by phospholipase C, and Ptd Ins acts 
solely as a pool replenishing the PIP^ metabolised (Michell 
et al., 1981). In contrast, kinetic analysis of thrombin 
induced phosphoinositide hydrolysis in platelets has indicated 
that there is direct metabolism of Ptd Ins, as well as of PTP^ 
(Wilson ejt aJL. , 1985c). This has been supported by the observed 
discrepancy between the mass amounts of DAG and Ins(l,4,5)P^ 
formed in thrombin stimulated platelets, suggesting that the 
excess DAG is formed directly from Ptd Ins hydrolysis (Ritten­
house & Sasson, 1985). It is conceivable that this hydrolysis
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of Ptd Ins in platelets by thrombin occurs as a direct result 
of a proteolytic action which is lacking in the effects of 
agonists in other cell types. It would therefore be instructive 
to examine whether phosphoinositide hydrolysis induced by weaker 
platelet agonists, devoid of proteolytic activity such as 
EP 171 (Figure 33)> demonstrate similar kinetic properties and 
discrepancies in DAG and Ins(l,4,5)P^ formation to those elicited 
by thrombin. Such studies may however be impeded by the relative 
ineffectiveness of these agonists at stimulating phosphoinositide 
hydrolysis (Figure 12). However monitoring of the effects of 
trypsin, and other proteases, on the above indices, and the 
use of specific protease inhibitors on thrombin stimulated 
platelet activation could circumvent this problem and help 
elucidate both the mechanism of action of thrombin and the role 
of direct Ptd Ins hydrolysis in platelet activation. These 
results imply that caution should be exercised when interpreting 
studies which use thrombin to probe platelet transduction 
processes.
3. Desensitisation
It is widely accepted that platelet functional responses 
exhibit the phenomenon of homologous desensitisation. However 
the role of inositol phospholipid hydrolysis and elevation of 
jca^^j^ in the underlying mechanism has not been widely 
investigated.
as monitored by Quin 2 or other indicators, is 
in dynamic equilibrium and is maintained by a variety of processes 
1 ) mobilisation from intracellular stores; 2) sequestration to
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intracellular stores; 3) influx from the external milieu;
4) extrusion to the extracellular space* Consequently the 
alteration of any one of these regulatory processes will have 
profound effects on the |ca^^j .
The agonist-induced elevation of |ca^^] is concentration 
dependent (Figure 37) and believed to reflect both mobilisation 
and influx of Ca^^ (Rink & Hall am, 1984; MacIntyre e_t al. , 
1983b), Furthermore the rapidity with which this elevation of 
[ca^ '*"j ^  declines also is concentration dependent and is perhaps 
indicative of sequestration and/or extrusion processes being 
activated to limit platelet activation (Figure 37). In a 
similar fashion, stimulus-induced formation of Ptd OH
is reversible and the rate of decline increases with agonist 
concentration (Figure 38). Thus the putative transduction 
process underlying the elevation of |ca^^] also is negatively 
regulated by increased agonist concentrations. The mechanism 
of this regulation may involve either receptor desensitisation 
or the formation of an endogenous mediator which feeds back 
to inhibit phosphoinositide hydrolysis and/or activate Ca^^ 
sequestration/extrusion. The latter mechanism may also be 
implicated in the phenomenon of desensitisation. The addition 
of agonists to platelets, prechallenged with the same agonist, 
fails to elicit any further formation of Ptd OH (Figure 39). 
This has been widely reported for platelet aggregation (e.g. 
0*Brien, I966; Evans & Gordon, 1974; Ruggles & Scrutton, 1979) 
and recently for elevation of jca^^j (Pollock & MacIntyre, 
1986), and has been attributed to receptor mediated, homologous 
desensitisation. However, if the second agonist differs from
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the first, then the evoked J Ptd OH formation was less
than that elicited by the second agonist if added alone (Figure 
39) perhaps indicative of heterologous desensitisation. These 
effects are comparable to those observed in blowfly salivary 
glands (Berridge & Fain, 1979) which was presumed to result 
from a depletion of the inositol phospholipids, as it was 
reversible by the subsequent addition of free inositol to 
allow d^ novo synthesis of the lipids (Fain & Berridge, 1979)* 
However, such a mechanism can be precluded in the present study 
as thrombin can elicit much more Ptd OH formation than combination 
of other agonists (Figures 3I> 39)* This indicates that there 
is more phospholipid precursor present than is utilised by 
other agonists, but this does not exclude the possibility of 
either, specific pools of phosphoinositides which are sensitive 
to individual agonist-induced phospholipase C activity, or, 
the "clumping" of receptors thereby limiting their accessibility 
to the membrane lipids (Berridge & Fain, 1979)> as mechanisms 
of heterologous desensitisation. It is also possible that 
the levels of G protein in the membrane is a limiting factor.
This however is unlikely as in other cells there is an excess 
of G proteins present (Rodbell, I980). Another possibility 
is the production of endogenous mediators which function to 
inhibit the platelet stimulatory transduction process(es).
Obvious candidates for such agents are the platelet inhibitory 
mediators, cAMP and cGMP.
- 135 -
3*1 Adenylate cyclase stimulants
Adenylate cyclase stimulants, such as PGI^ and PGD^> 
inhibit agonist induced platelet functional responses (Haslam 
et al., I98O; Bushfield e_t al. , I983), elevation of jca^^j 
(Peinstein e_t ad., I983; Bushfield e_t aJL. , I983; Figure 4o), 
phosphoinositide hydrolysis (Rittenhouse-Simmons, 1979» Figures 
42, 43) and protein phosphorylation (Lyons ad., 1975)* 
Kaser-Glanzmann and colleagues proposed that the inhibitory 
effects of cAMP were due to its stimulation of the uptake of 
Ca^* into various intracellular membranes (Kaser-Glanzmann et ad., 
1977)* Such an action of cAMP is consistent with the ability 
of stimulants of adenylate cyclase accelerating the rate of 
decline of an agonist induced elevation of jca^^J^ (Zavoico 
& Feinstein, 1984; Figure 36). However, such a mechanism has 
been challenged as cAMP was found to be ineffective at sequester­
ing Ca^* into the DTS (Menashi ad*, I982) and its inhibitory 
action was proposed to be independent of its effects on [ca^^J 
(Pannocchia & Hardisty, I983)* PGI^ has been shown to prevent 
agonist induced formation of Ins(l,4,3)P^ (Watson ad., 1984), 
indicative of an inhibitory effect at, or prior to, the level 
of phospholipase C, although the precise site of cAMP mediated 
inhibition is unclear. The platelet functional responses are 
differentially sensitive to increments in platelet cAMP levels.
The most sensitive responses (ATP secretion and aggregation) 
most probably are inhibited by an effect at a level distal to 
second messenger generation, whereas inhibition of shape change 
occurs only at levels of cAMP that also inhibit elevation of 
Ca^* and Ptd OH formation (Bushfield ejb sd. , I983)* A cAMP-
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dependent protein kinase mediated alteration of receptor 
structure (phosphorylation) and inhibition of G protein 
function and consequent impairment of phospholipase C activity 
are all other possible mechanisms.
PGI^ and PGD^ can reverse agonist induced elevation of 
^ (Figure 36) and formation of [^^P ] Ptd OH (Figure 38) 
respectively, in a manner similar to increasing agonist 
concentration. This may indicate that cAMP can act to limit or 
terminate agonist induced platelet activation. Consequently 
cAMP may serve as a putative endogenous mediator of desensitis­
ation. However, the effects of PGD^ on elevated [^^P j Ptd OH 
levels cannot be reproduced by the use of the stable cAMP 
analogue, 8 Br cAMP (Figure 60). Corresponding studies on an 
agonist induced elevation in [ca^^j ^  cannot be carried out 1in
intact cells as during the period required for incorporation 
of the stable analogue (five minutes) the levels of Ca^ "*" would 
have returned to basal levels. At the concentrations used in 
this study, PGD^ is not entirely specific for adenylate cyclase 
(MacIntyre et al., 1983a), and so its effects on elevated |ca^^]^ 
and/or j^ ^^ P J Ptd OH may not be solely mediated by cAMP. In 
addition platelet stimulatory agonists do not increase the 
cellular levels of cAMP (Haslam ^  , I98O) as may be expected
were it to play a regulatory role in platelet function.
3.2 Guanylate cyclase stimulants
Cyclic GMP is believed to be an intracellular messenger 
for various extracellular signals in a number of cells although
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the presence of substrates for cGMP dependent protein kinase(s) 
have only rarely been detected* The cGMP—dependent protein 
kinase shows similar catalytic properties to those of the cAMP— 
dependent protein kinase and so cGMP may provide a negative 
rather than positive stimulus (Nishizuka, 1984). Agents which 
stimulate guanylate cyclase (NaNP) or mimic cGMP (8 Br cGMP) 
cause muscle relaxation and so cGMP has been implicated as a 
feedback inhibitor, rather than a positive messenger, of 
muscarinic stimulated smooth muscle contraction (Schultz et al., 
1977)» thereby providing an immediate control preventing the 
cell from over-responding. In general, in cells, such as 
platelets, where cAMP inhibits the effects of stimulatory 
agonists, cAMP and cGMP are not mutually antagonistic, but 
rather similarly inhibit receptor mediated transduction processes 
and functional responses (Nishizuka, 1984). NaNP has a powerful 
inhibitory effect on human platelets (Glusa ejfc aJL. , 1974).
Moreover it has been reported that platelets synthesise cGMP 
in response to stimulatory agonists such as collagen, thrombin, 
adrenaline, ADP and 5HT (White et al., 1973» Haslam & McClenaghan, 
1974; Davies ejb al. , 1976). This possibility occurs as a 
consequence of arachidonate liberation (Davies e_b aJL. , 1976) 
although whether cyclo-oxygenase activity is a pre-requisite 
for cGMP formation is unclear (Davies et al., 1976; Best et al.,
1979)" On these grounds it has been proposed that cGMP is an 
endogenous negative mediator of platelet activity (Haslam ;^b aJL. ,
1980) and thus may be involved in the mechanisms underlying 
desensitisation.
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NaNP and/or 8 Br cGMP inhibit agonist induced elevation 
in ^a^^j (Figure 40; Nakashima at al • > 1986)» phosphoinositide 
hydrolysis (Figure 44; Takai e_t a^. » 1981b; Nakashima at ad. , 
1986) and protein phosphorylation (Takai at ad.» 1981b). This 
indicates that cGMP inhibits platelet activation at » or before» 
the level of phospholipase C. In addition» cGMP can terminate 
the agonist induced stimulation of the transduction process» 
as indicated by the reversal of agonist induced elevation of 
|ca^ '*’J ^  (Figure 36) and formation of [^^P ] Ptd OH (Figure 59) •
In contrast to cAMP stimulants » it appears that» at the 
concentrations used» NaNP is fairly specific for guanylate 
cyclase (MacIntyre e_b al.» 1985a) and» in the case of Ptd OH 
reversal» mimicked by the stable analogue » 8 Br cGMP (Figure 
60). This effect of cGMP to inhibit the formation of » and 
stimulate the removal of» stimulatory second messengers is 
further evidence for and consistent with a negative feedback 
role for this nucleotide within the cell. However» whether 
such a mechanism is physiologically relevant or is involved 
in the process of desensitisation in platelets is open to 
conjecture.
5.3 Protein kinase C stimulants
It has become evident that agonist-receptor interaction 
initiates a cascade of events» including the generation of two 
distinct second messengers» Ca^ "*" and DAG» which culminate in 
the cellular response (Berridge & Irvine» 1984). DAG» which 
is believed to activate a cytosolic enzyme» protein kinase C 
(Nishizuka» I983) and cytosolic free Ca^* may act independently 
or synergistically to initiate a variety of cellular responses
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in a host of cells (Nishiznka, 1984).
The tumour promoting class of compound, the phorbol esters, 
such as PMA, have been shown to mimic the stimulatory effects 
of DAG on protein kinase C (Castagna et al., 1982). However 
in contrast to the transient nature of DAG-mediated protein 
kinase C stimulation, phorbol esters permanently activate the 
enzyme, although recently it has been reported that DAG may be 
elevated for a longer period than originally believed (Duncan 
& Lloyd, 1986) perhaps resulting in a PMA-like activation of 
protein kinase C. Agents such as 4 # phorbol and 4 a phorbol 
didecanoate are structurally similar to the active phorbol esters 
and share many of their physico-chemical properties, but differ 
in that they do not activate protein kinase C (Castagna ejk al. ,
1982) and are widely used as controls to distinguish protein 
kinase C-mediated from non-specific effects of phorbol esters 
in experimental situations.
The phorbol esters are potent activators of numerous cells 
including platelets (Zucker e_fc ad., 1974; White ejk al. , 1974).
They have the capacity to stimulate ATP secretion in the absence 
of elevated jca^^j (Rink a^. , I983) and also demonstrate a 
marked synergism with calcium ionophore in promoting degranulation 
(5HT release) (Yamanishi at al., 1983); arachidonic acid release 
(Halenda ejfc aT., I985) and Tx biosynthesis (Mobley & Tai, 1985)* 
The release of arachidonic acid is believed to occur as a result 
of a protein kinase C-mediated phosphorylation of a protein 
(lipocortin) with anti phospholipase A^ activity (Touqui e_t aT. , 
1986). This phosphorylation removes the inhibitory constraint
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with the consequent liberation of arachidonic acid. Phorbol 
esters also stimulate neutrophils (De Chatelet e_fc al., I976). 
However, in contrast to the predicted synergism between protein 
kinase C activation and elevation of , they were shown
to activate an ATP-dependent calcium extrusion mechanism (Mottola 
&. Romeo, I982) and to attenuate an agonist induced elevation in 
[ca^ "*^ ] ^  (Lagast e_fc ^ .  , 1984).
In this study phorbol esters were shown to have a similar 
pronounced inhibitory action on an agonist induced increase in 
[ca^^J ^  in human platelets. Although the active compound,
PMA, has no effect on the resting | c a ^ ^ , it both inhibits 
(Figure 45) and reverses (Figure 56) an agonist induced elevation 
in |ca^^j . This regulatory effect has subsequently been 
confirmed (Zavoico et al., I985; Poll & Westwick, I986) and 
found to be directly dependent on the preincubation time 
(Krishnamurthi aT. , I986). Suppression of the agonist-induced 
elevation of jca^^J^ could perhaps be attributed to an activation 
of an extrusion process analogous to that thought to exist 
in the neutrophil. However as no reduction in the resting 
cytosolic calcium levels was observed then, either no such 
mechanism exists in the platelet, or it is only activated in 
the presence of elevated ^a^^j . The 40K protein has recently
been shown to act as an Ins(l,4,5)P^ phosphatase (Connolly & 
Majerus, I986) which would result in the removal of this inositol 
phosphate. Consequently, this would decrease the ability of 
the cell to mobilise calcium. Moreover PMA stimulates the 
déphosphorylation of Ins(l,4,5)P^ (Molina y Verdia & Lapetina,
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1986), an effect consistent with protein kinase C stimulating 
the removal Ins(l,4,5)P^ and this would partly explain the 
inhibitory effects of PMA on an agonist-induced elevation of
Phorbol esters also appear to interfere with phosphoinositide 
hydrolysis. PMA stimulates both the [^^P ] labelling (Figure 36; 
de Chaffoy de Courcelles e_t ah. , 1984a; Halenda & Feinstein,
1984) and the mass amounts (Halenda & Feinstein, 1984) of PIP 
and PIP^, although PIP significantly more so than PIP^. These 
alterations in the levels of the poly phosphoinositides were 
accompanied by a decrease in the [^^p] content (Figure 33;
Halenda & Feinstein, 1984) and mass (Halenda & Feinstein, 1984) 
of Ptd Ins. In contrast, there is no alteration in the resting 
cellular level of Ptd OH (Figure 35; Halenda & Feinstein, 1984), 
indicating that phosphodiesteric cleavage of inositol phospho­
lipids was not stimulated. However, the phorbol esters inhibit 
the agonist induced formation of [^^P] Ptd OH (Figures 47-54).
Were PMA to inhibit phospholipase C, then this would explain
both the suppression of [^^P] Ptd OH formation and attenuation 
2+of Ca flux. However as monitoring of Ptd OH formation is 
but an indirect index of phospholipase 0 activity, such an 
extrapolation is unwarranted. Inhibition of [^^P J Ptd OH 
formation is also consistent with the inhibition of DAG kinase. 
However, PMA inhibits the agonist induced hydrolysis of PIP^ 
(Figure 35; Zavoico e_fc ad., I983; Watson & Lapetina, I983) 
and formation of inositol phosphates (Watson & Lapetina, I983; 
Rittenhouse & Sasson, I983). This evidence indicates that
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inhibition at or before the level of phospholipase C, with 
the consequent suppression of PIP^ hydrolysis and impaired 
Ins(1 ,4,5)P^ formation, can account at least in part for the 
observations made in this study.
Protein kinase C allegedly mediates the so-called "calcium 
independent" mechanism of cellular activation. Therefore the 
observation that a stimulant of the enzyme acts to limit or 
terminate the production of stimulatory second messengers appears 
to be somewhat incongruous. Although the phosphorylation of 
the 40K protein, an indicator of protein kinase C activity, 
was not measured, in the present study, the experiments were 
performed using concentrations of PMA and preincubation times 
consistent with complete activation of the enzyme (Castagna 
et al., 1982; Yamanishi e_k al. , I983; Kaibuchi et al. , I983).
In addition, the synthetic analogue of DAG, l-oleoyl-2-acetyl- 
glycerol (OAG), has been shown to activate protein kinase C in 
a manner analagous to natural diglycerides and to be metabolised 
to the corresponding Ptd OH (Kaibuchi ak al., 1983)* These 
agents have been shown to increase the platelet levels of PIP 
and PIP^ (de Chaffoy de Courcelles e_fc ^ .  , 1984b), to inhibit 
the formation of inositol phosphates (Watson & Lapetina, I985) 
and dephosphorylate Ins(l,4,5)P^ (Molina y Vedia & Lapetina,
1986) in a manner similar to PMA. Moreover, H7 (l— 5“isoquino— 
linesulphonyl -2-methylpiperazine), the proposed protein kinase 
C inhibitor (Kawamoto & Hidaka, 1984), has been shown to 
prevent the inhibition of an agonist induced elevation of 
|ca^ '*’j ^  by phorbol esters (Tohmatsu e_t ad., I986; Poll &
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Westwick, I986) and the hydrolysis of inositol phospholipids 
(Tohmatsu ejb ad. , I986). Whilst none of these observations 
provide conclusive proof that inhibitory effects of phorbol 
esters are mediated by protein kinase C, they do provide some 
evidence that the observed effects are not a result of a 
non-specific action on the cell.
Interestingly, in human platelets the phorbol esters have 
an inhibitory effect on the adenylate cyclase system. PMA 
inhibits PGD^ but not PGI^ mediated accumulation of cAMP 
(Bushfield ^t al., 1986) indicating both that their effects
have a measure of selectivity and the complex nature of the 
interactions between transduction processes in the platelet.
If the effects of phorbol esters mimic those of endogenous 
DAG and are due to an action on protein kinase C, then this 
enzyme may play a bi-directional regulatory role in various 
cells. Indeed such a dual role for DAG has been proposed to 
be an elegant mechanism whereby the |ca^^] ^  can be regulated 
within certain limits (Dxummond, I985). In human platelets, 
phorbol esters and/or DAG have been reported to inhibit agonist 
induced ATP (Watson & Lapetina, I983); arachidonic acid and 
P.-thromboglobulin release (Krishnamurthi et al. , I986).
Inhibition of 5HT secretion (Watson & Lapetina, I985) which 
is antagonised by H7 (Poll & Westwick, I986) has also been 
reported, however this has been challenged (Krishnamurthi ejt al., 
1986). Consequently the functional significance in terms of 
platelet reactivity remains contentious.
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The effects of the phorbol esters on the cellular levels 
of phosphoinositides, discussed above, have been similarly 
reported in other cells. In lymphocytes, PMA enhances the 
incorporation into PIP and PIP^ with the corresponding decreased 
incorporation into Ptd Ins (Boon e_fc al., 1983)» The effects 
of phorbol esters on agonist elevated jca^^j has subsequently 
been demonstrated in a host of isolated cells including rat 
basophilic leukaemia cells (Sagi-Eisenberg e_t al. , 1983), rabbit 
neutrophils (Naccache ejt al. , I983), hepatocytes (Cooper et al.,
1983); astrocytoma cells (Orellana e_fc ah., I983), pituitary
cells (Drummond, I983); vascular smooth muscle (Brock e_t al.,
1986) and adrenal glomerulosa cells (Kojima e_t aT. , I986). 
Similarly phorbol esters have inhibitory effects on agonist 
induced phosphoinositide hydrolysis in cells other than platelets. 
Rat hippocampal slices (Labarca jet ad. , 1984), astrocytoma cells 
(Orellana ejfc al. , I983), mast cells (Okano jejfc aT. , I983); 
lymphocytes (Mellors et al., I983); vascular smooth muscle 
(Brock e_fc al. , I983; McMillan ejb al. , I986), hepatocytes (Corvera 
et al. , 1986) and adrenal glomerulosa cells (Kojima e_t al. ,
1986) all exhibit this phenomenon. The variety of cells in 
which there is evidence for an inhibitory action of phorbol 
esters on their agonist stimulated inositol phospholipid metabolis 
and consequent elevation of |ca^^] suggests that this is a 
frequent occurrence and thus may be of physiological significance.
Phorbol esters have also been found to influence other 
receptor-linked transduction processes, in particular the
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adenylate cyclase system. For example PMA inhibits the 
stimulation of adenylate cyclase activity in rat hepatocytes 
by glucagon (Heyworth e_fc a^. , 1984; Garcia-Sainz e_t ad., I985). 
Such an observation would suggest that the effects of phorbol 
esters were not specific for phospholipase 0.
As discussed above there is evidence for protein kinase C 
stimulants (phorbol esters and OAG) acting to inhibit agonist- 
induced phosphoinositide metabolism at, or prior to, phospholipase 
C. Decreased levels of the enzyme substrates (the phospho­
inosi tides) could account for the observed effects, however as 
PMA promotes both the [^^P] levels and mass of PIP and PIP^ 
this is unlikely. The activity of the 4OK protein as an 
Ins(l,4,5)P^ phosphatase most likely accounts at least in part 
for the observed effects on |ca^^j^.
However phorbol esters apparently affect the adenylate 
cyclase, as well as the phospholipase C, mediated system, and 
therefore it is possible that they act at a level which is 
present in both processes, such as receptors and/or G proteins.
The phorbol esters have been shown to affect agonist receptor 
interaction. Alpha^ adrenoceptors are phosphorylated in smooth 
muscle (Leeb-Lundberg _ejt ad., I985) and their affinity for 
agonists is reduced in hepatocytes (Corvera e_fc al., I986) and, 
in addition, muscarinic acetylcholine receptors on neuroblastoma 
cells are rapidly internalised (Liles jet ad. , I986) by phorbol 
esters. The insulin receptor has been reported to be phosphoryl­
ated by phorbol esters (Jacobs J^b ad., I983) and PMA and OAG 
both induce desensitisation to P-adrenergic agonist stimulation
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in the adenylate cyclase system of rat reticulocytes, an effect, 
mediated at the receptor level and which is antagonised by H7 
(Yamashita et al., 1986)# There are as yet no reports of phorbol 
esters influencing the number or structure of receptors in the 
human platelet. The phorbol esters may act on some common site 
or subunit of the various G proteins present in the membrane.
They have been shown to have an action at the level of the 
phospholipase 0 linked G protein consistent with preventing 
thrombin induced activity (Halenda e^ ad., I986). However the 
precise site of the negative regulation of cellular reactivity 
and various transduction processes by protein kinase C activation 
(by DAG and/or PMA) is still unclear.
Therefore there is some evidence that activation of protein 
kinase C may play a functional role as a bidirectional regulator 
of cellular activity. As well as stimulating the cell, protein 
kinase C may feed back inhibit the stimulatory transduction 
process and so avoids overstimulation of the cell. The DAG 
which is produced in response to agonists may have a role to 
play in the desensitisation of the human platelet.
6. Potentiation
Human platelets in vivo are exposed to a wide number of 
endogenous compounds (e.g. collagen, ADP, PAF, adrenaline, TxA^) 
which are believed to play a role in initiating or propagating 
the coagulatory process. These agonists exert a synergistic 
effect on platelet reactivity. However the precise mechanism(s) 
underlying this effect have not been widely investigated.
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The majority of studies have concentrated on the potentiation 
by ADP or adrenaline on thrombin, ^HT and PAF induced platelet 
functional responses. The former two agonists have been shown 
to be linked via to the inhibition of adenylate cyclase in 
intact human platelets, whereas thrombin, 5HT and PAF are believed 
to be mediated by phosphoinositide hydrolysis. As such this 
represents a means of evaluating the contribution of distinct 
transduction processes to the resultant cellular response.
Adrenaline, which itself neither elevates jca^^j^ nor 
causes inositol phospholipid metabolism (MacIntyre ejb a^. ,
1983b), significantly potentiates the effects of PAF, vasopressin 
and thrombin on human platelet phosphoinositide hydrolysis, at 
least as monitored as [^^P ] Ptd OH formation (Figures 63-67). 
Concomitant with this, adrenaline similarly enhances the increase 
in jca^^j elicited by an agonist (Bushfield ejt al. , 1987)*
This effect of adrenaline on agonist induced [^^P j Ptd OH 
levels was antagonised by the prior addition of the adenylate 
cyclase stimulants PGD^ or PGI^ (Figures 69, 70).
The mechanism of action of ADP is the subject of much 
conjecture. ADP can elevate jca^^j ^  (MacIntyre e_fc al. , 1983b) 
but is apparently ineffective at stimulating phosphoinositide 
metabolism (Figures l8-20). In common with adrenaline, ADP 
can potentiate PAF and vasopressin induced [^^p] Ptd OH 
formation (Figures 63, 64).
Studies using calcium ionophores and phorbol esters have 
indicated that neither increased elevation of jca^^j nor 
increased DAG (and so Ptd OH) levels alone could account for
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the observed potentiation by adrenaline of agonist induced 
platelet activity. However, a combination of both, as would 
be expected if phospholipase C activity were enhanced, could 
account for the observed effects (Bushfield e_fc ad., I987).
Such an action could occur were adrenaline or ADP, either as 
a result of occupancy of their specific receptor or due to 
a reduction in a specific intracellular cAMP pool to promote 
the binding of phospholipase C mediated agonist to their 
receptors. This could be achieved were adrenaline and ADP to 
alter the arrangement of the membrane lipids (irvine, I982). 
Alternatively, an enhanced coupling, or efficacy of the coupling 
process, of G proteins could account for the observed potenti­
ation. The structure of the putative phospholipase C linked 
G protein is unclear. This G protein in platelets has been 
reported to be different from either of those in the adenylate 
cyclase system (Houslay ejb ad., I986). Although thrombin has 
been reported to be linked to two G proteins the first is 
apparently and the second apparently novel (Grandt e_t ad. , 
1986). However, in rabbit neutrophils (Volpi e_fc ad., I983) 
and human leukemic cells (Brandt e^ al., I983); activation 
of phospholipase C is inhibited by pertussis toxin. As this 
toxin also inhibits to which adrenaline and ADP receptors
are linked in platelets, it is possible that the phospholipase 
C linked G protein is similar to N^. It is possible that as 
a consequence of this similarity, when ADP or adrenaline bind 
to their receptors, enhances the coupling of the phospholipase
C linked G protein to the enzyme thereby promoting its activity.
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7• Concluding remarks
This study was concerned primarily with the role of 
phosphoinositide hydrolysis in the stimulation of the human 
platelet, and its role in the development of desensitisation 
and the putative mechanism of potentiation within the cell.
The study has failed to elucidate the mechanism of action of 
ADP in stimulating human platelets and the enigma of how an 
elevation in jca^^j can occur in the apparent absence of 
phosphoinositide hydrolysis remains. It appears that there 
are receptor operated calcium channels present in the cellular 
membrane which are linked to the ADP receptor but which are 
independent of phosphoinositide hydrolysis. It appears that 
this is not unique to platelets as it also occurs in LTB^- 
induced neutrophil activation, and further studies in the 
platelet are required to identify the nature of these channels. 
In common with others, this study demonstrates that thrombin 
induced platelet activation is not solely as a result of 
agonist receptor interaction and indicates the need for caution 
when using this agonist to investigate transduction process 
within the cell. The investigations involved with putative 
mechanisms underlying desensitisation and potentiation have 
demonstrated the intricate and complicated interactions of 
the adenylate and guanylate cyclase and the inositol phospho­
lipid systems within the cell. Further studies in platelets, 
and other cells, are required to clarify these interactions 
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